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ABSTRACT
Background: The possibility of an association between the use of protease
inhibitors (PI) by HIV/AIDS patients and the occurrence of T2DM mellitus (T2DM) is
largely debated. Medicare recipients are disproportionally affected by T2DM.
Unfortunately, evidence is unavailable from that particular segment of the population.
Clinical management of HIV/AIDS is progressively expanding to include
chronic/metabolic complications, which may pose a significant economic burden to both
the patients and the Medicare system, which are disproportionally impacted.
Objectives: The aims of this project were to (1) examine the association between the use
of PIs and the odds of developing T2DM among Medicare beneficiaries with HIV/AIDS,
(2) assess any racial/ethnic disparity in odds of developing T2DM among Medicare
beneficiaries with HIV/AIDS and (3) to determine the economic burden of comorbid
T2DM among Medicare beneficiaries with HIV/AIDS.
Methods: This study used a nationwide Medicare claims data from 2013 to 2017 to
analyze a sample of Medicare beneficiaries diagnosed with HIV/AIDS based on the
International Classification of Diseases, Ninth & Tenth Revision, Clinical Modification
(ICD-9/10-CM) codes. In study aim 1 and 2, a nested case-control study design was used
to analyze the odds of developing T2DM among beneficiaries with HIV/AIDS.
HIV/AIDS positive beneficiaries enrolled continuously in Medicare Part A and Part B
were included as well as those who never enrolled in a Health Maintenance Organization
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(HMO) and those without a previous history of T2DM. A T2DM diagnosis was
determined using T2DM specific ICD-9/10-CM codes. Two matched therapy group pairs
– (PI versus non-PIs, PI versus no-ART) were generated using a 1:1 greedy Propensity
Score (PS) matching procedure. Multivariate logistic regressions were performed to
assess the odds of developing T2DM in both groups and for each race sub-group.
In study aim 3, a pooled cross-sectional study design was used to determine the
economic burden of comorbidity T2DM in beneficiaries with HIV/AIDS. The analytical
sample consists of HIV/AIDS positive beneficiaries enrolled continuously in Part A/B
and never enrolled in an HMO. We assessed records of T2DM diagnosis using T2DM
specific ICD-9/10-CM codes. Total medical costs, total prescription costs, total inpatient
costs, total outpatient costs, total out of pocket (OOP) and total Medicare costs were
assessed from Medicare claims and prescription drug files. Generalized linear models
with a log-link and a gamma distribution were used to examine the impact of comorbid
T2DM on different costs. All costs were adjusted to the 2017-dollar value using the
medical component of a consumer price index based on Medical Expenditure Panel
Survey (MEPS) guidelines.
Results: In study aims 1 and 2, the analytical sample consists of 2,353 beneficiaries with
HIV/AIDS which includes 342 beneficiaries with T2DM, 2011 beneficiaries without
T2DM, 1005 beneficiaries treated with PIs, 766 beneficiaries treated with non-PIs and
582 beneficiaries who had no-ART. Exactly 484 matched beneficiaries per therapy group
was generated for PI versus non-PI pair and 490 beneficiaries per therapy group for the
PI versus no-ART pair. Matched beneficiaries in the PI versus non-PI therapy group are
mostly older 55 years and above per group, mostly male beneficiaries – 77.1% (n=373)
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and consists mainly of Caucasians – 49% (n=237) and African Americans -45% (n=218)
per group. Matched beneficiaries in the PI versus no-ART therapy group are mostly older
than 55 years and above per group, mostly male beneficiaries – 75.9% (n=372) per group
and consists mainly of Caucasians – 42.7 % (n=209) and African Americans -50%
(n=245) per group. After adjusting for covariates: (1) in the PI versus non-PI pair: the
odds of a T2DM diagnosis was higher among PI-users: AOR= AOR=1.76 [95% CI: 1.172.64], Caucasian PI-users: AOR=1.81 [95% CI: 1.02-3.22] and African-American PIusers: AOR= 1.86 [95% CI: 1.03-3.36] compared to non-PI users on average, and (2) in
the PI versus no-ART pair: the odds of a T2DM diagnosis was higher among PI users
AOR=1.87 [95% CI: 1.25-2.81], Caucasian PI-users: AOR=1.96 [95% CI: 1.14- 3.39]
and African-American PI-users: AOR=2.05 [95% CI: 1.03-4.09] compared to ART naïve
beneficiaries on average.
In study aim 3, a total of 2,509 eligible beneficiaries were identified of which 19.9
% (n=498) had T2DM and 80.2% (n=2,011) are non-T2DM beneficiaries. Beneficiaries
with comorbid T2DM had a higher total prescription cost than non-T2DM beneficiaries
across all costs: (mean total medical: T2DM beneficiaries ($189,543) versus non-T2DM
beneficiaries ($124,052), P= <.0001). After adjusting for covariates, compared to
beneficiaries without comorbid T2DM, beneficiaries with comorbid T2DM had higher:
total hospitalization cost: 63.34% (95% CI: 42.73% -86.94 %), total outpatient cost:
50.26% (95% CI: 30.70%-72.75%), total OOP cost: 59.15% (95% CI: 40.02%-80.92%),
total Medicare cost: 27.95% (95% CI: 13.81%-43.84%) and total medical cost: 27.83%
(95% CI: 14.27%-43.00%), compare to non-T2DM beneficiaries, on average.
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Conclusion: Use of PIs is associated with a higher odd of T2DM diagnosis.
Results are consistent within African Americans and Caucasian race-sub-groups;
however, odds were higher among African Americans beneficiaries than Caucasians.
Comorbid T2DM may impose a significant economic burden on Medicare beneficiaries
with HIV/AIDS. The findings of this study suggest evidence-based risk management
approach in the clinical use of PIs to avoid HIV treatment-related T2DM among
Medicare population, who are already enormously predisposed as well as personalized
risk management approach in the context of racial variation in treatment-related T2DM.
The findings of this study could be helpful to the Medicare they seek to address concerns
about its future financial solvency amidst a growing aging population and increasing per
capita costs. Evidence of total OOP costs benefit the Medicare as they seek to reduce
drug costs to benefit HIV positive beneficiaries who face high OOP cost.
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CHAPTER 1
INTRODUCTION
Anti-retroviral Therapies (ARTs) are very effective in viral suppression and
immune system maintenance given that they act on different viral targets thereby ensuring
a reduction in HIV-related mortality rates. However, the safety and tolerability of ARTs
have been largely controversial. Butt and colleagues reported an increased risk of diabetes
among veterans infected with HIV 1. A multicenter study shows that HIV-infected patients
receiving Highly Active Anti-retroviral Therapy (HAART) are more than 4 times as likely
to have an increased rate of diabetes than HIV-negative participants2. Contrary to these
studies, Dimala et al. recently conducted a study to compare the diabetes risk score in
HIV/AIDS patients on HAART and HAART-naïve patients. Their findings showed no
statistically significant association between HAART and diabetes 3.
In addition to the on-going debate, evidence on the Medicare population is
unavailable because the focus of previous studies has been on other population rather than
the Medicare population, in whom the risk of diabetes is most prominent. Contrary to the
public perception that HIV is an infection that mainly affects young adults, recent studies
have revealed that the HIV epidemiology in individuals aged 65 and older has been
changing and worsening dramatically in the past decades and this population constitutes
over 85 percent of Medicare population.4
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Racial disparities in access to HIV medications are an important determinant of
racial variations in treatment outcomes and adverse medication related events. Racial
disparities in receipt of HAART have been reported in previous studies 5. This was found
to be true among Medicaid beneficiaries, which are expected to have equitable access to
care given that Medicaid is structured to provide equal access to healthcare for all eligible
enrollees. Racial disparity in access to care among patients enrolled in Medicaid may
suggest a potential disparity in treatment related adverse events not only among the
Medicaid population, but also among the Medicare population.
HIV infection, ART use, and age are important predisposing factors to metabolic
syndromes such as diabetic comorbidity in HIV/AIDS. Comorbid diabetes in HIV patients
is most likely to occur as treated patients grow older.6 These comorbidities may pose
significant clinical challenges as well as an economic burden for the US Medicare system
given the increasing number of surviving younger patients who will become eligible for
Medicare in the nearest decade.7
1.1

Human Immunodeficiency Virus (HIV)
HIV is the virus that attacks the human T-cells, specifically the CD4 cells ,which

protect the body from infection and other related foreign bodies.8 The HIV infection
destroys the CD4 cells of the human hosts, thereby making the host’s immune system
weak or unable to fight against infections.8 Thus, the human host ultimately becomes
more vulnerable to opportunistic infections.8 This can cause symptoms that signal
Acquired Immune Deficiency Syndrome (AIDS) which is the last stage of HIV
infection.8
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HIV is classified into HIV-1 and HIV-2 ,which are different and can both result in
AIDS.9 HIV-1 is the most common and most prevalent type of HIV globally. HIV-2 is
less common and occurs in a much smaller number of people mostly from the West
African regions.9 In the US, patients infected with HIV-2 constitute only about 0.01% of
all HIV cases.9 It is harder to transmit HIV-2 between humans and it also takes a longer
time for AIDS symptoms to manifest. HIV is spread through contact and exchange of
certain bodily fluids with an infected person. Fluid contact or exchange mainly occurs
during unprotected sexual contact or sharing of injection needles during medical
treatment, blood transfusions, or drug abuse. It can also be transferred from an infected
mother to her child through the placenta and breast milk.8
HIV infected person may experience any type of symptoms possible since the
infection targets and impairs the immune system. Common symptoms that have been
reported include fever and fatigue, sore mouth and throat, muscular aching, candida
infection of the mouth, constant diarrhea, swollen lymph glands, seborrheic dermatitis
and vaginal yeast infection.8 To detect the HIV infection, two major laboratory tests
which involve a series of blood screenings may be conducted.9 Typically, the first test to
be ordered by healthcare providers is the Enzyme Immunoassay (EIA), also referred to as
the Enzyme-Linked Immunosorbent Assay (ELISA). ELISA detects HIV antibodies and
antigens in the blood. It is recommended for individuals who have been exposed to HIV
or those at high risk of contracting HIV.9 Following a positive ELISA test is the
confirmation of HIV infection which is performed using the HIV differentiation assay.9
Two main laboratory indices may be used to monitor treatment progress in an HIV
infection, namely: the CD4 count and the level of HIV RNA viral loads. A CD4 count
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less than 500 count/ml indicates immune suppression while a high-level of HIV RNA
viral loads indicates severe infection.9
1.2

Acquired Immunodeficiency Syndrome (AIDS)
AIDS represents the terminal stage of the HIV infection during which patients

experience severe damage to the immune system and a resultant presence of numerous
opportunistic infections in the host’s system.10 According to the Centers for Disease
Control (CDC), AIDS begins when HIV infected patients present with a CD4 cell count
less than 200 count/ml.10 At this point the HIV/AIDS patients could experience illnesses
such as pneumocystis carinii pneumonia, candida esophagitis, cryptococcal meningitis,
AIDS dementia, toxoplasmosis encephalitis, progressive multifocal leukoencephalopathy,
wasting syndrome, mycobacterium avium and cytomegalovirus infection.10 Currently,
HIV/AIDS has no cure. However, available treatments do delay the progression of the
disease, improves quality of life10, and increases life expectancy of HIV/AIDS patients to
70 years.11
1.3

HIV/AIDS in The United States
In the United States (US), approximately 1.1 million people are living with

HIV/AIDS, with approximately 37,600 new infections reported annually.12 Although the
importance of prevention and treatment has been met with huge government efforts, 1 in
7 of those infected are not aware that they have HIV virus.13 Over 700,000 people have
died of HIV/AIDS related illnesses since the HIV epidemic began in the US in 1980s.12
Although the size of the epidemic is small, relative to the entire US population,12 it has
continued to disproportionately impact certain population subgroups and regions. The

4

Southern region, in particular, is home to over 45% of US citizens currently living with
HIV/AIDS, and accounts for about 50% of all new infections.12,14
The HIV epidemic disproportionately impacts racial minorities, compared to the
Caucasian majority.12 The majority of new HIV/AIDS infections occur among African
Americans and Hispanics.12,15 Out of 1.1 million people living with HIV in the US,
468,800 are African American; accounting for more people living with HIV than other
ethnic groups.13 Furthermore, survival after an HIV diagnosis is lower in African
Americans than among other racial groups. African Americans accounted for more than
50 % of HIV/AIDS related deaths in 2016.12
1.4

HIV/AIDS Treatment and Medications
Antiretroviral therapy (ART) represents different classes of medicines used in the

treatment of HIV/AIDS. Eight classes of ARTs have been approved by the Food and
Drug Administration (FDA) and most of the member classes are currently in use.16,17 The
primary therapeutic goal of ART use is to achieve maximum and stable viral load
suppression, restore and sustain the immune system and its functions, improve quality of
life, and reduce HIV-related morbidity and deaths.17 As shown in table 1.1, FDA
approved classes of ARTs include: Nucleoside Reverse Transcriptase Inhibitors (NRTIs),
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs),
integrase strand-transfer inhibitors, fusion inhibitors, post attachment inhibitors,
chemokine receptor antagonists and Pharmacokinetic Enhancers (PE).16,17
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1.4.1 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Nucleoside Reverse Transcriptase Inhibitors (NRTIs) are effective against HIV-1
and HIV-218 and act by interrupting HIV replication through competitive inhibition of the
HIV reverse transcriptase enzyme disrupting the HIV DNA chain.19 The reverse
transcriptase enzyme is a specific DNA polymerase that enables transcription of the HIV
RNA into a double-strand pro-viral DNA. This DNA, upon elongation, is incorporated
into the host-cell genome through the addition of purine and pyrimidine nucleosides.19
The NRTIs are structurally identical to the purine and pyrimidine nucleosides and are
therefore incorporated into the pro-viral DNA chain, resulting in disruption of pro-viral
DNA formation.19 NRTI was among the first of the ARTs to be approved for treatment
of HIV/AIDS and they remain an integral component of the current standard treatment
guidelines. The FDA approved seven classes of NRTIs which are currently in use
including: abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir, and
zidovudine.20 Several adverse effects reported with the use of NRTIs include: lactic
acidosis, pancreatitis, hepatic steatosis, lipoatrophy and hepatic neuropathy.20
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Table 1.1 List of FDA approved single ART class
Brand Name

Generic Name (Other
Acronyms (other
names)
names)
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Ziagen
Abacavir sulfate
ABC
Emtriva
Epivir

Emtricitabine
Lamivudine

FTC
3TC

Viread

Tenofovir disoproxil
fumarate
zidovudine

TDF (Tenofovir DF)

Retrovir

AZT, ZDV
(Azidothymidine)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Pifeltro
Doravirine
DOR
Sustiva
Efavirenz
EFV
Intelence
Viramune
Viramune
XR
Edurant

Etravirine
Nevirapine
Extended release
Nevirapine
Rilpivirine

ETR
NVP

Protease Inhibitors (PIs)
Reyataz
Atazanavir

FDA approval
date
December 17,
1998
July 2, 2003
November 17,
1995
October 26, 2001
March 19, 1987
August 30, 2018
September 17,
1998
January 18, 2008
June 21, 1996
March 25, 2011

RPV (rilpivirine
hydrochloride)

May 20, 2011
June 20, 2003

Aptivus
Fusion Inhibitors

Tipranavir

ATV (atazanavir
sulfate,)
DRV (darunavir
ethanolate)
FOS-APV, FPV
(fosamprenavir
calcium)
RTV
SQV (Saquinavir
mesylate)
TPV

Fuzeon
CCR5 Antagonists
Selzentry
Integrase Inhibitors
Tivicay

Enfuvirtide

T-20

March 13, 2003

Maraviroc

MVC

August 6, 2007

Dolutegravir

DTG, (Dolutegravir
sodium)

August 13, 2013

Prezista

Darunavir

Lexiva

Fosamprenavir

Norvir
Invirase

Ritonavir
Saquinavir
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June 23, 2006
October 20, 2003
March 1, 1996
December 6, 1995
June 22, 2005

Isentress

Raltegravir

RAL (Raltegravir
potassium)

Isentress
HD
Post-Attachment Inhibitors
Trogarzo
ibalizumab-uiyk

October 12, 200
May 26, 2017

Pharmacokinetic Enhancers
Tybost
cobicistat

Hu5A8, IBA,
Ibalizumab, TMB355, TNX-355

March 6, 2018

COBI, C

September 24,
2014

1.4.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) are a class of ART
that act by non-competitively binding on the p66 subunit at a hydrophobic pocket distant
of HIV reverse transcriptase enzyme, thereby altering the active site and limiting viral
activities.21 All NNRTI classes of ART exhibit similar mechanisms of action. Members
of the NNRTI class include nevirapine, delavirdine, etravirine, rilpivirine, and
efavirenz.20 All member classes are effective against HIV-1 with etravirine having an
additional activity against HIV-2.22 One commonly reported adverse event of NNRTIs is
a rash, which manifests within the first few weeks of therapy and resolves as therapy
continues.20 Other adverse events include hepatotoxicity, insomnia, vivid dreaming,
dizziness, hallucinations, and confusion.20
1.4.3 Protease Inhibitors (PIs)
Protease Inhibitors (PIs) are a class of ARTs which act by competitively
inhibiting the HIV protease enzyme responsible for the maturation of viral cells late in
the viral cycle. The HIV protease enzyme facilitates the maturation of viral cells and
peptide cleavage by directly binding onto the HIV protease enzyme. PIs prevent
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subsequent cleavage of polypeptides and viral cell maturation. 23 They are effective
against HIV-1 and HIV-2 clinical isolates.23 Members of the PI class include ritonavir,
atazanavir, darunavir, fosamprenavir, indinavir, nelfinavir, saquinavir, amprenavir,
lopinavir/ritonavir, and tipranavir.
1.4.4 Integrase Strand-Transfer Inhibitors (INSTIs)
Integrase Strand-Transfer Inhibitors (INSTIs) are known for their ability to
competitively bind metallic ions in viral active sites to prevent the covalent linkage of
pro-viral DNA to the cellular DNA.24,25 Members of the INSTI class include raltegravir,
elvitegravir, and dolutegravir. Given that HIV integrase do not have human homolog,
selective inhibition of target enzymes will result in a minimal number of adverse
events.26,27 Commonly reported side effects include mild to moderate gastrointestinal
effects and headaches.20
1.4.5 Fusion Inhibitors
Fusion inhibitors extracellularly inhibit the fusion of HIV cells onto CD4 cells or
other host targets, thereby preventing viral activities on the host.28,29 Due to the unique
mechanism of action, fusion inhibitors are suitable in patients with high treatment
resistance as its action provides an extra site for targeting viral cells.28,29 The most
frequently used fusion inhibitor is enfuvirtide. Injection site reactions, subcutaneous
nodules, erythema, pruritis, pains and ecchymoses are commonly reported adverse
events.30,31
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1.4.6 Chemokine Receptor Antagonist (CCR5)
The only approved member class of Chemokine Receptor Antagonist (CCR5) is
maraviroc, which is a prototype of CCR5.20 Maraviroc selectively and reversibly binds
the CCR5 co-receptor, thereby preventing the binding of the V3 loop and fusion of the
HIV cellular membrane.32 It is active against tropical HIV-1 CCR5 and is associated with
several commonly reported adverse events such as cough, pyrexia, dizziness, rash,
musculoskeletal symptoms, abdominal pains, and upper respiratory tract infections.33
1.4.7 Post-Attachment Inhibitors
Post-attachment inhibitors are indicated in HIV-1 multidrug resistance cases in
which HIV is irresponsive to other ART regimens. Ibalizumab is the first class of postattachment inhibitors approved by the FDA and is also the most recently approve
ART.20,33 Ibalizumab is a monoclonal antibody which binds onto the extracellular domain
2 of viral cell receptors.29 Conformational disruption associated with the binding of
ibalizumab results in the prevention of coupling between gp120-CD4 complexes and
CCR5 or CXCR4, which ultimately disallows viral entry and fusion.20,32 The most
common side effects include diarrhea, dizziness, nausea, and immune reconstitution
syndrome.34
1.4.8 Pharmacokinetic Enhancers (PE)
The Pharmacokinetic Enhancers (PE) class of ARTs is often referred to as
boosting agents and constitute only a single member class called cobicistat, which acts by
inhibiting CYPE3A.20 It is often used as a combination component with protease
inhibitors in both treatment-naïve and treatment-experienced patients.20
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1.4.9 Combination Anti-Retroviral Therapy (cART)
Combination anti-retroviral therapy (cART) refers to the use of two or more
antiretroviral drugs combined based on clinical recommendations for effective treatment
of HIV/AIDS. Table 1.2 shows a list of FDA approved cART.16,17
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Table 1.2 List of FDA approved Combination Anti-Retroviral Therapy (cART)
Brand Name

Generic Name (Other
Acronyms (Other
names)
names)
NRTIs Based cARTs
Combivir
lamivudine and
3TC / ZDV
zidovudine
Epzicom
abacavir and lamivudine
ABC / 3TC
Truvada
Tenofovir disoproxil
FTC / TDF
fumarate and
emtricitabine
Cimduo
Lamivudine and tenofovir 3TC / TDF
disoproxil fumarate
Descovy
Emtricitabine and
FTC / TAF
tenofovir alafenamide
Trizivir
Abacavir, lamivudine, and ABC / 3TC / ZDV
zidovudine
PI Based cARTs
Kaletra
lopinavir and ritonavir
LPV/r, LPV / RTV

FDA approval
date
September 27,
1997
August 02, 2004
November 17,
1995
February 28,2018
April 04,2016
November
14,2000
September 15,
2000

Multi-Class Combinations
Atripla
Complera
Evotaz
Prezcobix
Stribild
Genvoya
Symfi Lo
Symfi

Efavirenz, emtricitabine
and tenofovir disoproxil
fumarate
Emtricitabine, rilpivirine,
and tenofovir disoproxil
fumarate
Atazanavir sulfate,
cobicistat
cobicistat, darunavir
ethanolate
elvitegravir, cobicistat,
emtricitabine, tenofovir
disoproxil fumarate
Elvitegravir, cobicistat,
emtricitabine, and
tenofovir alafenamide
Efavirenz, lamivudine,
and tenofovir disoproxil
fumarate
Efavirenz, lamivudine,
and tenofovir disoproxil
fumarate

EFV / FTC / TDF

July 12, 2006

FTC / RPV / TDF

August 10, 2011

ATV / COBI

January 29, 2015

DRV / COBI

January 29, 2015

QUAD, EVG / COBI /
FTC / TDF

August 27, 2012

EVG / COBI / FTC /
TAF

November 05
,2015

EFV / 3TC / TDF

February 05,
2018

EFV / 3TC / TDF

March 22, 2018
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Delstrigo
Julica
Dovato
Symtuza
Biktarvy
Triumeq

Doravirine, lamivudine,
and tenofovir disoproxil
fumarate
Dolutegravir and
rilpivirine
Dolutegravir and
lamivudine
Darunavir, cobicistat,
emtricitabine, and
tenofovir alafenamide
Bictegravir, emtricitabine,
and tenofovir alafenamide
Abacavir, dolutegravir,
and lamivudine

DOR / 3TC / TDF

30-August-18,
2018

DTG / RPV

November 21,
2017
April 9, 2019

DTG / 3TC
DRV / COBI / FTC /
TAF

July 17, 2018

BIC / FTC / TAF

February 17,
2018
August 22, 2014

ABC / DTG / 3TC

Since the introduction of cART in 1996, HIV management has improved
significantly, resulting in improved mortality and morbidity. Evidence from clinical trials
and observational studies has shown a significant reduction in morbidity and mortality
among people with HIV/AIDs since the advent of cART.35-40 Over the last few decades,
combination therapy has become better tolerated with simplified dosing (once daily fixed
dose combinations) that improves compliance.35,41,42 cART fundamentally changed the
epidemiology of HIV with the ability to confer stable suppression of HIV viral loads and
boosting of the CD-4 cell counts.37
According to the 2019 Department Of Health & Human Services (DHHS) Panel
on Antiretroviral Guidelines for Adults and Adolescents (The Panel), effectiveness and
preservation of future treatment options are key considerations in determining which
classes of ARTs are combined as cARTs, as well as when a combination is used as a
‘preferred’ regimen or an ‘alternative’ regimen.43 The choice of a cART regimen depends
on the patients’ specific clinical conditions such as: the presence of transmitted HIV drug
resistance, potential drug to drug interactions, expected adverse events, comorbidities,
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socio-economic factors, and whether it is to be used for initial therapy or for ART-naïve
patients.43 A cART regimen is designated as a ‘preferred’ or ‘alternative’ regimen based
on clinical trial evidence on efficacy in virologic suppression, tolerability, and toxicity
profiles.43 The ‘preferred’ cART regimen is designated for use in ART-naïve patients as
well as ART-experienced patients who are initiating cART therapy. Conversely, a
regimen designated as ‘alternative’ cART is used when there are comparative advantages
in terms of either efficacy, resistance, tolerability, or potential for compliance, when
compared to the preferred regimen.43
Three main ART combination constituents were identified by the panel for initial
therapy in ART-naïve patients. They include (1) NNRTI-based regimens, (2) Protease
inhibitor-based regimens, and (3) Triple Nucleoside Transcriptase based-regimens.43
The panel recommends the following NNRTI-based combinations:
i)

Efavirenz + (zidovudine or tenofovir or stavudine) + lamivudine as ‘preferred’
initial NNRTI-based regimens.

ii)

Efavirenz + (didanosine or abacavir) + lamivudine can be used as alternatives.

iii)

Nevirapine-based regimens can be used as alternatives.43

Efavirenz containing cARTs are not to be used by pregnant women or women at
reproductive age due to its teratogenicity properties.43 NNRTI based combinations have a
well-documented high anti-virologic, high immunologic efficacy and high potential for
compliance and adherence due to their ease of use compared to the PIs.43 They have
fewer negative drug interactions compared to the PIs.43 NNRTI based combinations are
PIs sparing (i.e. preserve PIs use in case of resistance for NNRTI cARTs). One of the key
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disadvantages is that resistance due to NNRTIs usually cut across the entire NNRTI
member class.43 The panel recommends lopinavir/ritonavir + (zidovudine or stavudine) +
lamivudine as ‘preferred’ protease inhibitor-based regimens for use in PI-based
combination regimens.43 The panel recommends a 3-NRTI regimen which consists of the
combination of abacavir, zidovudine (or alternately, stavudine), and lamivudine to be
used only when other combinations such as a NNRTI-based, or a PI-based regimen
cannot or should not be used as initial therapy for reasons such as important drug to drug
interactions.43
1.5 Type 2 Diabetes Mellitus (T2DM) in The Unites States
Diabetes is a chronic metabolic disorder characterized by insufficient insulin, a
lack of insulin production, or muscular insensitivity to insulin, which is a naturally
occurring hormone that helps in glucose utilization and metabolism.44 Diabetes consists
of three types: type 1 diabetes mellitus, type 2 diabetes mellitus (T2DM), and gestational
diabetes. Type 1 diabetes is characterized by autoimmune destruction of the beta cell of
the pancreas that produces insulin, thereby resulting in an insufficient amount of insulin
or total lack of insulin in the body.45 This condition is often hereditary, and patients
require exogenous insulin intake to survive. T2DM is characterized by a combination of
insulin deficiency and muscular insensitivity to insulin, resulting in the inability to
stabilize and maintain normal blood glucose levels.44 T2DM is the most common type of
diabetes and occurs in about 90% of people with diabetes.44
1.5.1 Epidemiology of T2DM in the United States
T2DM is one of the most prevalent chronic conditions and the seventh leading
cause of deaths in the United States.46 T2DM is a major risk factor for cardiovascular
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disease and a leading cause of kidney failure, nontraumatic lower extremity amputations,
and blindness among adults in the U.S.46 In 2020, the National Diabetes Statistics Report
noted that an estimated 34.2 million people in the U.S. are diagnosed with T2DM which
represents about 10.5 % of the total population (all ages) and 2.8 % of the adult U.S.
population. Over 1.5 million new cases of T2DM (7 in 1000 persons) were reported in
2015, of which 50 % were 45 to 65 years of age.47 The economic burden of T2DM is
high, with an estimated national cost of $327 billion in 2017.47 Approximately 73 %
($237 billion) represents direct health care expenditures for T2DM, while 27 % ($90
billion) were costs incurred due to overall lost productivity and diabetes related deaths.47
1.5.2 T2DM management
The major goal in the treatment of T2DM is to control and maintain patients’
blood glucose levels to a normal range using medications, good lifestyle habits, and diet.
The first treatment approach for T2DM is weight reduction through T2DM diets and
exercise. If symptoms and elevated blood glucose levels persist, diabetes medications
including oral or injected dosage forms, are prescribed. Insulin is prescribed if elevated
blood glucose levels persist after oral or injected anti-diabetes medication. Various
classes of diabetes medications have been approved by the FDA: alpha-glucosidase
inhibitors, amylin analogs, antidiabetic combinations dipeptidyl peptidase 4 inhibitors,
incretin mimetics, insulin, meglitinides, non-sulfonylureas, SGLT-2 inhibitors,
sulfonylureas, and thiazolidinediones.
In 2013, the American Association of Clinical Endocrinologists (AACE) and the
American College of Endocrinology (ACE) jointly recommended twelve management
algorithms with the purpose of driving comprehensive management approaches for
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T2DM.48 This algorithm represents practice guides to clinicians with emphasis on the
whole patient, his or her spectrum of risks and complications, and evidence-based
treatment approaches.48
The twelve recommended management algorithms include: (1) Continuous and
effective lifestyle management with concurrent medical therapy, (2) Frequent blood
glucose level monitoring to prevent therapy driven hypoglycemia and other risks that
could lead to severe or non-severe hypoglycemia, (3) Both diet and weight-loss
medication should be used to minimize the risk of obesity in order to prevent the
progression of obesity-driven diabetes, (4) T2DM treatments and the hemoglobin A1C
targeting should be individualized with a focus on the specific risk factors of the patient
such as age, presence of other disease conditions, adherence to treatment and motivation
level, time since first diabetes diagnosis, life expectancy, and risk of hypoglycemia. This
is important because clinicians depend on patients for fasting and postprandial glucose
monitoring and reporting, (5) An A1C level of ≤ 6.5% is considered optimal in the
management of diabetes, (6) Treatment with and choice of antidiabetic medication should
be individualized based on the patient’s specific risk factors and other attributes, (7)
Other comorbidities such as cardiac and cerebrovascular conditions as well as kidney
disease should be considered while choosing antidiabetic medication, (8) In the presence
of these comorbidities, T2DM management should be comprehensive, (9) Speedy
normalization of blood glucose levels and management of associated comorbidities and
risk factors should be as fast as possible to slow and avoid further complications, (10)
Costs of medication, management and potential for adherence in terms of types of dosage
and form should determine choice of medication, (11) To individualize treatment and
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achieve effective glycemic control, clinicians should utilize professional continuous
glucose monitoring (CGM), and finally (12) In complying with these algorithms, all
medication to be used should be FDA approved.48
1.6

The Overview of Medicare and Healthcare Coverage
Medicare is the US national health insurance program established in 1965 to

provide health care coverage primarily to elderly people 65 years old or older who have
over 4 quarters of work credit. It was expanded in 1972 to additionally provide coverage
for younger adults with disabilities who qualify for Social Security Disability Insurance
(SSDI) and have received SSDI payments for at least 24 months. It also includes
coverage for younger adults with End-Stage Renal Disease (ESRD) or Amyotrophic
Lateral Sclerosis (ALS) (Lou Gehrig’s disease).49 Since expansion, Medicare has
provided health and financial coverage for over 60 million beneficiaries including the
elderly and those under 65 with long-term disabilities.49
Most Medicare beneficiaries live with multiple chronic conditions and/or
disabilities and survive on limited income. In 2016, reports on the financial and clinical
characteristics of Medicare beneficiaries showed that over 50 % of Medicare patients had
savings below $74,450 and were living on incomes below $26,200. The report also
showed that about 32% of Medicare beneficiaries had a functional impairment, 25% were
in poor health, 22% had multiple chronic conditions (often 5 or more), 15% were younger
than 65 and had long term disabilities, over 12% were 85 years old and above, and 3%
(about 3 million Medicare beneficiaries) live in long-term care facilities.50
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Medicare insurance provides coverage to beneficiaries through Part A, Part B,
Part C and Part D insurance plans. Medicare Part A covers in-patient care services,
Skilled Nursing Facilities (SNF), some home health services, and hospice care. Medicare
Part B covers services such as physician visits, outpatient services, and some home health
and free preventive services such as prostate cancer screening and mammography.50 Part
C, also known as the Medicare Advantage program, constitutes enrollment in private
insurance plans such as health maintenance organization (HMO) or preferred provider
organization (PPO) while also enrolled in Part A and Part B. These beneficiaries obtain
prescription drugs through Part D.50 Part D was established in 2006 and provides
coverage for outpatient prescription drugs through contracting with private insurance
plans that offer retail prescription drug coverage to Medicare beneficiaries.50 Contracting
private insurance plans includes stand-alone prescription drug plans (PDPs) which work
alongside the original Medicare plans and the Medicare Advantage Plans with
Prescription Drug coverage (MA-PDs). These are built into the Medicare advantage
plan.50 A summary of current deductible amounts and coinsurance rates for Part A and
Part B over different kinds of healthcare service provision is listed in Table 1.3.51
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Table 1.3: Summary of current Medicare Part A and Part B coverage and copays, 2020
Coverage

Patients Co-pay

Medicare Co-pay

Medicare Part A
Hospital Care (Inpatient)
i.
Day 1 to 60
ii. Day 60 to 90
iii. Day 90+ (Lifetime Reserve
Days)
iv.
Days after lifetime reserve
days

i.
ii.
iii.
iv.

$1,408 deductibles
$352 coinsurance
per day
$704 coinsurance
per day
All cost

Skilled Nursing Facility Care
i.
First 20 days
i.
No cost
ii. Days 21 to 100
ii. $176
iii. Days after 100 days
iii. All cost
Home Health Services
Part-time or intermittent skilled
No Cost
nursing care, and or physical therapy
Hospice Care
i.
Palliative care (comfort care)
i.
No cost
ii. Prescription drug from
ii. $5 per prescription
outpatient
iii. 5 % of the
iii. Inpatient respite care
Medicare approved
amount
Medicare Part B
Medical Services
Physician’s services, Outpatient care
Home health services, Durable
medical equipment (DME), Mental
health services, Other medical
services
Durable Medical Equipment and
Supplies
Outpatient Hospital Services

Outpatient Medical and Surgical
Services and Supplies

$198 deductible
20% co-insurance if the
doctor or other health care
provider accepts
assignment
20% coinsurance for
Medicare-approved
amount after $ 198
deductible is met.
20% coinsurance for
Medicare-approved
amount after $ 198
deductible is met
20% coinsurance for
Medicare-approved
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i.
ii.
iii.
iv.

Balance
Balance
Balance
No cost

i.
ii.
iii.

All cost
Balance t
No cost

All Cost
i.
ii.
iii.

All cost
Balance
Balance

Balance after $198
deductibles

Balance after $198
deductibles
Balance after $198
deductibles
Balance after $198
deductibles

X-rays, casts, stitches, outpatient
surgeries
Laboratory tests
Blood test, urinalysis, Human
Papillomavirus, Lab pap test,
colorectal screening, hepatis C, HIV
test etc.
Breast Cancer Screening:
Mammogram
i.
Once a year for women 3539 years old
ii. More than once a year

Home Health Services
Medical social services, part-time or
intermittent home health aide
services, DME and medical supplies
for use at home

amount after $ 198
deductible is met
No cost

100 % of the cost
of the approved

i.

No cost

i.

100 % cost

ii.

20% coinsurance
for Medicareapproved amount
after $ 198
deductible is met

ii.

Balance
after $198
deductibles

No cost

100 % of the cost
of the approved
care

1.6.1 Medicare Population and HIV/AIDS
Medicare is an important source of health coverage for people with HIV. It is
currently the largest source of federal government healthcare spending on HIV, providing
health coverage for one quarter of all HIV patients currently under care.49
1.6.1.1 Epidemiology of HIV/AIDS among the Medicare population
In 2014, 0.4% of all Medicare beneficiaries with fee-for-service redeemed claims
for HIV/AIDS treatment.52 The prevalence of HIV/AIDS in the US has increased over
time owing to the availability of earlier diagnoses, improved therapy, and steady
incidence rate.53,54 As the number of HIV/AIDS survivors increases following
advancements in treatment, and a steady number of new infections grows, the number of
Medicare beneficiaries living with HIV/AIDS also increases. The number of Medicare
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beneficiaries with HIV rose from 42,500 in 1997 to 120,000 in 2014.49 Consequently, the
number of diagnosed and undiagnosed elderly Medicare beneficiaries has also increased
because a large segment of the HIV population has grown older and now qualifies for
Medicare.49 Approximately 21% of Medicare beneficiaries with HIV are elderly (65
years and above) and qualify for Medicare based on age only. The remaining 79%
includes younger, disabled individuals who qualify for Medicare based on disability and
are receiving SSDI payments.49 However, it has been estimated that over 50% of the
individuals with HIV will be over 50 years of age in the near future55, thus indicating an
upward trajectory in the prevalence of HIV among the elderly population.
In addition, unprotected sexual behavior still plays a huge role in HIV infection
among the elderly who are sexually active late into life.56,57 Elderly individuals are
generally perceived as a low-risk population, and consequently, providers often do not
routinely collect and record their sexual habits and activities. In the same vain, elderly
people don’t readily share their sexual habits with providers.55,58,59 Furthermore, the
physiology of the older population changes in ways that increase susceptibility to HIV
infection among those that remain sexually active. Post-menopausal women do not
worry about becoming pregnant and are more likely to have unprotected intercourse.58,60
Age related thinning and dryness of the vaginal epithelium can expose vaginal epithelial
tissues to abrasions, and consequently facilitate HIV infection.58 It has been shown that
the postmenopausal cervix may undergo immune changes, producing target cells such as
CD4+ and CCR5+ T-cells with a greater number of inflammatory factors which
facilitates HIV acquisition and replication.61,62
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Racial disparity in the prevalence of HIV/AIDS among Medicare beneficiaries
has been reported. Medicare beneficiaries with HIV are disproportionately African
American. They have the highest prevalence of infection (1.6%), followed by Hispanics
(0.8%), and Indian/Alaska Native (0.4%). Caucasians and Asian/Pacific Islanders had the
lowest prevalence of all races (0.2%).52 Other relevant demographic disparities have also
been recognized. Medicare beneficiaries with HIV are disproportionately men (74%) and
mostly dual eligible for both Medicaid and Medicare (69%).49
1.6.1.2 Health care benefits for HIV-positive Medicare beneficiaries
Medicare provides a wide range of coverage for several healthcare services such
as hospital care, medical care and physician visits, and prescription drugs. However,
under the traditional Medicare Parts A and B, beneficiaries with HIV/AIDS are not
covered for all the necessary health care services. Also, there is no OOP expenditure cap
associated with Medicare parts A and B. As a result, the Medicare Part D plan provides
much needed cost-sharing assistance specifically for Medicare beneficiaries with
conditions that involved treatment with costly medications, including those with HIV.
Part D subsidizes prescription drug costs for beneficiaries enrolled in private plans
through low income subsidy (LIS) programs with catastrophic benefits. In 2014,
approximately 77 % of Medicare beneficiaries with HIV qualified for the LIS program.
Consistent with the Center for Medicare and Medicaid (CMS) guidelines and the
Affordable Care Act (ACA) codified law which designated Anti-retroviral therapy (ART)
as one of the ‘six protected’ drug classes, Medicare Part D plans are required to cover all
ARTs including those in the coverage gaps.49 In addition to ARTs coverage, Medicare
provides risk-based coverage for preventive measures such as HIV laboratory tests and
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screening. Medicare provides coverage for once-a-year voluntary HIV tests for Medicare
beneficiaries within the age range of 15 to 65 years old and pregnant beneficiaries,
regardless of the risk of HIV infection. Beneficiaries younger than 15 and older than 65
are only covered if they are at increased risk of HIV infection.49
In addition to Medicare benefits, HIV positive beneficiaries benefit from
supplemental health coverage from Medicaid, the Ryan White HIV/AIDS Program,63
and other payers. Low income dual eligible beneficiaries benefit from Medicaid
supplemental coverage for premiums and cost sharing.49 Eligible beneficiaries may
receive payments of health coverage expenses from the Ryan White HIV/AIDS Program
and additional services, such as case management and transportation assistance.
Specifically, the Ryan White HIV/AIDS Program provides primary medical care, social
support services, as well as funding of medications for low-income HIV patients who
may be underinsured.63 The program is committed to reducing HIV transmission among
HIV positive patients living in hard-to-reach areas. This is accomplished through grant
provisions for HIV care to relevant local communities and states, medication provision,
and prevention education and aids to reduce transmission.63 More than 50 % of people
with HIV receive HIV treatment and care from the Ryan White HIV/AIDS Program,
which means that over 500,000 patients receive HIV care and services through the
program annually.63
1.6.1.3 Medicare spending on HIV
Since the beginning of the HIV epidemic, the combined global and domestic
federal expenditure for HIV has risen to $34.8 billion in the 2019 fiscal year.64 Growth in
domestic expenditure has been largely driven by Medicaid and Medicare through
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mandatory treatment policies.64 Medicare has surpassed Medicaid in funding for HIV
over the years due to the growing number of HIV patients who survive the infection
reaching the age of eligibility for Medicare. Since the introduction of Medicare Part D
which provides cost sharing assistance to Medicare beneficiaries and dual eligible with
HIV, Medicare has become the agency of the federal government with the largest source
of funding for HIV care.49 In the 2016 fiscal year, 2% of Medicare expenditures were
directed toward HIV care, which is a total of $10 billion. This represents approximately
51% of all federal spending on HIV care. In 2014, the average Medicare per capita
spending for Medicare beneficiaries was $45,489 of which 59% ($26,761) constituted
prescription drug spending through Part D Medicare plans. 49 It is worthy of note that
annual per capita Medicare spending in 2014 was significantly higher among Medicare
beneficiaries who are recipients of Low Income Subsidy (LIS) compared to those who
are not. 49
1.6.2 Medicare population and diabetes
In a study conducted by Andes et al which exclusively used Medicare data for
1999-2017 showed that the national prevalence of diabetes among Medicare fee-forservice beneficiaries rose from 23.3% in 2001 to 31.6% in 2015.65 Prevalence varies
among beneficiaries of different racial identification. African Americans, Hispanics and
Asian/Pacific Islanders have prevalence rates that are significantly higher than the
national prevalence rate, while the Caucasian Medicare beneficiaries have a prevalence
below the national prevalence rate- 29.2%.65 African-Americans have the highest
prevalence (47.4), followed by Hispanics (46.3) and Asian/Pacific Islanders (43.5)
compared to Caucasian Medicare beneficiaries. Cases of new diabetes diagnoses were
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recorded at the rate of 3.0% in 2015 across all ethnicities.65 Incidence rates vary across
race according to Andes et al, with incident rates among Hispanics being (5.2%), African
Americans (5.1 %) and Asian/Pacific Islanders (4.7 %). All of these were well above the
national incidence rate of 3.0%, whereas the Caucasian Medicare beneficiaries incidence
rate (2.8 %) was below the national rate.65 Among beneficiaries aged 68 and above, the
overall prevalence and incidence of diabetes were 31.6% and 3.0% respectively. 65
Gender disparity in national prevalence and incidence rates were also reported.
Men have a higher national prevalence rate (34.3) and incidence rate (3.5) than women.
This variation was sustained from 2001 through 2015. 65 When assessing the modifier
effect of race on prevalence rates among men and women, results showed that the
prevalence rate was higher in men among Caucasians and Asians/Pacific Islanders, and
higher in women among African Americans and Hispanics. 65
1.6.2.1

Medicare coverage and spending for T2DM
Generally, Medicare Part B and Part D provide coverage for medications and

necessary supplies needed for diabetes management. Medicare Part B covers fasting
blood glucose screening once a year and two times a year for high risk beneficiaries.
High risk beneficiaries are those with a genetic family history of diabetes and those with
other chronic conditions that are risk factors to diabetes – high blood pressure, obesity,
history of pre-diabetes (abnormal tri-glyceride levels and history of high blood sugar
levels), and abnormal cholesterol.
As described in Table 1.3, beneficiaries with diabetes are not charged for
screening if their physicians accept Medicare approved amounts but may be charged a
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20% copay for the doctor’s visit. Medicare Part B also covers supplies such as sugar
monitoring equipment, lancet devices and lancets, blood sugar test strips and solutions.
Medicare may cover external insulin pumps and insulin DME, and medical nutritional
therapy for diabetes, however, patients may pay 20% of the Medicare approved amount
after the yearly deductible as shown in Table 1.3. For beneficiaries with high risk,
Medicare Part B provides coverage for the initial 10-hour diabetes self-management
education and training, as well as a two-hour post training follow up each year. During
complications such as foot diseases, Medicare Part B provides coverage for professional
foot care every six months (so long as the beneficiary did not visit a footcare professional
for another reason) and special footwear.
Medicare Part D provides coverage for diabetes medications and supplies for
enrolled beneficiaries with diabetes. Diabetes medications covered include various
classes of antidiabetic medications such as sulfonylureas, biguanides, thiazolidinediones,
alpha glucosidase inhibitors, and injectable insulin which are not associated with insulin
infusion pumps (Medicare Part B covers insulin administered with insulin infusion
pumps as DME). Medicare Part D may also cover insulin associated supplies such as
syringes and needles, gauze and alcohol swabs. Medicare beneficiaries on Part D may
pay certain coinsurance or Part D deductibles depending on which private plan they are
enrolled in - PDP or MA-PDP.
Medicare beneficiaries with diabetes experience significant challenges and
financial burdens regarding access to care and OOP expenses.66 The increasing cost of
prescription drugs for different disease conditions, including diabetes, has been a huge
concern to policy makers. Specifically, the cost of insulin has been shown to drive up
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patient and Medicare expenditure for diabetes. Between 2007 and 2017, expenditure on
insulin alone by Medicare, private insurance plans, and patients has risen from $1.4
billion to $13.3 billion.66 This translates to an increased cost from $862 in 2007 to $3,949
per insulin user which represents about a 358 % increase.66 Considering the increased
number of Medicare beneficiaries using insulin and the increased price of insulin, the
aggregate total OOP expenditure increased from $236 million to $968 million between
2007 and 2016. This represents an 81% increase in OOP expenditure per beneficiary
between 2007 and 2016 ($324 to $588).66
1.7

HIV Infection, Treatment and Metabolic Syndrome.
Diabetes and complications of glucose metabolism are associated with HIV

infection and treatment.67 Three different kinds of patients exist based on when diabetes
or HIV were diagnosed. Some patients were diagnosed with diabetes at the onset of HIV,
some have pre-existing diabetes before HIV diagnosis, and some developed diabetes or
have signs of diabetes after the initiation of ART.68 The underlying pathogenesis of
metabolic dysregulation is different among these groups of patients.68
After HIV diagnosis, HIV patients commonly present with metabolic
dysregulation such as dyslipidemia, lipodystrophy, metabolic syndromes and
dysregulated glucose metabolism.68 In addition to HIV infection, HIV patients are
predisposed to the same risk factors for T2DM and metabolic syndrome. These risk
factors include older age, duration of HIV infection, high viral load, low CD4 count,
being a male, high waist/hip ratio, and ethnicity.69,70 Furthermore, impaired glucose
tolerance and insulin resistance are key parts of diabetes pathogenesis in patients with
HIV infection.69-73 The major contributors to metabolic syndrome in HIV/AIDS are
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iatrogenic. Anti-retroviral-related T2DM, lipodystrophy, and metabolic dysfunction
including insulin resistance have been reported to have increased among patients treated
with ARTs.74
HIV patients could have an effective viremic control but may be highly
predisposed to metabolic syndrome. This is explained by the interaction between HIV
infection, antiretroviral therapy (ART), and inflammation. Figure 1.1 shows the
interaction between HIV infection, HIV treatment with ARTs and inflammation, which
independently and collectively result in several chronic conditions such as cardiovascular
disease, dyslipidemia, insulin resistance, and lipodystrophy.75 There is existing evidence
that shows that the activation of the immune system following either HIV infection or
treatment with ART is associated with insulin resistance.75
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HIV Infection

Inflammation

Cardiovascular diseases
Dyslipidemia,
Insulin resistance
Lipodystrophy

ARTs use

Figure 1.1: Interrelationship of HIV infection, ARTs, and inflammation with metabolic
syndrome.
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1.7.1

Biology of HIV infection, ARTs, and metabolic syndrome
According to the World Health Organization’s (WHO) provisional report,

metabolic syndrome consists of a combination of metabolic dysfunctions resulting from
insulin resistance, obesity and impaired glucose regulation manifesting as impaired
glucose tolerance.76 Typically, the presence of at least five metabolic dysregulation
components such as elevated triglyceride levels and blood glucose levels, central obesity,
high blood pressure and decreased high density lipoprotein levels constitutes metabolic
syndrome diagnosis.77 The cascade of physiological processes that triggers metabolic
syndrome involves factors such as peroxisome proliferator‑activated receptor gamma
(PPAR), tumor necrotic factor‑alpha (TNF), adipose tissue, interleukins, fuel oxidation,
and insulin secretion dysfunction.78
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Metabolic Syndrome

Figure 1.2: Pathophysiology of metabolic syndrome from HIV infection, ARTs and other
factors
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1.7.1.1 Metabolic syndrome and HIV infection
HIV infection is associated with metabolic syndrome through two major
physiological pathways which include, (1) cellular apoptosis and the body’s
inflammatory response to the HIV infection which leads to insulin resistance and, (2)
Mitochondria dysfunction induced by cell apoptosis.
HIV specific inflammatory markers have been implicated in several chronic
disease conditions including T2DM.79 In addition, the body’s response to inflammation
results in the suppression of anti-diabetic functions of adiponectin, thereby impairing
tissue sensitivity to insulin leading to hyperglycemia and T2DM. 80 Cellular apoptosis
involves the binding of the HIV proteins gp120 and gp41 to the CD4/CXC chemokine
receptor 4, thereby mediating apoptosis through the fusion/hemifusion process referred to
as gp4 induced hemifusion. 80 Studies have shown that gp41 induced hemifusion derives
virion-induced apoptosis which triggers inflammatory mediators such as, TNF‑α,
interleukins and C‑reactive protein (CRP) levels, which are associated with impaired
muscle response to insulin and adiponectin suppression (an adipose-specific collagen-like
molecule with anti-diabetic activity) thereby resulting in T2DM development.81
Cytotoxic protease secreted during HIV infection causes apoptosis through
cellular proteins such as actin, Bcl2, and procaspase. 80 Activation of cytotoxic proteases
depends on cytochrome c which is exclusively domicile in the mitochondria. 80 During
activation following apoptotic signal, ions in the mitochondria are distributed
asymmetrically on both sides of the internal sections of the mitochondria membrane. 80
The mitochondrial permeability transition pore complex (PTPC) opens, resulting in the
loss of trans-mitochondrial potential and mitochondrial disruption. 80 This leads to the
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release of apoptogenic factors which includes the cytochrome c and procaspase‑9. 82 83
Mitochondrial disruption and subsequent host cell apoptosis which results from
uncontrolled release of cytochrome c triggers host inflammatory response. 82 The
inflammatory response involves the release of inflammatory mediators, such as
interleukins and C-reactive protein (CRP), at levels which suppress adiponectin 83 and
induce muscular insulin resistance 82 resulting in metabolic syndrome (Figure 1.2).
1.7.1.2 Metabolic syndrome and ARTs
The use of ART and its combination regimens has shown great clinical benefits in
HIV treatment. However, long term use has been associated with metabolic syndrome as
an adverse event. Furthermore, the use of these therapies can trigger a cascade of
activities that results in the development of dyslipidemia, lipodystrophy and
mitochondrial dysfunction. Specifically, ARTs stimulates an increased release of TNF‑α
which contributes to the impairment of fatty acid metabolism, lipid oxidation, and
suppression of lipolysis.84 This impact on lipid metabolism results in altered fat
distribution and major alterations in the lipid profile, which is characterized by an
increase in the levels of triglycerides (hypertriglyceridemia), a low‑density lipoprotein
cholesterol, and a decrease in HDL cholesterol.85 Altered glucose homeostasis has also
been reported during HIV treatment with ARTs. In vitro studies suggested a physiologic
process that involves an insulin sensitive glucose transporter that is responsible for
glucose uptake - GLUT‑4. Indinavir inhibits GLUT‑4, thereby preventing muscular and
adipocyte’s glucose uptake. 86,87 Although all member classes of PIs inhibit GLUT-4,
several studies have reported that atazanavir did not inhibit GLUT-4. 87,88 Metabolic
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syndrome develops in patients treated with ARTs through two major pathways which
may include lipodystrophy, dyslipidemia, and mitochondria dysfunction.
Lipodystrophy and dyslipidemia are the two major clinical manifestations of
metabolic syndrome. Lipodystrophy results from ART and HIV infection induced
alterations in lipid metabolism89 while dyslipidemia is characterized by
hypertriglyceridemia, hypercholesterolemia, and low levels of HDLs 90, which results
from impaired lipoprotein metabolism.91 PI related metabolic syndrome occurs due to PIinduced alteration in the expression of sterol regulatory element‑binding protein‑1 and
PPAR‑γ which are key elements required for cellular adipocytes differentiation.92 Thus,
in the process, cellular adipocytes differentiation is inhibited which leads to impairment
of lipid metabolism and consequently lipodystrophy and dyslipidemia.92 Along the line,
dyslipidemia and hyperglycemia develop as well as hypertriglyceridemia.
Hypertriglyceridemia is known to be associated with acute pancreatitis which is
characterized by beta cell function disruption and the subsequent development of
T2DM.93 Another pathway through which use of ARTs could be linked to metabolic
syndrome is mitochondrial toxicity or mitochondrial disruption which involves
polymerase-C hindrance and draining of mitochondrial deoxynucleic acid (DNA).94
Mitochondrial disruption results in insulin resistance which potentially leads to T2DM
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CHAPTER 2
LITERATURE REVIEW
First, this chapter presents the literature review of relevant peer reviewed articles
that evaluated HIV treatment with PIs and the risk of developing T2DM. Reviewed
studies were cross-sectional studies, case-control studies, cohort studies, and randomized
control trials. The characteristics of these studies are summarized in Table 2.1 and Table
2.2. Second, this chapter reviews literature regarding the disparity in race/ethnicity as
applies to the risk of developing T2DM among HIV/AIDS positive patients treated with
PIs. Third, this chapter details the review of literature regarding additional costs of
T2DM comorbidities among patients with HIV/AIDS. Finally, the study objectives,
specific aims, and hypothesis as well as significance and innovation are discussed in this
chapter.
2.1

Protease Inhibitors and Development of T2DM
The safety and tolerability of protease inhibitors (PI) has been widely investigated

and findings are largely controversial in terms of the risk of T2DM, insulin resistance and
related metabolic syndromes. Table 2.1 summarizes some characteristics of studies that
report that use of PIs is associated with the risk of T2DM. Among reviewed crosssectional studies, Barry et al studied 164 HIV patients and compared patients on PI-based
combination therapy with those on non-PI based combination therapy. They found that
patients on PI-based combinations had greater triglyceride changes than non-PI based
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combinations and their seronegative counterparts. 95 Furthermore, Behrens et al showed
that PI-based ART combinations were significantly associated with impaired glucose
tolerance. Non-combination PI-based ART and their associations with the risk of T2DM
have also been widely explored.96 Andrew Carr et al compared the occurrence of
peripheral lipodystrophy, hyperlipidemia, and insulin resistance in 116 patients receiving
protease inhibitors versus 32 HIV patients who are protease inhibitor naïve. 97 They
found that protease inhibitor therapy was associated with significantly higher triglyceride
levels.97 Maganga et al compared the risk of glucose metabolism disorder among HIV
positive ART-naïve patients and HIV positive patients on various ARTs, such as
lopinavir and ritonavir, nevirapine, efavirenz, tenofovir, stavudine, zidovudine and
seronegative patients. This finding indicates that patients on ARTs have 5-fold greater
odds of having glucose metabolism disorder compared to ART-naïve groups and
seronegative patients. 98 Samaras et al reported that HIV patients receiving protease
inhibitors were more commonly presenting with metabolic syndrome, which is associated
with a nine fold prevalence of T2DM.6
In a case-control study conducted in Taiwan, 1,534 HIV patients enrolled in a
prospective cohort study and were followed for 14 years.99 Out of the eligible 824 HIV
positive patients, only 50 patients developed diabetes. Lo et al matched two controls per
case and they found that exposure to protease inhibitors were significantly associated
with diabetes.99
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Table 2.1: Characteristics of selected studies that reported significant association between use of PIs and T2DM
Author
(Years)
Barry
(2014) 95

Behrens
(1999) 96
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Carr (1998)
97

Maganga
(2015) 98

Study title

Data source

Study
Sample
Treatment
design
size
Cross164
HAART
sectional

Outcomes

Results

HIV, Metabolic
Syndrome X,
Inflammation,
Oxidative Stress, and
Coronary Heart
Disease Risk

Miami
Veterans
Administration
Medical
Center Health
Records

Impaired glucose
tolerance, beta cell
function and lipid
metabolism in HIV
patients under
treatment with
protease inhibitors
A syndrome of
peripheral
lipodystrophy,
hyperlipidemia and
insulin resistance in
patients receiving
HIV protease
inhibitors
Glucose Metabolism
Disorders, HIV and
Antiretroviral

Laboratory
results of
participants

Cross49
sectional

Laboratory
results of
participants

Cross195
sectional

PIs

Fasting
blood
glucose

Bugando
Medical

Cross454
sectional

ART

Oral glucose HIV-infected adults
tolerance
on ART had a higher
test (OGTT) risk of diabetes (OR

Fasting
blood
glucose

Use of PI based
HAART was
associated with
greater
triglyceridemia, and
lipidemia than it was
for non-PI-exposed
HIV+ subjects,
PI based ART Oral glucose PI are use is
combinations tolerance
associated with
test (OGTT) impaired glucose
tolerance and
hyperproinsulinemia
Use of PI was
associated with
hyperlipidemia and
insulin resistance

Samaras
(2007) 6

39
Lo (2009)
99

Therapy among
Tanzanian Adults

Centre HIV
clinic

Prevalence of
metabolic syndrome
in HIV-infected
patients receiving
highly active
antiretroviral therapy
using International
Diabetes Foundation
and Adult Treatment
Panel III criteria:
associations with
insulin resistance,
disturbed body fat
compartmentalization,
elevated C-reactive
protein, and
[corrected]ccc
hypoadiponectinemia
Risk factors for
incident diabetes
mellitus among HIVinfected patients
receiving combination
antiretroviral therapy
in Taiwan: a casecontrol study

Crosssectional
lipodystrophy
case definition
cohort

Cross788
sectional

HAART

National
Taiwan
University
Hospital

Casecontrol

PIs

824

= 5.72 (2.78–11.77),
p<0.001) than HIVnegative adults.
International Metabolic syndrome
Diabetes
was more common
Federation
in those currently
definition of receiving protease
metabolic
inhibitors (P = 0.04)
syndrome

Diagnosis
diabetes

Current use of
protease inhibitors is
associated with
Incident DM (OR
2.528; 95% CI
1.186-5.389)

Capeau
(2012) 74

Ten-year diabetes
incidence in 1046
HIV-infected patients
started on a
combination
antiretroviral
treatment
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Ledergerber Factors Associated
(2007) 100
with the Incidence of
Type 2 Diabetes
Mellitus in HIVInfected Participants
in the Swiss HIV
Cohort Study
Squillace
Triglyceride/HDL
101
(2016)
ratio and its impact on
the risk of diabetes
mellitus
development during
ART
Tsiodras
Effects of protease
(2000) 102
inhibitors on
hyperglycemia,
hyperlipidemia, and

47 French
clinics

Cohort

1046
PIs
patients

Fasting
blood
glucose

The incidence of
diabetes was
associated with
short-term exposure
to indinavir (0–
1year: hazard ratio =
2.53)

Swiss HIV
Cohort Study

Cohort

8253

PIs and
NRTIs

Type 2
diabetes

PIs and was
associated with the
risk of developing
type 2 diabetes
mellitus

Icona
Foundation
study

Cohort

3546

PIs and other
ARTs

Type 2
diabetes

PI
(atazanavir/ritonavir)
is associated with
DM (1.30; CI 95 %
7.98)

outpatient and
inpatient
medical
records

Cohort

221

PI and NRTI

Type 2
diabetes

PIs were
independently
associated with
hyperglycemia
AIRR, 5.0; 95%

lipodystrophy: a 5year cohort study
Risk factors for newonset diabetes
mellitus in patients
receiving protease
inhibitor therapy

Northern
Alberta HIV
program

Justman
(2003) 104

Protease inhibitor use
and the incidence of
diabetes mellitus in a
large cohort of HIVinfected women
Diagnosis, prediction,
and natural course of
HIV-1 proteaseinhibitor-associated
lipodystrophy,
hyperlipidemia, and
diabetes mellitus: a
cohort study
Incidence of
hyperlipidemia in a
cohort of 212 HIVinfected patients
receiving a protease
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Hughes
(2005) 103

Carr
(1999)105

Calza
(2003) 106

Cohort

Type 2
diabetes

[CI], 1. 3-19.4), and
hypertriglyceridemia
AIRR, 6.1; 95% CI,
3.1-11.7)
PI is significantly
associated with
developing DM (OR
1.52, 95% CI 1.07 to
2.17; P=0.02)

496

PI

Six inner-city
Cohort
clinical sites in
the United
States

1785

PI and
Type 2
NRTI/NNRTI diabetes

Multivariate models
identified PI use
[HR] = 2.90 [95%
CI: 1.50-5.60]

St Vincent’s
Hospital

Cohort

113

PI

Type 2
diabetes

Impaired glucose
tolerance occurred in
16% of proteaseinhibitor recipients
and diabetes mellitus
in 7%

Tertiary
hospital

Cohort

212

PI

Fasting
blood
glucose

PI use show
statistically
significant increase
in serum triglyceride
levels (P<0.005)

Mulligan
(2000) 107

Tripathi
(2015) 108
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Salehian
(2005) 109

Woerle
(2003) 110

inhibitor-based
antiretroviral therapy
Hyperlipidemia and
University of
insulin resistance are
South
induced by protease
California
inhibitors independent
of changes in body
composition in
patients with HIV
infection
Incidence of diabetes
mellitus in a
population-based
cohort of HIVinfected and nonHIV-infected persons:
the impact of clinical
and therapeutic
factors over time
Prevalence and
incidence of diabetes
in HIV-infected
minority patients on
protease inhibitors
Mechanisms for the
deterioration in
glucose tolerance
associated with HIV

Cohort

29

PI

fasting
glucose;
insulin;
triglycerides

Changes in glucose
and lipid metabolism
are induced by PI
therapy

Medicaid

Cohort

6816

PI and other
ARTs

Type 2
diabetes

A significantly
higher risk of
diabetes with
cumulative exposure
to PI (adjusted
relative risk 1.35.
95% CI 1.03–1.78),

Inner-city HIV
outpatient
clinic

Cohort

101

PI

Type 2
diabetes

Pls increase the
likelihood of
diabetes developing

Infectious
Disease Clinic

RCT

27

PI

Type 2
diabetes

PI regimens impair
glucose tolerance in
patients infected
with HIV

protease inhibitor
regimens
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Among reviewed cohort studies, Capeau et al, followed 1,046 patients in France
and found that short-term exposure to indinavir is associated with increased incidence of
T2DM.74 In Ledergerber et al, 6,513 patients were followed for 6 years prospectively
and it was found that indinavir demonstrated a strong association with the risk of
T2DM.100 In a cohorts study of 221 HIV infected patients who were followed for 5 years,
Tsiodras et al show that the use of PIs is associated independently to elevated glucose
and triglyceride levels.102 In another study, Hughes et al followed a cohort of 496 HIV
patients in Canada for 6 years and found that the use of PIs was significantly associated
with the development of diabetes.103 Justman et al compared the use of PIs with RTIs in a
cohort of 1,785 non-pregnant HIV positive women who were followed for four years in
California. The study concluded that patients on PIs have a threefold increase in
incidences of diabetes compared to RTI users.104
Furthermore, when PI users were compared with PI naïve HIV patients, the result
persisted in Carr et al. who reported that hyperlipidemia and impaired glucose were
significantly common among PI users compare to PI-naïve HIV patients when followedup at the end of 2 years.105 Moreover, in a prospective cohort of 231 HIV patients that
were followed for over 3 months, Calza et al. reported that the use of PI-based cARTs
are associated with elevated serum triglycerides. Ritonavir or lopinavir/ritonavir,
specifically, were found to be predictors of an increase in serum triglyceride levels.106
The effects of PI were further examined using insulin resistance to measure
outcomes in a cohort study of 41 patients followed for 4 months by Mulligan et al and his
colleagues. They reported that in patients treated with PI therapy, insulin levels doubled.
Additionally, fasting glucose and triglyceride levels also increased significantly.107
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Moreover, in a cohort study of 235 patients, those switching from lopinavir/ritonavir to
an atazanavir based ritonavir-boosted (ATV/r) or an un-boosted regimen after an initial
48 weeks, had a significant decrease in mean glucose levels and insulin resistance.111
This study suggests that patients who have achieved initial viral suppression while on
lopinavir/ritonavir + two NRTIs can switch to atazanavir + two NRTIs to ensure recovery
and improvement in both lipid and glycemic metabolism.111 These studies further buttress
the relationship between lopinavir/ritonavir based medication and glycemic metabolic
syndrome or diabetes. Furthermore, Tripathi et al. utilized a marginal structural modeling
approach to compare incidence of diabetes in HIV patients on HAART and their matched
seronegative counterparts. They found that cumulative exposure to protease inhibitors are
significantly associated with a higher risk of diabetes.108
The association between PIs use and development of diabetes is stronger in the
presence major confounders and strong risk factors for diabetes such as Hepatitis C Virus
(HCV) infection and increasing age. In a cohort study of 1,230 HIV patients, both the
HCV infection and the use PI were independently associated with an increased risk of
diabetes. Additionally, the risk of developing diabetes was highest among PI users with
the HCV co-infection.112 In a 3 year retrospective cohort study of 101 patients Salehian et
al. found that the likelihood of developing diabetes among protease inhibitor users
increased with age and may also have a racial disparity.109
In a randomized controlled trial that examined the effect of ARTs on the risk of
developing diabetes, Woerle et al. evaluated beta-cell function, glucose production,
glucose disposal and free fatty acid turnover in 13 HIV infected volunteers exposed to a
protease inhibitor based cART as well as 14 healthy volunteers monitored over 12 weeks.
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The results showed that exposure to a protease inhibitor based cART was significantly
associated with impaired glucose tolerance.110
Conversely, several cohort studies have reported contradicting results. Table 2.2
summarizes some characteristics of studies that report contradicting results. In a
longitudinal cohort study of 1,748 HIV-infected Thai patients followed for 9 years by
Opas et al., univariate cox proportional regression showed that use of protease inhibitors
such as Lopinavir/ritonavir, Atazanavir/ritonavir and indinavir were not significantly
associated with the risk of developing T2DM.113 In an observational, prospective,
multicenter study of 1,594 HIV positive patients, Riyaten et al. reported that, based on a
multivariate cox proportional hazard model, the use of protease inhibitors such as
ritonavir, combination of nevirapine, emtricitabine combination and ritonavir-boosted
indinavir, as well as combination of zidovudine, lamivudine and ritonavir-boosted
indinavir were not associated with the risk of T2DM development in the patients.114
According to Squillace et al., lopinavir/ritonavir, fosamprenavir/ritonavir,
indinavir/ritonavir, saquinavir/ritonavir were not significantly associated with the risk of
developing T2DM in a retrospective cohort study that included 3,546 participants.101
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Table 2.2 Characteristics of studies that did not detect an association between use of PIs and T2DM
Author
(Years)
Opas
(2017) 113

Tien (2007)
115

47

Ryaten
(2015) 114

Squillace
(2016) 101

Study title

Data source

Study
design
Cohort

Sample
size
1948

Treatment

Outcomes

Results

New-onset diabetes
in HIV-treated adults:
predictors, long-term
renal and
cardiovascular
outcomes
Antiretroviral therapy
exposure and
incidence of diabetes
mellitus in the
Women's Interagency
HIV Study.
New-Onset Diabetes
and Antiretroviral
Treatments in HIVInfected Adults in
Thailand

Bangkok,
Thailand HIV
clinic

ARTs

Type 2
diabetes

PI use is not
significantly
associated with
diabetes

Women's
Interagency HIV
Study

Cohort

2088

ART

Type 2
diabetes

Exposure to PI was
associated with
diabetes incidence in
adjusted analyses

50 public
hospitals
throughout
Thailand
(NCT00433030)

Cohort

1594

PIs and
NRTIs

Type 2
diabetes

Icona Foundation Cohort
study

3546

PIs and
other
ARTs

Type 2
diabetes

ritonavir and indinavir
plus ritonavir
combination were not
significantly
associated with onset
of diabetes
PI
(atazanavir/ritonavir)
is associated with DM
(1.30; CI 95 % 7.98)

Triglyceride/HDL
ratio and its impact
on the risk of
diabetes mellitus
development during
ART

Abraham
(2015) 116

Butt (2009)
117

Black South
African
women with HIV

Cohort

103

ARTs

Type 2
diabetes

Lopinavir not
significantly
associated with
diabetes

Veterans Aging
Cohort Study

Cohort

3227

ARTs

Type 2
diabetes

PI is not a significant
predictor of diabetes
0.99 (0.94-1.04)

Metabolic changes
associated with
antiretroviral therapy
in HIV-positive
patients

City of Porto
Alegre (Southern
Brazil)

Cohort

110

HAART

Type 2
diabetes

PI regimen is not
significantly
associated with
changes in glucose
and triglyceride levels
(p=0.741
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Changes in blood
pressure, glucose
levels, insulin
secretion and
anthropometry after
long term exposure to
antiretroviral therapy
in South African
women
HIV infection and the
risk of diabetes
mellitus

Almeida
(2009) 118

49

Wand
(2007) 119

Metabolic syndrome,
cardiovascular
disease and type 2
diabetes mellitus
after initiation of
antiretroviral therapy
in HIV infection

Trial
International
Coordinating
Committee
(INITIO)

Cohort

881

ART

Fasting
blood
glucose

PI and PI regimen is
not significantly
associated with
diabetes.

Gomes
(2016) 120

Incidence of diabetes
mellitus and obesity
and the overlap of
comorbidities in
HIV+ Hispanics
initiating
antiretroviral therapy

Dominican HIV
Cohort

Cohort

153

ART

Fasting
blood
glucose

PI is not significantly
associated with risk of
impaired glucose or
diabetes

Rasmussen
(2012) 121

Risk of diabetes
mellitus in persons
with and without
HIV: a Danish
nationwide
population-based
cohort study

Danish HIV
Cohort Study

Cohort

4984

HAART

Diabetes

Atazanavir and
ritonavir is not
significantly
associated with risk of
diabetes

De Wit
(2008) 122

Spangnuolo
(2017) 123
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De Wit
(2008) 122

Incidence and Risk
Factors for NewOnset Diabetes in
HIV-Infected
Patients

Data Collection
on Adverse
Events of AntiHIV Drugs
(D.A.D)

Cohort

33,389

cART

Diabetes

exposure to ritonavir
were associated with
decreased risk of
diabetes- 0.94 (0.89–
0.99)

Associations of
statins and
antiretroviral drugs
with the onset of type
2 diabetes among
HIV-1-infected
patients

San Raffaele
Scientific
Institute (Milan,
Italy)

Cohort

6,195

ART

Type 2
diabetes

HIV patients treated
with atazanavir or
darunavir were less
likely to develop
diabetes

Incidence and Risk
Factors for NewOnset Diabetes in
HIV-Infected
Patients

Data Collection
on Adverse
Events of AntiHIV Drugs
(D.A.D)

Cohort

33,389

cART

Diabetes

exposure to ritonavir
were associated with
decreased risk of
diabetes- 0.94 (0.89–
0.99)

Spangnuolo
(2017) 123

Associations of
statins and
antiretroviral drugs
with the onset of type
2 diabetes among
HIV-1-infected
patients

San Raffaele
Scientific
Institute (Milan,
Italy)

Cohort

6,195

ART

Type 2
diabetes

HIV patients treated
with atazanavir or
darunavir were less
likely to develop
diabetes
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Furthermore, in the ‘Women’s Interagency HIV Study (WIHS), which is a multicenter
prospective cohort study, Tien et al. compared 1,524 HIV infected women who were on a
protease inhibitor based HAART to those not on a protease inhibitor based HAART, and
564 seronegative women, show that there is no significant difference in the incidence of
diabetes between the groups after a 1 year follow-up period.115
In Abraham et al., use of PI- Lopinavir was not associated with the risk of
developing T2DM.116 In Butt et al., multivariate result of the 3,327 HIV-infected and
3,240 HIV-uninfected subjects show that protease inhibitors are not a predictor of
diabetes after adjusting for other covariates.117 Almeida et al. did not detect a significant
association between the use of protease inhibitors and the risk of diabetes.118 Also, Wand
et al. compared the use of NNRTI with a combination of PI + NNRTI, and PI only in a
cohort study and reported that neither the use of PI + NNRTI, PI, or NNRTI were
significant predictors of diabetes.119 Similarly, long term exposure to protease inhibitors
was not found to be a significant predictor of diabetes in a large multicentered Data
Collection on Adverse Events of Anti-HIV Drugs (D:A:D) cohort study of 32,437
patients followed over a 6 year period.122 In patients receiving protease inhibitors
containing cART regimen, Gomes et al., found that the use of a regimen containing a
protease inhibitor is not significantly associated with the risk of impaired glucose or
diabetes.120 This result persists in Rasmussen et al., which reported that the use of
protease inhibitors such as indinavir, nelfinavir, atazanavir, ritonavir +/−lopinavir are not
significantly associated with the risk of diabetes among HIV positive patients in
Denmark.121
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Furthermore, several studies reported that use of a protease inhibitor confers a
protective effect from the risk of diabetes among patients with HIV/AIDS. In Tien et al.,
exposure to ritonavir and nevirapine were both associated with a reduced risk of
diabetes.115 Similarly, De Wit et al. concluded that exposure to ritonavir was associated
with a decreased risk of diabetes.122 Furthermore, in another cohort study of 6,195 HIV
patients, Spangnuolo et al. reported that HIV patients treated with atazanavir or
darunavir were less likely to develop diabetes.123
2.2

Race/ethnicity Disparity in PI use and Development of T2DM
Racial variation in the prevalence of HIV/AIDs is well documented in the

literature with the highest prevalence reported among African Americans. 124 Nearly half
of all HIV/AIDS incidents occur among African Americans with a prevalence rate 8
times higher than in Caucasians.124 African-Americans are also shown to have poorer
HIV infection prognoses and death rates that are 9 times higher than those of
Caucasians.125-127 Several studies suggest that this racial disparity in health indices is a
function of various factors related to demography, socio-economy, access to quality
healthcare, individual habits, as well as attitudes and level of trust in the healthcare
system.125-127
Even though access to HIV care is critical for the survival of HIV/AIDS patients,
access to ARTs and HIV treatment is not equitably distributed among HIV/AIDS patients
in the US. Gebo and his colleagues examined racial disparity in receipt of HAART in
2001and found that racial disparities do exist.5 Furthermore, Fleishman et al. concluded
that being a younger African American female is associated with lower receipt of
ART.128 Palacio and his colleagues reviewed the literature and concluded that, based on
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available evidence, HIV positive minorities have lower ART use compared to HIV
infected Caucasians.129 Despite Medicaid’s potential for equitable access to care through
equity in insurance coverage for all enrollees, there is evidence that racial/ethnic disparity
in receipt of HAART exists between both Medicaid beneficiaries enrolled in Fee-ForServices and managed care130-132.
Given evidence of racial disparity in HIV/AIDS treatment, potential disparity in
HIV/AIDS treatment outcomes and adverse events such as the risk of diabetes may exist.
An effective risk management in the clinical use of ART would require proper
consideration of how the risk of diabetes following the use of ART varies among HIV
infected patients of different ethnicities. Based on the literature review, no studies have
examined possible racial/ethnic disparity in the development of diabetes following PI
based treatment among HIV infected Medicare recipients. To fill this knowledge gap, we
therefore seek to examine the racial disparity in the development of diabetes among HIV
positive Medicare patients who are on PI.
2.3

Economic Burden of Comorbid T2DM
Improvement in the methods of HIV detection, early diagnosis, and treatment

with ARTs has resulted in improvement in patient’s survival and, consequently, a steady
growth in the population of HIV survivors. 133 Access to potent ARTs reduce morbidity
and mortality which increases the life expectancy among patients with HIV/AIDS.
Consequently, the number of elderly patients with HIV/AIDS increases proportionately.
HIV/AIDS infected patients over the age of 65 are predisposed to age-related chronic
complications in addition to treatment-related adverse events.68 Comorbidities with
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HIV/AIDS among the elderly not only constitute challenges in clinical management but
may also cause a major economic burden for patients and insurers.
HIV/AIDS and ART-associated diabetes and other metabolic syndromes are
commonly encountered in clinical management of HIV/AIDS and is most likely to occur
as treated patients grow older.6 Comorbidities with HIV/AIDS may pose significant
clinical challenges as well as an economic burden on the US Medicare system given the
increasing number of surviving elderly with HIV/AIDS- the population demographic that
is most predisposed to diabetes and other age related chronic conditions.7 Studies show
that 83% of elderly HIV patients had at least one comorbidity compared to 69% in
elderly non-HIV patients and 63% in younger HIV patients.134 A longitudinal study of
Medicare beneficiaries reports that the prevalence of diabetes in elderly patients with
HIV is 19.4% and 27.3% (hyperlipidemia).135 In Taiwan, the prevalence of diabetes
among men and women 60 years old and above are 21% and 16.7% respectively.136
Economic burden due to diabetes comorbidity among HIV/AIDS patients has
been reported. Among HIV positive Medicare beneficiaries enrolled in California
Medicare, the mean per capital expenditure for HIV/AIDS patients with complicated and
uncomplicated diabetes is as high as $92,992 and $66,275 respectively per annum.7
Although, the prevalence and expenditure of diabetes comorbidity in California is
known, the current national economic burden of diabetes comorbidities among HIV
positive Medicare beneficiaries is not known. As clinical management of HIV/AIDS is
progressively expanding to include chronic and metabolic complications as well as
treatment-related adverse effects, this study seeks to specifically explore the national
economic burden of diabetes comorbidity in terms of total OOP cost to the patients, total
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prescription cost, total Medicare cost, total inpatient cost, total outpatient cost and overall
total healthcare costs. Understanding the economic burden of diabetes comorbidity on the
Medicare system and individual patients could motivate the development of policy and
regulatory strategies that drive efficient resource allocation to contain the additional
economic burden on patients and the Medicare system.
2.4

Literature Gaps
Based on the review of literature, the following literature gaps were identified and

have informed the objectives of this study.
 Evidence of an association between PIs use and the development of T2DM
has been largely debated in research across the world. Given the available
inconclusive and controversial evidence, more research is needed to support
or refute currently available evidence in order to draw conclusions.
 To date, no study has explored this association among Medicare beneficiaries.
Thus, evidence of PIs use and the odds of developing diabetes among the
Medicare population with HIV/AIDS is unknown.
 To date, no study has examined possible racial/ethnic disparity in the
development of diabetes following treatment with PI among HIV infected
Medicare beneficiaries.
 To date, no study has evaluated the national economic burden of comorbid
diabetes among Medicare beneficiaries living with HIV/AIDS.
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2.5

Study Objectives and Specific Aims
The objectives of this project were to (1) examine the association between

treatment with PIs and the risk of developing T2DM among Medicare beneficiaries living
with HIV/AIDS, (2) assess racial/ethnic disparity in odds of developing T2DM among
HIV/AIDS positive beneficiaries treated with PI and (3) to determine the economic
burden of comorbid T2DM among Medicare beneficiaries living with HIV/AIDS
2.5.1 Aim 1: Treatment with PI and development of T2DM
Aim 1: To assess the association between treatment with PIs and development of
T2DM among Medicare beneficiaries with HIV/AIDS.
Use of PI has been associated with the risk of metabolic syndrome which includes
development of T2DM among patients with HIV/AIDS. While this evidence is currently
being debated globally, evidence among the Medicare population is yet to be reported.
We, therefore, hypothesize an increased odds of developing T2DM among Medicare
HIV/AIDS positive beneficiaries treated with PIs compare to those treated with non-PIs
and those who had no-ARTs.
Hypothesis 1.1: We hypothesize that HIV/AIDS positive Medicare beneficiaries
treated with PIs are more likely to develop T2DM compared to HIV/AIDS
positive beneficiaries treated with non-PIs.
Hypothesis 1.2: We hypothesize that HIV/AIDS positive Medicare beneficiaries
treated with PIs are more likely to develop T2DM compared to HIV/AIDS
positive beneficiaries who had no-ARTs.
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2.5.2

Aim 2: Racial disparity in development of T2DM following treatment with PI

Aim 2: To examine racial/ethnic disparities in development of T2DM following
treatment with PIs among Medicare beneficiaries with HIV/AIDS.
Racial disparity in the epidemiology of HIV infection and treatment have been reported.
As a result, racial disparity in development of T2DM following treatment with PIs may
exists. We, therefore, hypothesized that the odds of developing T2DM following PI use
may vary among Caucasian and African American HIV/AIDS positive Medicare
beneficiaries.
Hypothesis 2.1: Comparing PIs versus non-PIs therapy group, we hypothesize that
the odds of developing T2DM following treatment with PIs is higher among
African American race compared to the odds of developing T2DM after treatment
with PI among the Caucasian beneficiaries.
Hypothesis 2.2: Comparing PIs versus no-ART therapy group, we hypothesize
that the odds of developing T2DM after treatment with PIs is higher among the
African American race compared to the odds of developing diabetes after
treatment with PI use among the Caucasian beneficiaries.
2.5.3 Aim 3: Economic burden of comorbid T2DM in beneficiaries with HIV/AIDS
Aim 3.1: To assess the incremental healthcare cost associated with comorbid T2DM
among beneficiaries with HIV/AIDS
Although the economic burden of diabetes comorbidity in California Medicare is known,
the current national economic burden of comorbid T2DM among HIV/AIDS positive
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Medicare beneficiaries is unknown. We, therefore, hypothesize that total medical cost,
total prescription cost, hospitalization cost, outpatient cost, total Medicare and OOP cost
will increase for Medicare beneficiaries with comorbid T2DM compare to those without
comorbid T2DM.
Hypothesis 3.1: In HIV/AIDS positive Medicare beneficiaries with comorbid
T2DM, total medical costs are higher compared to HIV/AIDS positive
beneficiaries without comorbid T2DM
Hypothesis 3.2: In HIV/AIDS positive Medicare beneficiaries with comorbid
T2DM, total Medicare expenditures are higher compared to HIV/AIDS positive
beneficiaries without T2DM
Hypothesis 3.3: In HIV/AIDS positive Medicare beneficiaries with comorbid
T2DM, total cost of hospitalization is higher compared to HIV/AIDS positive
beneficiaries without comorbid T2DM
Hypothesis 3.4: In HIV/AIDS positive Medicare beneficiaries with comorbid
T2DM, total outpatient cost is higher compared to HIV/AIDS positive
beneficiaries without comorbid T2DM
Hypothesis 3.5: In HIV/AIDS positive Medicare beneficiaries with comorbid
T2DM, total OOP cost is higher compared to HIV/AIDS positive beneficiaries
without comorbid T2DM.

59

CHAPTER 3
CONCEPTUAL FRAMEWORK
This chapter presents the conceptual framework based on Andersen’s behavioral
model of health services, which was used to emphasize contextual and individual
determinants of access to care. This chapter also presents discussions on how the
Andersen’s model is adapted in this study to conceptualize the relationships between
treatment with PIs and T2DM, racial/ethnic variation in risk and the economic burden of
diabetes among individuals with HIV/AIDS.
3.1

Andersen’s Behavioral Model
Andersen’s behavioral model of health service utilization was first developed in

the late 1960’s and has undergone several modifications over the years.137 This model is
based on contextual and individual determinants of access to healthcare. Contextual
determinants consist of the environment and circumstances impacting on health care
access. Contextual determinants are aggregate level determinants ranging from small
units (family, work group) to large units (country, community) unlike the individual
determinants. The model suggests that each of the contextual and individual determinants
constitute three major components of determinants which include: (1) predisposing
factors that impacts health care access, (2) enabling factors that can facilitate or prevent
the use of available health care and, (3) healthcare needs and other related conditions that
inform healthcare use. 137
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3.1.1 Individual characteristics domain
Predisposing characteristics at the individual level include age, gender, weight,
height and genetic factors which may predict health care needs and predisposition to
certain healthcare conditions which could motivate health care needs.138 Common
chronic disease conditions such as T2DM cardiovascular diseases, age-related macular
degeneration, depression, and cancer are not only age related and linked to family history
but also has multifactorial and polygenetic etiology.139 Social factors consist of factors
related to an individual’s status in the community and his/her ability to cope with
immediate challenges and financial demands to addressing these challenges. These
factors may include individual’s education level, race and ethnicity as well as occupation.
Social factors may also include units of a society such as the family and friends as well as
religious and social organizations that helps by improving societal cohesion and the
social support needed to improve access to health care services.140 Furthermore, culture
and belief systems could impact the individual’s perception of illness and treatment
approaches.141 Belief systems may greatly impact their perception of needs for health
care as well as use of health care services.141
Enabling factors to accessing health care ranges from having the resources to pay
for healthcare services, presence of affordable health insurance in terms of effective
prices for services, low cost sharing amount and deductibles. Social support from social
organizations, religious organizations and social networks could be considered enabling
factors from the perspective of emotional support, informational and affectionate support,
and in some cases, financial support to obtain healthcare services.142 The need for health
care, in general, is a function of both the patient’s perceived healthcare needs and
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evaluated health care needs, which are based on objective, professional medical
judgment. Professional judgment stems from the state of the art and sciences of medical
practice, clinical guidelines and protocols, practice patterns, training, and competency of
professional experts.140 These constitute individual characteristics factors as shown in
Figure 3.1.
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Figure 3.1: The Andersen’s behavioral model
Source: Andersen RM, Davidson PL, Baumeister SE. Improving access to care in America. Changing the US health care system:
key issues in health services policy and management 3a edición San Francisco: Jossey-Bass. 2007:3-31.

3.1.2

Contextual characteristics domain
Collective individual demographic characteristics such as being elderly, married,

female or male defines context characteristics and explains the way in which these
characteristics may influence the availability of certain health care services when
compared to a setting with a younger, single population.140 Social support at this level
constitutes community or county-based support because it is available in the community
where people live. This kind of support may have an impact on the local population’s
health and access to care. Additional context predisposing characteristics may include
spatial segregation and distribution of race and ethnicity within certain populations,
educated versus uneducated people groups, employment rate and crime rates within a
community.143 Common and diverse belief systems, culture, political ideologies and
prevailing organizational values underpin the organization of healthcare, as well as how it
is financed and made available to the community members.140
The major enabling factors in the context of characteristics or population-based
factors that impact access to care consist largely of governmental (legislative, executive
or judicial) public health policies designed to enable aggregate access to health care for the
community or for a relevant community sub-group.140 The Affordable Care Act (ACA)
represents a good example of a legislative public health policy which impacts access to
care from the local to the national level. Other policies may include private and internal
organizational policies that may enable access to aggregate care. Some may include
managed care organization policies concerning product pricing, marketing or product lines
and quality assessment policies from the National Committee for Quality Assurance
(NCQA).140 From the perspective of contextual enabling factors, financial policies, in
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addition to health policies ,represent available resources to pay for health care. Those
policies also consider the communities’ per capita income and wealth and incentives for
payment of health care services. In addition they consider provider’s methods of
compensation that would sustain a reasonable cost of health care and health insurance
coverage in the community.140 Availability and distribution of health facilities,
providers/personnel ratio to patients, physician and hospital bed ratios and the way in
which the facilities are structured for healthcare delivery represents organizational enabling
factors that impact on access to care in the community.
Need characteristics in the context perspective constitutes the environment where
people live and how it predicts their perceived or evaluated health needs. The model
suggests that physical environment, such as quality of housing, water, and air, could
suggest how healthy the environment might be and the prevailing health needs.140 Death
and injury rates as well as environmental causative factors could also suggest the
community health status and aggregate health care needs.140 High mortality or morbidity
rates may be linked to specific environmental factor such as road accidents, disease
epidemics, infant mortality and a high prevalence of chronic conditions. These individual
and context characteristics typically influence health behavior and the prevailing health
outcomes.
3.1.3

Health behaviors
Health behaviors are those health-related activities and habits that individuals

exhibit towards their health care. They may include healthy living such as diet and
nutrition, exercise, alcohol and drug abuse, health consciousness and adherence to
medical advice and medication use or non-compliance. Good health behavior is a
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function of how well the provider interacts with a patient during the care process.
According to Donabedian, the process of medical care constitutes an effective interaction
between the provider and the patient that would lead to the patient exhibiting essential
behavior and habits that will benefit their health. This includes adherence to care,
compliance with medications, and dieting.144 A quality care process could be determined
by measures such as patient and physician communication, provider counselling and
education, prescription patterns, ordering of necessary diagnostic tests, and relevant vital
signs examinations. Personal health service use is an essential component of healthy
behavior. Based on the model, the contextual predisposition, enabling, and need factors
occurring through the individual characteristics predicts health services use.140 The use of
health services may occur as inpatient care, outpatient care, dental care or ambulatory.
The type of care is determined by predisposing factors such as age, gender, genetic
dispositions, enabling factors such as availability of facilities, insurance and financial
resources to afford care and finally the perceived and evaluated healthcare need such as
pain, diagnosis and laboratory results. For instance, a patients perceived need for dental
care may result from a tooth ache, pain, bleeding gums, social conditions, health beliefs,
and/or enabling resources.140 The severity of condition of the patient’s health based on
evaluated need would predict more intensive care at the inpatient level rather than less
intensive care at the outpatient level.
The Andersen’s behavioral model suggest that contextual characteristics can
influence health behaviors and outcomes in multiple ways through individual
characteristics.140
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For instance, the Medicaid expansion policy leads to increased insurance rates for lowincome children and members of society, thereby resulting in increased health services
use.
3.1.4

Outcomes
Patients’ health behavior, personal health services, individual characteristics, and

global context environment influence their health outcome or perceived health status.
Based on this model, the purpose of personal healthcare use is to reduce the perceived or
evaluated health care needs which is measured as health status improvement from the
patient’s perspective and the physician’s evaluated perspective.140 A patient’s perceived
health outcomes may include lack of pain after treatment, improvement in daily
functionality, and improved general well-being. Comparatively, evaluated health status
includes laboratory test results and analysis of biomarkers of disease prognosis. The
patient’s perceived outcomes can also be measured as their satisfaction of the health care
services, they received, which could be measured in terms of a patient’s rating of the
provider on patient communication, waiting time, hospitalization days, and frequency of
re-admissions. Whether or a not a patient switches care plans could also be used as a
measure for satisfaction from the health insurance perspectives.145
With the increasing need and interest in patient-centered care, Patient Reported
Outcomes (PRO) is increasingly being used to measure overall treatment benefits from
the perspective of the patient. Typically, PROs are used for the purpose of documenting
patient experiences with treatment in terms of side effects, the improvement of
symptoms, and quality of life.146 Thus, incorporating quality of life in the Andersen’s
behavioral model would better explain a patient’s perceived reduction in quality of life
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related to their healthcare needs.140 Quality of life measures is one of the seven constructs
used in patient reported outcome instruments (PRO) and it is the most frequently used of
the PRO measurement constructs. Several PRO tools are constructs such as Functional
Assessment of Cancer Therapy—Breas (FACT-B), European Organization for Research
and Treatment of Cancer Quality of Life Questionnaire—Core 30, EuroQol 5Dimensions and EORTC QLQ—Breast Cancer Module.146
3.2

Adapted Model
This model is applied in this dissertation to explain the association between use of

PIs and the odds of developing T2DM among HIV positive Medicare beneficiaries
continuously enrolled in Medicare Part A, Part B and Part D, to explain racial variations
in the development of T2DM, and additional costs of healthcare use due to comorbid
T2DM . Figure 3.2 represents the conceptual framework adapted from Andersen’s
behavioral model for this dissertation. The adapted model consists of the individual and
contextual characteristics and outcomes.
Environmental or regional factors are important predisposing factors to certain
disease conditions which predict regional healthcare use and health outcomes. For
instance, regional disparity in the prevalence of T2DM can be seen in that it is
disproportionately distributed in the Southern regions of the US, also referred to as the
‘diabetes belt’.147 Regional disparities in T2DM prevalence is a function of
disproportionate distribution of risk factors of T2DM, infrastructures and facilities that
enable a healthy life-style.147 A recent study suggested that community-level correlates of
T2DM prevalence were significantly different between the ‘diabetes belt’ and other US
regions.148
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The Medicare Prescription Drug, Improvement, and Modernization Act of 2003
which established the Medicare Part D prescription drug program on January 1, 2006
represents context based enabling factors through the Low-Income Subsidy (LIS)
program, which is offered to Medicare beneficiaries. With this legislative Act,
beneficiaries can access expensive HIV/AIDS medication through Medicare Part D and
additional cost sharing assistance for those eligible for LIS.
Individual predisposing characteristics include demographic factors such as age
and gender which are known to be associated with health care use. Race/ethnicity is a
relevant social factor because of its association with T2DM and HIV/AIDS, and thus
predicts access to care and health outcomes for individuals with these conditions. The
epidemiology of T2DM and HIV/AIDS varies across race/ethnicity among Medicare
beneficiaries.12,65 Individual enabling factors is constituted of their enrollment in
Medicare Part A and Part B insurance plans and dual eligibility in both Medicare and
Medicaid which impacts health care use. Another individual enabling factors for health
care access include enrollment in both Medicare and Medicaid, otherwise known as dual
eligibility. Dual eligible beneficiaries receive extended and more comprehensive
coverage with cost sharing assistance since Medicaid covers services which Medicare
does not cover and vice versa. Also, Medicaid provides supplemental coverage that helps
to cover premiums and cost sharing for low-income dual beneficiaries.49 Individual need
for healthcare is constituted of the patient’s perceived symptoms and evaluated need for
HIV/AIDS and diabetes treatment based on diagnostic tests and clinical assessment.
In the adapted model, Medicare beneficiaries diagnosed of HIV/AIDS or diabetes
are either hospitalized or treated on an outpatient basis and receives medication through
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Medicare Part D. The health behavior domain also includes study outcomes, which in this
dissertation is the diagnosis of diabetes following treatment with PIs as an adverse drug
event. This dissertation aims to determine the odds of developing T2DM among
HIV/AIDS patients treated with PIs compare to those treated with other medications.
Based on the physiological process of HIV treatment and the risk of diabetes, use of PIs
is associated with T2DM through impact on insulin sensitivity, resulting in insulin
resistance, and consequently T2DM. Secondary outcomes in the adapted models include
race/ethnicity variation in the development of T2DM and a measure of additional cost of
care due to T2DM comorbidities among beneficiaries with HIV/AIDS. The presence of
diabetes among HIV/AIDS positive Medicare beneficiaries may constitute additional
healthcare utilization and a corresponding incremental economic burden to Medicare,
patients, and the entire US healthcare system.
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Figure 3.2: Adapted Andersen’s Behavioral Model

CHAPTER 4
RESEARCH METHOD
This section discussed various aspects of research methodology including data
sources, the study design, the study population, definition of case and control groups,
variables, and statistical analysis.
4.1

Data Source
A random sample of national Medicare administrative claims data from the years

2013 to 2017 was used to analyze Medicare population with HIV/AIDS. Medicare is the
US federal health insurance program established in 1965 to provide healthcare coverage
for Americans aged 65 years or older, regardless of income level or medical history.50
Medicare coverage was expanded in 1972 to provide coverage for individuals under 65
years of age with long-term disability and who receive Social Security or Railroad
Retirement Board benefits, and individuals with End Stage Renal Disease.50,149 Currently,
Medicare provides health coverage to 60 million people who are disabled or elderly. This
coverages provides basic health services such as inpatient care, physician visits,
prescription drugs, preventive services, skilled nursing facilities, home health care, and
hospice care.50 Approximately 84 % of beneficiaries are eligible for Medicare benefits
because of age, while 16 % are younger beneficiaries who receive benefits because of
disabilities such as end-stage renal failure.12
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Medicare health insurance constitutes Part A (hospital insurance), Part B (medical
insurance), Part C (Medicare Advantage) and Part D coverage types. Parts A, B, and D
are available through traditional Medicare Fee-For-Service (FFS) plans. Part A insurance
type is a plan that provides coverage for care received in inpatient settings, SNF,
hospices, or home health care settings. Part B, also known as medical insurance, covers
physician services such as injections, procedures, diagnostic tests, other outpatient care,
DMEs, preventive services, and some home health care regardless of whether care was
received in an inpatient or outpatient setting. Almost all Medicare beneficiaries are
enrolled in either of Part A, Part B, or both.150 In 2006, Medicare offered Part D,
prescription drug coverage, to eligible beneficiaries. Beneficiaries enrolled in the Part D
plan receive benefits that help pay for outpatient prescription drug costs, which is
essential for low income patients with especially expensive drug costs.50 Plan D coverage
is voluntary and occurs through contractual arrangements between Medicare and private
plans such as PDPs and MA-PDs.50 The Part D plan also provides additional financial
benefits for enrollees with low incomes and modest assets. In 2018, 25% of the over 43
million Medicare beneficiaries who were enrolled in either a PDP or MA-PD received a
low-income subside.50
Typically, Medicare data include enrollment information of each beneficiary,
including information such as enrollment eligibility, demographic characteristics and
claims information. This information captures nearly all aspect of healthcare services
throughout all levels of healthcare.151. For services provided to Medicare beneficiaries,
physicians and other healthcare providers submit claims to the Center for Medicare and
Medicaid Services (CMS). The CMS then review and process the claims for
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reimbursement to the healthcare providers. From the reviewed claims, the CMS generates
Standard Analytical Files (SAF) annually. Typically, the SAF contains final researchers
encrypted claims for Parts A and B services and Part D prescription drugs for services
received in the hospital, physician offices, hospice, and SNFs through December 31 of
the latest available calendar year.149 SAF also contains beneficiary’s enrollment and
demographic information such as gender, age and race/ethnicity as well as provider
characteristics such as the provider’s unique number, the physician’s clinical specialty,
the national physician number and geographic information for facilities.149 This study
uses a national random sample of 1 million Medicare beneficiaries. It is suitable for this
study because it covers nearly all health care utilizations for each eligible beneficiary
across all levels of healthcare services provision. Specifically, it is rich in information
such as demographic data, claims and costs, clinical and diagnosis information,
prescription drug use and costs, all payments sources, along with mortality and discharge
information.
4.2

Study Design
In study aim 1 and 2, we performed a nested case-control study of Medicare

beneficiaries living with HIV/AIDS to analyze the association between treatment with PI
and development of T2DM. (Figure 4.1.) In study aim 3, a pooled cross-sectional study
design was used to analyze the economic burden of comorbid T2DM among beneficiaries
diagnosed with HIV/AIDS for a pooled period of 2013 - 2017. The study protocol was
approved by the University of South Carolina Institutional Review Board (IRB) as
exempt from human subject protection review since it is an observational study with
administrative claims.
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Figure 4.1: Study design sketch for study aim 1 and 2

4.3

Study Population
In study aims1 and 2, we identified beneficiaries with diagnosis of HIV/AIDS

based on the International Classification of Diseases, 9th Revision, Clinical Modification
(ICD-9-CM) code for HIV/AIDS (042-044, 079.53, V08)152 and/or International
Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) code for
HIV/AIDS (B20.xx, Z21)153 between 2013 to 2017. Six months washout period starting
from January 1 to July 1, 2013 was applied to determine new T2DM diagnosis. (Figure
4.1.) The cohort entry date was set as the date after the washout period (July 1, 2013).
The study included only beneficiaries that were continuously enrolled in Medicare Part A
and B plans throughout the analytical time frame to ensure complete diagnosis
information and medical records. Medicare beneficiaries enrolled in HMOs were also
excluded.
In study aim 3, the study sample includes Medicare beneficiaries who have been
diagnosed with HIV/AIDS based on the ICD-9-CM code for HIV/AIDS (042-044,
079.53, V08)152 and/or ICD-10-CM code (B20.xx, Z21).153 To ensure a complete
diagnosis and medical records, only beneficiaries that were continuously enrolled in
Medicare Part A and B throughout the analytical time frame were included. Medicare
beneficiaries enrolled in HMOs were excluded. The study excluded Medicare
beneficiaries with End Stage Renal Disease (ESRD) because healthcare expenditure for
beneficiaries with disabilities such as ESRD is more than twice as much for people with
persistent or chronic disabilities than for those with temporary or no disability.154
Excluding these patients would help prevent extreme or outlying cost observations and its
possible impact on regression estimate.
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4.4

Case and Control Groups
In study aim 1 and 2, we identified cases as HIV/AIDS positive beneficiaries with

diagnosis of T2DM based on the ICD-9-CM code (250.xx) or ICD-10-CM code
(E11.xxx).155 The first diagnosis of T2DM was set as the index date. Control group
included HIV/AIDS positive beneficiaries who had no record of a T2DM diagnosis.
(Figure 4.1.)
4.5

Measurements

4.5.1 Dependent and independent variables
Medication exposure variable for this study were classified into (1) PI treatment
defined as cumulative treatment with PIs (≥ 60-day supply), (2) non-PI treatment defined
as cumulative treatment with PIs (≤ 60-day supply); and or treatment with other ARTs;
and; (3) no-ART treatment defined as beneficiaries with no ART prescriptions.
Measurement of PI use in this study is a modified form of measurement approach used in
Tripathi et al 108 (Table 4.1). Tripathi et al calculated exposure to ART based on 30-day
exposure while in this study, we calculated PI use based on a 60-day cumulative use.
Treatments were based on the most recent prescription date preceding the index date or
December 31, 2017 whichever came first. Drug use information was extracted from the
prescription drug event file component of the Medicare data using the generic name
variable. Two therapy comparison groups were created from the medication exposure
variables as follows: (1) cumulative treatment with PI (≥ 60 days) versus cumulative
treatment (≤ 60-day) and or treatment with other ARTs and (2) cumulative treatment with
PI (≥ 60 days) versus no treatment with ART. The outcome of interest for study aims 1
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and 2 was the diagnosis of T2DM determined based on ICD-9-CM code (250.xx) or ICD10-CM code (E11.xxx).155 T2DM diagnosis variable was categorized into two level
binary variables- T2DM= 1 for positive diagnoses and T2DM=0 for negative T2DM
diagnoses.
In study aim 3, the main predictor variable was comorbid T2DM assessed based
on ICD-9-CM code (250.xx) or ICD-10-CM code (E11.xx)155. The predictor variable
was categorized into two level binary variable- T2DM= 1 for positive diagnoses and
T2DM=0 for negative T2DM diagnoses. The outcomes measures in study aim 3 were six
relevant measures of economic burden such as the costs of health care services received(1) total hospitalization cost, (2) total outpatient cost, (3) total prescription costs, (4) total
Medicare costs, (5) total OOP and (6) total medical costs. The Assessment of the
economic burden based on these costs ensures availability of evidence of economic
burden across all facets of health care service types -inpatient, outpatient and OOP.
The Medicare inpatient and outpatient analytical file consist of cost variables
which include: ‘claim payment amount’, ‘claim pass thru per diem amount’, ‘claim
utilization day count’, ‘NCH beneficiary inpatient deductible amount’, ‘NCH beneficiary
part a coinsurance liability amount’, ‘NCH beneficiary blood deductible liability amount’
and ‘NCH primary payer claim paid amount’.156 Total Medicare cost was calculated by
summing up the ‘claim payment amount’ and the product of the ‘claim pass thru per diem
amount variable’ and the ‘claim utilization day count variable’ in the inpatient and
outpatient files and calculating average annual Medicare cost per patient.156 Total OOP
cost was calculated by summing up the NCH beneficiary inpatient deductible amount
variable, NCH beneficiary Part A coinsurance liability amount variable, and the NCH
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beneficiary blood deductible liability amount variable from both the inpatient and
outpatient files and calculating average annual OOP per patient.156 Total inpatient costs
were calculated by summing up the total Medicare inpatient payments + OOP inpatient
costs + NCH primary payer claim paid amount in the inpatient file and calculating
average annual inpatient cost per patient. Total outpatient cost was calculated by
summing up the total Medicare outpatient costs + OOP outpatient costs + NCH primary
payer claim paid amount in the outpatient file and calculating average annual cost per
patient.156 Total prescription drug costs were determined using the gross drug cost
variable- ‘TOT_RX_CST_AMT’. Total medial costs were calculated by summing the
total OOP costs, total Medicare payments, and the total prescription cost and calculating
average annual medical cost per patient.
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Table 4.1: List of peer reviewed studies and measurement approach for ART exposure
Author
(Years)
Rasmussen
(2012) 121

Neto
(2013)157

Tripathi
(2015)108

Garcíabenayas
(2006)158

Study Title

Study Design

Risk of diabetes mellitus
in persons with and
without HIV: a Danish
nationwide populationbased cohort study

Cohort Study

Dyslipidemia and fasting
glucose impairment
among HIV patients
three years after the first
antiretroviral regimen in
a Brazilian AIDS
outpatient clinic

Retrospective
Cohort Study

Incidence of diabetes
mellitus in a population‐
based cohort of HIV‐
infected and non‐HIV‐
infected persons: the
impact of clinical and
therapeutic factors over
time
Higher Risk of
Hyperglycemia in HIVInfected Patients Treated
with Didanosine Plus
Tenofovir

Retrospective
Cohort Study

Retrospective
Cohort Study

ART Measurement
Approach
Patient initiated on a
specific ART regimen
was considered exposed
to such regimen for the
rest of the observation
period independent of
cessation or changes in
antiretroviral therapy.
Only patients on their
first ART regimen were
studied. In case of
change or
discontinuation of initial
ART regimen, ART
regimen used for at least
70% of the study period
was considered.
Exposure to
combination ARTs was
based on 30-day
cumulative use.

Exposure to ART was
based on unmodified
use of any ART regimen
for a period of 12
month.

Estimating the economic burden based on health expenditures over the years
requires an adjustment for inflation to dollars of equivalent purchasing power because
costs incurred this year for instance is not the same as the costs incurred over the previous
years for the same items or services received. Prices for health care changes annually and
faster than overall price inflation. Thus, selecting indexes that are specific for medical
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expenditures and also account for changes in healthcare prices is paramount for correctly
estimating health care expenditure.159
Consequently, the Personal Health Care Index (PHC) and the Personal
Consumption Expenditure Health Indexes (PCE) are recommended over the medical
component of the consumer price index (CPI-M) and the GDP price index for medical
care by the Medical Expenditure Panel Survey (MEPS).160 While the PHC and the PCE
indexes are more appropriate for estimating personal health care expenses than both the
GDP price index and the CPI-M, CPI-M is the most appropriate for pooling OOP.
Conversely, the GDP price index is the least appropriate in medical expenditure
research.160 This is due to the fact that the GDP price index includes expenditures from
medical and public health research which are not useful in health care services utilization
and cost estimation.160 The PHC index was constructed based on the components of the
CPI-M and Producer Price Index (PPI) by the CMS office of the Actuary, and the PCE
was constructed from the CPI and PPI by the Bureau of Economic Analysis (BEA).160
In this study, PHC was used to adjust for inflation to 2017 dollar for inpatient and
outpatient costs while CPI-M was used for OOP costs. (Table 4.2) The following
equation represents the formula used to obtain the 2017 U.S. dollar values.
2017 Dollar Value = 2013 Dollar Value x 1.052 (Corresponding inflation factors)
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Table 4.2 CPI-M and inflation factor of medical care services from 2013 to 2017
Inpatient
Year

PHC- Hospital

Outpatient

2013

102.2

Inflation
Factor
(2017/x
years)
1.052

2014

103.5

1.039

100.6

0.995

435.3

1.092

2015

104.5

1.029

99.5

1.006

446.8

1.064

2016

105.7

1.017

99.7

1.004

463.7

1.025

2017

107.5

1.000

100.1

1.000

475.3

1.00

Care

PHCPhysician/Clinical
services

OOP

100.1

Inflation
Factor
(2017/x
years)
1.000

CPI-

425.1

Inflation
Factor
(2017/x
years)
1.118

M
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Source: Using Appropriate Price Indices for Analyses of Health Care Expenditures or Income Across
Multiple Years. Medical Expenditure Panel Survey: Agency for Healthcare Research and Quality.
https://meps.ahrq.gov/about_meps/Price_Index.shtml

4.5.2 Potential confounders
Based on the conceptual framework as adapted from the Andersen’s behavioral model
of health services utilization, potential confounding factors included were predisposing
characteristics, enabling factors and healthcare needs. Specifically, covariates included in the
multivariate regressions were predisposing characteristics (age, gender and race), enabling
factors (regions, dual eligibility status) healthcare needs (Charlson Comorbidity Index (CCI),
and Chronic Hepatitis C and B virus infections (HCV & HBV). Covariates were measured
from Medicare beneficiary summary files and claims. This study used CCI as a measure of
comorbidities which is widely used to measure the number of chronic disease comorbidities.
It is calculated based on ICD-9-CM or ICD-10-CM codes identified in the Medicare database.
Diabetes and HIV/AIDS were excluded from the CCI calculation. HBV/HCV was determined
using HBV infection specific ICD-9-CM codes 0702, 07020, 07021, 07022, 07023, 07030,
07031, 07032, 07033,VO261161 or ICD-10-CM codes: B181, B1910, B189 162 and HCV
infection specific ICD-9-CM codes: 07054, 07044, 07070, 0707, 07071,07041, VO262,
07051161 or ICD-10-CM codes: B182, B1920 and B189.163
4.6

Propensity Score Matching
Differences in subject’s baseline demographic and clinical characteristics may have

influenced assignment into therapy groups, and this consequently may impact the result of
this study. To minimize these differences in characteristics and selection biases, PS matching
was performed for each of the therapy group pairs (1) PI use versus non-PI use and (2) PI use
versus no-ART.164 The PS matching approach generates a pseudo-randomized population
where beneficiaries are similar in terms of their baseline characteristics and differ only by
their therapy group.
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Patient-specific propensity scores were estimated by fitting a logistics regression
model predicting the odds of being prescribed PIs instead of (1) non-PIs and (2) no-ARTs,
including covariates such as age, gender, sex, race, HCV/HBV, regions and dual eligibility.
PS-matched study sample was created by matching on the propensity scores based on a 1:1
greedy matching algorithm. CCI characteristics were excluded in the PS matching to enable
matching of at least 40% of the complete sample. Using 0.3 cut-off, units were matched only
if the difference in the logits of the propensity scores for pairs of units from the two groups is
less than or equal to 0.3 times the pooled estimate of the standard deviation. Residual
unmatched beneficiaries were excluded. Balance and comparability of baseline characteristics
across therapy groups were evaluated using chi-square test. P-value greater than 0.05 was
considered a good balance in baseline characteristics. This study leveraged a case-control
study with a PS matching methodology employed by Nussbaum et al. 165 In their study, they
used PS matching approach to generate matched therapy groups- preoperative radiotherapy
versus no radiotherapy and (2) postoperative therapy versus no radiotherapy and compared
overall patient’s survival between the matched groups.165
4.7

Statistical Analysis
In study aims 1 and 2, we describe baseline characteristics of unmatched and PS

matched eligible beneficiaries using chi-square test to compare covariate’s balance between
both therapy group pairs. Unadjusted logistic regression was performed to determine crude
associations between PI use and the odds of developing T2DM for each therapy group pair,
and unadjusted association within race sub-groups. In study aim 3, baseline covariates were
compared between history of T2DM status using chi-square for categorical covariates.
Independent two-group tests were performed to compare different costs between beneficiaries
with a history of T2DM while unadjusted GLM analysis was performed to determine
unadjusted impact of patients with a previous history of T2DM on different healthcare costs.
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Multivariate logistic regressions were performed to determine the odds of developing T2DM
and racial variations in the odds of developing T2DM. A multivariate Generalized Linear
Model (GLM) was performed to determine the impact of comorbid T2DM on different health
care costs. All data analysis was carried out using SAS version 9.4 (SAS Institute, Cary, NC).
4.7.1 Bivariate analysis
Therapy group pairs (PI versus non-PIs and PI versus no-ART) in both matched and
complete datasets were compared using chi-square to determine balance across covariates
(age, gender and race, regions, dual eligibility status, HBV & HCV and CCI). For continuous
variables such as cost domains, an independent two-group t-test was used to determine mean
cost differences between beneficiaries with T2DM compare to those without T2DM.
Unadjusted regression was performed to determine the association between treatment with PI
and the odds of developing T2DM, racial variation in odds of developing T2DM and the
effect of comorbid T2DM on different healthcare costs.
Unadjusted logistics regression was performed for each therapy group pair as in
Formula 4.1 to determine unadjusted odds of developing T2DM.
In (odds that Y=1) = â0 + â1 (Therapy group) + μi

 Y is a dummy variable indicator for T2DM diagnosis
▪

0: Negative T2DM diagnosis

▪

1: Positive T2DM diagnosis

 Therapy groups
▪

PI versus non-PI pair
▪

0: Non-PI

▪

1: Pi
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(Formula 4.1)

▪

PI versus no-ART
▪

0: No-ART

▪

1: PI

In Formula 4.1, ‘â1’ was the coefficient for the predictor of interest. The odds ratio comparing
the odds of developing T2DM between therapy groups pair was measured as ‘exp(â1)’.
Unadjusted logistics regression was performed for each therapy group pairs to
determine odds of developing T2DM using Caucasian and African American sub-groups as in
Formula 4.2
In (odds that Y=1) = â0 + â1 (Therapy group [race-subgroup]) + μi

(Formula 4.2)

 Y is a dummy variable indicator for T2DM diagnosis
▪

0: Negative T2DM diagnosis

▪

1: Positive T2DM diagnosis

 Therapy groups
▪

▪

PI versus non-PI pair
▪

0: Non-PI

▪

1: Pi

PI versus no-ART
▪

0: No-ART

▪

1: PI

In both race sub-group bivariate logistic regression model, ‘â1’ represents the coefficient of
predictor of interest. The odds ratio comparing the odds of developing T2DM with respect to
the compared therapy group pairs within Caucasian or African American subgroups was
measured as ‘exp(â1)’.
Unadjusted GLM regression was performed in Formula 4.3 to determine unadjusted
impact of history of T2DM on different health care costs: (1) total Medicare costs, (2) total
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prescription costs, (3) total OOP , (4) total healthcare costs, (5) total hospitalization cost and
(6) total outpatient cost.

Log (E (Y)) = â0 + â1 (Comorbid T2DM) + μi

(Formula 4.3)

 Y is a continuous variable representing each of the cost domains: Total cost of
hospitalization, total outpatient costs, total Medicare costs, total prescription drug
costs, total OOP and total healthcare costs.
 Comorbid T2DM is dummy variable indicating comorbid T2DM
▪

0: No diabetes diagnosis

▪

1: Diabetes diagnosis

In each bivariate GLM regression, ‘â1’ represents the coefficient of predictor of interest
which is the estimate of percentage changes in cost between group with comorbid T2DM and
group without comorbid T2DM measured as ‘[exp(â1-1) *100].

4.7.2 Multivariate analysis
4.6.3.1 Aim 1: Treatment with PIs and odds of developing T2DM
After generating two PS matched data sets for - (1) PI versus non-PI and (2) PI versus
no-ART, multivariate logistic regression was performed as in Formula 4.4 to determine the
odds of developing T2DM for each comparison pairs.
In (odds that Y=1) = â0 + â1 (Therapy group) + â2 (Predisposing characteristics) + â3
(Enabling factors) + â4 (Healthcare need) + μi
 Y is a dummy variable indicator for T2DM diagnosis
▪

0: Negative T2DM diagnosis

▪

1: Positive T2DM diagnosis

 Therapy groups
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(Formula 4.4)

▪

▪

PI versus non-PI pair
▪

0: Non-PI

▪

1: Pi

PI versus no-ART
▪

0: No-ART

▪

1: PI

 Predisposing characteristics includes various demographic variables
▪

Age group: 1: 18-34 (Reference), 2: 35-44, 3: 45-54, 4: 55-64 and 5: > 64

▪

Gender: 1: Male, and 2: Female (Reference)

▪

Race: 1: Caucasian (Reference), 2: African Americans and 3: Others

 Enabling factors includes region and residence where Medicare beneficiaries leave
▪

Dual Eligibility Status: 0: No and 1: Yes

▪

Regions: 1: West, 2: South, 3: Midwest and 4: Northeast

 Healthcare needs: This includes clinical characteristics variables
▪

Charlson Comorbidity Index (CCI): ≤ 1, 2 and 3+

▪

Hepatitis C & B virus infection (HCV& HBV): positive HCV or HBV
diagnosis=1 and negative HCV and HBV diagnosis=0.

In Formula 4.4, ‘â1’ was the coefficient for the predictor of interest. The odds ratio comparing
the odds of developing T2DM between therapy groups pairs was measured as ‘exp(â1)’.
4.6.2.2 Aim 2: Racial disparity in odds of developing T2DM following treatment with PIs
Using the PS matched data sets for - (1) PI versus non-PI comparison and (2) PI
versus no-ART therapy, an analysis of Caucasian and African American race sub-groups was
performed using multivariate logistic regression model to assess variations in the odds of
developing T2DM for both therapy pairs within Caucasian and African American subgroups.
In Formula 4.5, a multivariate race sub-group analysis did not include race variables since
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race sub-groups were being assessed. A multivariate logistic model for each therapy group
pair (in Formula 4.5) was performed separately for Caucasian and African American subgroups.
In (odds that Y=1) = â0 + â1 (Therapy group [race sub-group]) + â2 (Predisposing
characteristics) + â3 (Enabling factors) + â4 (Healthcare need) + μi

(Formula 4.5)

 Y is a dummy variable indicator for diabetes diagnosis
▪

0: Negative T2DM diagnosis

▪

1: Positive T2DM diagnosis

 Therapy groups
▪

▪

PI versus non-PIs therapy group pair
▪

0: Non-PI

▪

1: PI

PI versus no-ART therapy group pair
▪

0: No-ART

▪

1: PI

 Predisposing characteristics includes various demographic variables
▪

Age group: 1: 18-34 (Reference), 2: 35-44, 3: 45-54, 4: 55-64 and 5: > 64

▪

Gender: 1: Male, and 2: Female (Reference)

 Enabling factors includes region and residence where Medicare beneficiaries leave
▪

Regions: 1: West, 2: South, 3: Midwest and 4: Northeast

▪

Dual Eligibility Status: 0: No and 1: Yes

 Healthcare needs: This includes clinical characteristics variables
▪

Charlson Comorbidity Index (CCI): ≤ 1, 2 and 3+

▪

Hepatitis C & B virus infection (HCV & HBV): positive HCV or HBV
diagnosis=1 and negative HCV and HBV diagnosis=0.
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In each of the race sub-group multivariate regression, ‘â1’ represents the coefficient of
the predictor of interest. The odds ratio comparing the odds of developing T2DM between the
compared therapy group pairs within Caucasian or African American subgroups was
measured as ‘exp(â1)’.
4.6.2.3 Aim 3: Effects of comorbid T2DM on healthcare costs
In aim 3, GLM with log link and gamma distribution was used to assess the economic
burden of comorbid T2DM. Cost and utilization data are often skewed, gamma distributed,
and violates independent observation assumption. These characteristics violate Ordinary Least
Squares regression (OLS)-normality and homoscedasticity assumptions given that it is often
right-hand skewed with significant heteroskedasticity.166,167 The independent observation
assumption is commonly violated by cost data, given that multiple individuals using the same
healthcare services may incur similar total health care costs.
Gamma GLM is suitable for modeling positively skewed data, non-negative data
with variances not proportional to the square of the means and of which there are certain
forms of heteroscedasticity.168 In addition, it has been demonstrated in Amal Saki et al.
that gamma GLM is a good model for estimating the population mean of healthcare cost
data.169 Although, non-normally distributed data could be normalized using
transformations, the back transformation to the original scale may generate a biased
estimate if the error term has inconsistent variance which is often the case with count
data.170 Even if back transformation is considered a valid approach, interpretation of
results is often a concern because estimates of a transformed scale cannot generate
inference to healthcare mean cost.171 Given the above concerns, GLM modeling is the
most appropriate model to use in cost estimation because it directly models costs in its
original scale, corrects possible skewed distribution of cost data, and generates estimates
that can be inferred to healthcare costs.
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To use a gamma GLM for this study, the decision on what link and distribution
would be used in analysis of cost data is made based on statistical tests. Box-Cox
procedure was performed to generate possible links that could be used for the GLM
modeling as shown in Table 4.3 below.172 To determine the distribution, the modified
Park test procedure on raw-scaled residuals was used to select the distribution family to be
used based on the relationship between variance and mean as shown in Table 4.4
below.172 At lambda = 0, the mean and variance relationship are orthogonal, thus Gaussian
distributional assumption is considered. At lambda =1, mean and variance relationship are
proportional, thus Poisson-like distribution assumption is considered. At lambda = 2,
mean and variance relationship is quadratic and thus Gamma distributional assumption is
considered. At lambda = 3, the mean and variance relationship are cubic thus, inverse
Gaussian distributional assumption is considered.172 Based on the modified Park test
performed, gamma distribution was considered for the cost analysis using GLM in this
study.
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Table 4.3: Link options for GLM modeling
Lambda

Links

-1

Inverse

0

Logarithm

0.5

Square Root

1

Linear

2

Square
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Table 4.4: Distribution options for GLM modeling
Lambda

Mean & variance relationship

Distribution

0

Orthogonal

Gaussian NLLS

1

Proportional

Poisson

2

Quadratic

Gamma

3

Cubic

Inverse Gaussian

The GLM in Formula 4.6 was used to determine the economic burden of comorbid
T2DM among HIV/AIDS positive Medicare beneficiaries. This was repeated for each of
the six cost domains: (1) total Medicare costs, (2) total prescription costs, (3) total OOP,
(4) total medical costs, (5) total hospitalization cost and (6) total outpatient cost.
Log (E (Y)) = â0 + â1 (comorbid T2DM) + â2 (Predisposing characteristics) + â3 (Enabling
factors) + â4 (Healthcare need) + â5 (Therapy group) + μi
(Formula 4.6)
 Y is a continuous variable representing each of the cost domains: Total cost of
hospitalization, total outpatient costs, total Medicare costs, total prescription drug
costs, total OOP and total healthcare costs.
 Comorbid T2DM is dummy variable indicating comorbid T2DM
▪

0: No diabetes diagnosis

▪

1: Diabetes diagnosis

 Therapy groups
▪

PI versus non-PIs therapy group pair
▪

0: Non-PI

▪

1: PI
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 Predisposing characteristics includes various demographic variables
▪

Age group: 1: 18-35 (Reference), 2: 35-44, 3: 45-54, 4: 55-64 and 5: > 64

▪

Gender: 1: Male, and 2: Female (Reference)

▪

Race: 1: Caucasian (Reference), 2: African Americans and 3: Others

 Enabling factors includes region and residence where Medicare beneficiaries leave
▪

Regions: 1: West, 2: South, 3: Midwest and 4: Northeast

▪

Dual Eligibility Status: 0: No and 1: Yes

 Healthcare needs: This includes clinical characteristics variables
▪

Charlson Comorbidity Index (CCI): ≤ 1, 2 and 3+

▪

Hepatitis C & B virus infection (HCV & HBV): positive HCV or HBV
diagnosis=1 and negative HCV and HBV diagnosis=0.

In each multivariate GML regression, ‘â1’ represents the coefficient of a predictor of interest,
which is the estimate of percentage changes in cost between groups with a comorbid T2DM
and groups without a comorbid T2DM measured as ‘exp(â1-1) *100’.
4.8

Sensitivity Analysis
We performed sensitivity analysis to evaluate the robustness of the results in aim 1

and 2 to possible analytical perturbations resulting from the matching approach used.
Specifically, PS matching approach includes only the matched subjects in the final matched
dataset and exclude unmatched subjects, which could impact the main results. To evaluate the
sensitivity of these exclusions on the main results, logistic regressions were re-fitted using the
inverse probability-of-treatment weighting (IPTW) (instead of matching) which is a type of
PS analytical methods that uses the full sample in the analysis.
IPTW uses PSs to form weights and create a pseudo-population in which the baseline
characteristics and assignment to PI treatment are independent of each other (mimicking the
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randomization setting). The term pseudo-population assumes that the weighted group could
have been generated from a population in which there was no confounding.173 IPTW is
performed by estimating each individual’s probability (PS) to be assigned to their respective
treatment groups (either PI or non-PI) based on observed characteristics, and then generate
weight by the inverse of this estimated PS. Beneficiaries treated with PIs are assigned a
weight of a 1/p(Z=1|X), and beneficiaries treated with the control (non-Pi or no-ART) are
assigned a weight of 1/(1-p(Z=1|X), where Z is a binary treatment indicator (PI-status) and X
is a vector of observed baseline characteristics.173 The generated weight were stabilized to
avoid extreme weights which may results in an analysis that is dependent on a few individuals
with extreme weights.173
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CHAPTER 5
RESULTS
The results of this dissertation are shown in three major sections in this chapter.
The first section includes the sample selection flow chart (used for study aim 1 and 2), the
descriptive and multivariate results for study aim 1. Section two contains the descriptive
and multivariate results of aim 2. Section three includes the sample selection flow chart,
descriptive and multivariate results.
5. 1 Treatment with PI and Development of T2DM
Figure 5.1 describes the flow chart of the sample selections, baseline demographic
and clinical characteristics of Medicare beneficiaries with HIV/AIDS. It also presents the
multivariate results of PI use on the odds of developing T2DM.
5.1.1 Flow chart for sample selection for aim 1 and 2
Using 2013 to 2017 Medicare data with 1 million Medicare beneficiaries, we
generated study aims 1 and 2 samples in three main segments as shown in figure 5.1. First,
we identified 2,627 beneficiaries with diagnosis of HIV/AIDS from the Medicare
outpatient and inpatient files. Second, we identified 182,007 beneficiaries with diagnosis
of T2DM from the Medicare outpatient and inpatient file. Exactly 66,388 beneficiaries
with diagnosis during the washout period (Jan 1 to July 1, 2013) were excluded, resulting
in a total of 115,619 beneficiaries with T2DM. We excluded a total of 115,100
beneficiaries who had no record of HIV/AIDS diagnosis, to obtain a sample of 2,627
HIV/AIDS beneficiaries, which were either diagnosed with T2DM (case) or not (control).
Third, a total of 183 beneficiaries were excluded if (1), they were enrolled in an HMO
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plan or (2), if they were not continuously enrolled in Part A and B plan resulting in 2,444
beneficiaries with HIV/AIDS. After excluding 91 beneficiaries diagnosed of T2DM
before treatment with PIs, a total of 2,353 HIV/AIDS positive beneficiaries were selected
in the final sample. The final sample consists of 342 HIV/AIDS positive beneficiaries
with diagnosis of T2DM (case) and 2,011 HIV/AIDS positive beneficiaries without a
diagnosis of T2DM (control).
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Inpatient & outpatient files:
diagnosis of T2DM:
N=182,007

Inpatient and Outpatient file:
Diagnosis of HIV/AIDS
N=2,627

No record of
HIV/AIDS
diagnosis
-115,100

Beneficiaries with
HIV/AIDS Case and control
N=2,627

Exclude if:

Exclude if:
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Beneficiaries with HIV/AIDS
Case and control
N=2,444
Exclude
if:

Case: N=342

Exclude
if:
T2DM diag.:
N=115,619

 Enrolled in HMO plan
 Not continuously enrolled in
Part A and B

-183

Final Sample: N=2,353

-66,388

T2DM diagnosis before
use of PIs
-91

Control: N=2,011

Figure 5.1 Sample selection flow chart for study aims 1 & 2

Diagnosed
during the
washout
period: Jan 1 July 31, 2013

5.1.2 Baseline characteristics of matched and unmatched samples
5.1.2.1 PI versus non-PIs
Table 5.1 below shows a comparison of baseline demographic and clinical
characteristics of beneficiaries between PI and non-PI therapy groups for both matched and
unmatched selected beneficiaries. In the complete sample, beneficiaries treated with PIs
significantly differ from beneficiaries treated with non-PIs in terms of age groups (65+ years:
21.2 % vs. 28.5 %; p=0.001), race category (Caucasians: 42.1 % vs. 49.5 %; p=0.007), CCI (
3+: 34.1 % vs. 28.9 %; p=0.036) and dual eligibility status (p=0.0548). However, both groups
are similar in terms of gender (female: 24.8 % vs. 27.0 %; p=0.284), census region (Midwest:
15.9 % vs. 18.7 %; p=0.100) and HBV/HCV status (Positive: 27 % vs. 25.9%; p=0.598).
A total of 484 beneficiaries per group where matched after 1:1 greedy PS matching,
based on age, gender, race, region, HBV/HCV, and dual eligibility characteristics. Beneficiary
characteristics included in the PS matching were balanced between both PI and non-PI
therapy groups- age group (65+ years: 28.3 % vs. 28.3%, p=1.000), gender (female: 22.9 %
vs. 22.9 %,p=1.000), race category (Caucasians: 49.0 % vs. 49.0 %; p=1.000), census region
(Midwest: 16.1% vs. 16.1 %; p=1.000), HBV/HCV (positive: 7.4 % vs. 7.4 %; p=1.000) and
dual eligibility (yes: 62.6 % vs. 62.6 %; p=1.000). CCI factors were not included in the
matching. Beneficiaries treated with PIs significantly vary from those treated with non-PIs in
terms CCI (3+: 32.2% vs. 22.3 %; p= <.0001
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Table 5.1. Baseline characteristics of beneficiaries treated with PIs vs. non-PIs: Complete and matched sample
PI versus non-PI comparison
Complete Dataset
PIs
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Age Group
18 - 44 (Ref.)
45 - 54
55 - 64
65+
Gender
Male
Female
Race
Caucasian
African America
Other Race
Census Region
Midwest
Northeast
South
West
Hepatitis B & C Virus
Negative
Positive

(n=1005)

Matched Dataset

Non-PI
(n=766 )

N

%

N

%

152
331
309
213

15.1
32.9
30.8
21.2

103
204
241
218

13.5
26.6
31.5
28.5

756
249

75.2
24.8

559
207

73.0
27.0

423
494
88

42.1
49.2
8.8

379
334
53

49.5
43.6
6.9

160
217
467
161

15.9
21.6
46.5
16.0

143
189
326
108

18.7
24.7
42.6
14.1

734
271

73.0
27.0

568
198

74.2
25.9

PIs
(n=484)
P-Values

Non-PIs
(n=484 )

N

%

N

%

87
109
150
138

18.4
22.5
30.9
28.3

87
109
150
138

18.4
22.5
30.9
28.3

373
111

77.1
22.9

373
111

77.1
22.9

0.007

237
218
29

49.0
45.0
6.0

237
218
29

49.0
45.0
6.0

1.000

0.100

78
93
225
88

16.1
19.2
46.5
18.2

78
93
225
88

16.1
19.2
46.5
18.2

1.000

448
36

92.6
7.4

448
36

92.6
7.4

0.001

0.284

0.598

P-Values

1.000

1.000

1.000

Charleson Comorbidity Index
≤1 (Ref.)
2
3+
Dual Eligibility Status
No
Yes

358
304
343

35.6
30.3
34.1

311
234
221

40.6
30.6
28.9

197
808

19.6
80.4

179
587

23.4
76.6

PI: Protease Inhibitors, ART: Anti-Retroviral Therapy

0.036

0.0548

186
142
156

38.4
29.3
32.2

251
125
108

51.9
25.8
22.3

181
303

37.4
62.6

181
303

37.4
62.6

<.0001

1.000

101

5.1.2.2 PI versus no-ART
Table 5.2 compares beneficiary’s baseline demographics and clinical characteristics between
the group treated with PIs and those not treated with ART for both matched and unmatched
selected beneficiaries. For the unmatched sample, some of the clinical and demographic
characteristics of beneficiaries in the PI therapy group are different from beneficiaries in the
no-ART therapy group -age groups (65+ years: 21.2 % vs. 38.1 %; p=<0.0001), gender
(female: 24.8 % vs. 29.7 %; p=0.032), race category (Caucasians: 42.1 % vs. 54.5 %;
p=<.0001), CCI ( 3+: 34.1 % vs. 23.2 %; p=<.0001) and dual eligibility status (Yes: 80.4 %
vs. 52.2 %; p=<.0001). However, both groups are similar in terms of beneficiaries’ census
region (Midwest: 15.9 % vs. 15.8 %; p=0.629) and HBV & HCV status (Positive: 22.7 % vs.
22.7%; p=0.998). A total of 496 beneficiaries per group where matched after 1:1 greedy PS
matching, based on age, gender, race, region, HBV/HCV, and dual eligibility characteristics.
For the PS matched sample, beneficiary characteristics included in the PS matching were
balanced between both PI and no-ART therapy group pairs - age group (65+ years: 27.8 % vs.
27.8 %, p=1.000), gender (female: 24.1 % vs. 24.1 %,p=1.000), race category (Caucasians:
42.7 % vs. 42.7 %; p=1.000), census region (Midwest: 16.9% vs. 16.9 %; p=1.000), HBV &
HCV (positive: 6.7 % vs. 6.7 %; p=1.000) and dual eligibility (yes: 64.9 % vs. 64.9 %;
p=1.000). Beneficiaries in the PI therapy group significantly vary from those in no-ART
therapy group in terms CCI (3+: 33.7 % vs. 22.9 %; p= <.0001) which was not included in the
PS match
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Table 5.2 Baseline characteristics of beneficiaries treated with PIs vs. No-ART therapy groups: Complete and matched sample
PI versus No-ART Naive comparison
Complete Dataset
PIs
(n=1005)
N
%
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Age Group
18 - 44 (Ref.)
45 - 54
55 - 64
65+
Gender
Male
Female
Race
Caucasian
African America
Other Race
Census Region
Midwest
Northeast
South
West
Hepatitis B & C Virus
Negative

No-ART
(n=582 )
N
%

152
331
309
213

15.1
32.9
30.8
21.2

89
109
162
222

15.3
18.7
27.8
38.1

756
249

75.2
24.8

409
173

70.3
29.7

423
494
88

42.1
49.2
8.8

317
226
39

54.5
38.8
6.7

160
217
467
161

15.9
21.6
46.7
16.0

91
126
251
105

15.9
22.0
43.8
18.3

777

77.3

450

77.3

Matched Dataset

P-Values

PIs
(n=490)
N
%

No-ART
(n=490 )
N
%

P-Values

87
114
153
136

17.8
23.3
31.2
27.8

87
114
153
136

17.8
23.3
31.2
27.8

372
118

75.9
24.1

372
118

75.9
24.1

<.0001

209
245
36

42.7
50.0
7.4

209
245
36

42.7
50.0
7.4

1.000

0.629

83
96
217
94

16.9
19.6
44.3
19.2

83
96
217
94

16.9
19.6
44.3
19.2

1.000

457

93.3

457

93.3

<.0001

0.032

0.998

1.000

1.000

1.000

228
22.7
Positive
Charleson Comorbidity Index
358
35.6
≤1 (Ref.)
304
30.3
2
343
34.1
3+
Dual Eligibility Status
197
19.6
No
808
80.4
Yes
PI: Protease Inhibitors, ART: Anti-Retroviral Therapy

132

22.7

33

6.7

33

6.7

295.0
152.0
135.0

50.7
26.1
23.2

177
148
165

36.1
30.2
33.7

248
130
112

50.6
26.5
22.9

278
304

47.8
52.2

172
318

35.1
64.9

172
318

35.1
64.9

<.0001

<.0001

<.0001

1.000
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5.1.3 Distribution of PI class prescription
Figure 5.1 below shows the distribution of PI prescription by sub-class for the full
sample. Among selected beneficiaries who were treated with PIs, ritonavir was the most
frequently prescribed PI (n=388) followed by darunavir (n=236), atazanavir (n=170) and
lopinavir/ritonavir combination (n=151). Fosamprenavir calcium and nelfinavir mesylate
have similar PI prescription distributions- (n=30) and (n=21) respectively. Indinavir
sulfate, tipranavir and saquinavir mesylate were the least prescribed PI sub-class with
frequencies-n=2, 3 and 4 respectively.
Figure 5.2 below shows the distribution of PI prescriptions by sub-class in the
matched sample. After matching, the distribution of PI prescriptions was consistent with
the distribution in the full sample. Ritonavir was the most frequently prescribed PI
(n=184) followed by darunavir (n=112), atazanavir (n=81) and lopinavir/ritonavir
combination (n=73). While fosamprenavir calcium and nelfinavir have similar
prescription distribution -n=18 and12 respectively, tipranavir, indinavir sulfate and
saquinavir mesylate were the least prescribed PI sub-class with frequencies-n=1, 2 and 3,
respectively.
Figure 5.2 below shows the distribution of PI prescription by sub-class for the full
sample. Among selected beneficiaries who were treated with PIs, ritonavir was the most
frequently prescribed PI (n=388) followed by darunavir (n=236), atazanavir (n=170) and
lopinavir/ritonavir combination (n=151). Fosamprenavir calcium and nelfinavir mesylate
have similar PI prescription distributions- (n=30) and (n=21) respectively. Indinavir
sulfate, tipranavir and saquinavir mesylate were the least prescribed PI sub-class with
frequencies-n=2, 3 and 4 respectively. Figure 5.3 below shows the distribution of PI
prescriptions by sub-class in the matched sample. After matching, the distribution of PI
prescriptions was consistent with the distribution in the full sample.
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Ritonavir was the most frequently prescribed PI (n=184) followed by darunavir (n=112),
atazanavir (n=81) and lopinavir/ritonavir combination (n=73). While fosamprenavir
calcium and nelfinavir have similar prescription distribution -n=18 and12 respectively,
tipranavir, indinavir sulfate and saquinavir mesylate were the least prescribed PI sub-class
with frequencies-n=1, 2 and 3 respectively.
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Figure: 5.2 Distribution of PI prescription class: Unmatched sample (PI: n=1005)
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Figure: 5.3 Distribution of PI class prescription: Matched sample (PI: n=484)
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5.1.4 Unadjusted logistic regression analysis
Table 5.3 presents the results of unadjusted logistic regression comparing the odds of
developing T2DM between PI versus non-PI therapy groups and PIs versus no-ART therapy
group. Bivariate analysis shows that the odds of developing T2DM was 2.06 times higher in
beneficiaries treated with PIs than beneficiaries treated with non-PIs (OR:2.06; 95% CI: 1.393.06). In the PI versus no-ART therapy pair, unadjusted results show that the odds of
developing T2DM was 2.13 times higher in beneficiaries treated with PIs compared to those
not treated with ART (OR:2.13; 95% CI: 1.45-3.14).
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Table 5.3 Unadjusted association between PI and development of T2DM

OR

95 % CI

P-Value

Medication Exposure
Non-PIs (Ref)
PIs
2.06
1.39
3.06
0.0003
Medication Exposure
ART Naive (Ref)
PIs
2.13
1.45
3.14
0.0001
PI: Protease Inhibitors, OR: Odds ratio, T2DM: Types II diabetes Mellitus,
ART: Anti-Retroviral Therapy, CI: Confidence Interval
5.1.5 Adjusted logistic regression analysis
5.1.5.1 PIs versus non-PIs
In the adjusted logistic regression analysis, we controlled for potential
confounding factors at the baseline. (Table 5.4) We found that the odds of
developing T2DM between beneficiaries treated with PIs and those treated with
non-PIs was still significant after adjusting for potential confounders.
Compared to beneficiaries treated with non-PIs, those treated with PIs were 76
% more likely to develop T2DM after adjusting for covariates (OR=1.76; 95%
CI: 1.17-2.64). Only, CCI of 3+ were statistically significantly associated with
the development of T2DM. Compared to beneficiaries with comorbidity of ≤ 1,
those with a comorbidity of 3 or more were 2.93 times more likely to develop
T2DM after adjusting for covariates.
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Table 5.4 Adjusted logistic regression analysis of factors associated
with development of T2DM: PIs versus non-PIs therapy group
Medication Exposure
Non-PIs (Ref)
PIs
Age Group
18 - 44 (Ref.)
45 - 54
55 - 64
65+
Gender
Female (Ref)
Male
Race
Caucasian (Ref)
African America
Other Race
Census Region
Midwest (Ref)
Northeast
South
West
Hepatitis B & C Virus
Negative (Ref)
Positive
Charleson Comorbidity Index
≤1 (Ref)
2
3+
Dual Eligibility Status
No (Ref)
Yes

AOR

95 % CI

P-Value

1.76

1.17 2.64

0.0066

1.20
1.00
1.31

0.64 2.27
0.54 1.85
0.70 2.46

0.6889
0.4946
0.3646

0.98

0.63 1.54

0.9313

1.35
1.84

0.87 2.09
0.88 3.82

0.9811
0.1966

1.04
0.88
0.90

0.54 2.00
0.46 1.67
0.51 1.60

0.6676
0.6700
0.7382

1.57

0.82 3.00

0.1741

1.81
2.93

1.08 3.05
1.79 4.82

0.7948
0.0002

1.64

1.03 2.61

0.0370

PIs:Protease Inhibitors, AOR: Adjusted Odds ratio, T2DM:
Types II diabetes Mellitus, CI: Confidence Interval
5.1.5.2 PIs versus no-ARTs
In the adjusted logistic regression analysis, we controlled for potential confounding
factors at the baseline. (Table 5.5) We found that treatment with PIs was still significantly
associated with higher odds of developing T2DM compared to beneficiaries not treated with
ARTs, after adjusting for covariate. Compared to beneficiaries in the no-ARTs therapy group,
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those treated with PIs were 87 % more likely to develop T2DM after adjusting for covariates
(OR=1.87; 95% CI: 1.25-2.81). Covariates statistically significantly associated were CCI of
3+ and dual eligibility status. Compared to beneficiaries with comorbidity of ≤ 1, those with
comorbidity of 3 or more were 3.58 times more likely to develop T2DM after adjusting for
covariates (OR=3.58; 95% CI: 2.22-5.76). After adjusting for covariates, beneficiaries who
are eligible to Medicare and Medicaid were 1.55 times more likely to develop T2DM compare
to beneficiaries who are not dual eligible.
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Table 5.5 Adjusted logistic regression analysis of factors associated with development of
T2DM: PIs versus no-ARTs
AOR

95 % CI

P-Value

Medication Exposure
No-ART (Ref)
1.87
1.25
2.81
0.0025
PIs
Age Group
18 - 44 (Ref.)
1.00
0.54
1.85
0.6697
45 - 54
0.79
0.42
1.49
0.3241
55 - 64
0.95
0.50
1.84
0.8894
65+
Gender
Female (Ref)
0.91
0.59
1.41
0.6766
Male
Race
Caucasian (Ref)
1.64
1.08
2.50
0.5663
African America
2.02
0.92
4.46
0.2363
Other Race
Census Region
Midwest (Ref)
1.23
0.60
2.49
0.7696
Northeast
1.14
0.57
2.25
0.9351
South
1.27
0.70
2.31
0.5259
West
Hepatitis B & C Virus
Negative (Ref)
0.91
0.47
1.77
0.7786
Positive
Charleson Comorbidity Index
≤1 (Ref.)
1.60
0.95
2.71
0.4623
2
3.58
2.22
5.76
<.0001
3+
Dual Eligibility Status
No (Ref)
1.55
0.99
2.43
0.0565
Yes
PI: Protease Inhibitors, AOR: Adjusted Odds ratio, T2DM: Types II diabetes Mellitus,
ART: Anti-Retroviral Therapy, CI: Confidence Interval
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5. 2

Racial Disparity In Development of T2DM Following Treatment With PI
Table 5.6 presents the description of matched samples of African American and

Caucasian Medicare beneficiaries with HIV/AIDS across each comparison group, the
unadjusted race-subgroup logistic regression of treatment with PIs and development of
T2DM, and the multivariate race-subgroup logistic regression of treatment with PIs and
development of T2DM for each comparison group.
5.2.1 Descriptive Analysis
Tables 5.6 ad 5.7 shows chi-square test results comparing baseline characteristics
of matched sample of African Americans and Caucasians for balance across PIs versus
non-PIs and PIs versus no-ARTs therapy groups.
5.2.1.1 PIs versus non-PIs
Matched sample of African American sub-groups consists of a total of 218
beneficiaries per group which are similar in terms of their clinical and demographic
characteristics - age group (65+ years: 31.7 % vs. 31.7 %, p=1.000), gender (female: 33 % vs.
33 %,p=1.000), census region (Midwest: 14.7% vs. 14.7 %; p=1.000), HBV & HCV
(positive: 23.4 % vs. 23.4 %; p=1.000) and dual eligibility (Yes: 68.8 % vs. 68.8 %; p=1.000).
(Table 5.6) CCI characteristics were not included in the propensity matching process thus,
beneficiaries in the PIs therapy group were significantly different from beneficiaries in the
non-PIs therapy group in terms of CCI characteristics. CCI (3+: 41.3 % vs. 26.2 %; p= 0.001).
Within the Caucasian sub-group, a total of 237 Caucasian beneficiaries per therapy
group were matched. (Table 5.6) Matched groups are similar in terms of their clinical and
demographic characteristics - age group (65+ years: 35.5 vs. 35.5 %, p=1.000), gender
(female: 14.4 % vs. 14.4 %,p=1.000), census region (Midwest: 18.6 % vs. 18.6 %; p=1.000),
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HBV & HCV (positive: 7.2 % vs. 7.2 %; p=1.000) and dual eligibility (yes: 56.1 % vs. 56.1
%; p=1.000). Beneficiaries in the PIs therapy group were significantly different from
beneficiaries in the non-PIs therapy group in terms of CCI characteristics. CCI (3+: 30.4 %
vs. 19.4 %; p= 0.005).
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Table 5.6 Baseline characteristics of matched sample of African American and Caucasian: PIs versus non-PIs
African Americans
Caucasians
PIs
Non-PIs
PIs
Non-PIs
(n=218)
(n=218 )
(n=237)
(n=237 )
Covariates
N
%
N
%
P
N
%
N
%
Age Group
18 - 44 (Ref.)
43
19.7
43
19.7
32
13.5
32
13.5
45 - 54
38
17.4
38
17.4
53
22.4
53
22.4
1.000
55 - 64
68
31.2
68
31.2
69
29.1
69
29.1
65+
69
31.7
69
31.7
83
35.0
83
35.0
Gender
Male
146
67.0
146
67.0
1.000
203
85.7
203
85.7
Female
72
33.0
72
33.0
34
14.4
34
14.4
Census Region
Midwest
32
14.7
32
14.7
44
18.6
44
18.6
Northeast
43
19.7
43
19.7
41
17.3
41
17.3
1.000
South
125
57.3
125
57.3
92
38.8
92
38.8
West
18
8.3
18
8.3
60
25.3
60
25.3
Hepatitis B & C Virus
Negative
167
76.6
167
76.6
1.000
220
92.8
220
92.8
Positive
51
23.4
51
23.4
17
7.2
17
7.2
Charleson Comorbidity Index
92
38.8
124
52.3
≤1 (Ref.)
76
34.9
110
50.5
0.001
2
52
23.9
51
23.4
73
30.8
67
28.3
3+
90
41.3
57
26.2
72
30.4
46
19.4
Dual Eligibility Status
No
68
31.2
68
31.2
1.000
104
43.9
104
43.9
Yes
150
68.8
150
68.8
133
56.1
133
56.1
PI: Protease Inhibitors, ART: Anti-Retroviral Therapy

P

1.00

1.000

1.000

1.000

0.005
1.000

5.2.1.2 PIs versus no-ARTs
Matched sample of African American sub-groups consists of a total of 245
beneficiaries per group.(Table 5.7) Beneficiaries in the PIs therapy group were similar in
terms of their clinical and demographic characteristics - age group (65+ years: 22.5 % vs. 22.5
%, p=1.000), gender (female: 30.2 % vs. 30.2 %,p=1.000), census region (Midwest: 16.0% vs.
16.0 %; p=1.000), HBV & HCV (positive: 7.8 % vs. 7.8 %; p=1.000) and dual eligibility
(Yes: 73.1 % vs. 73.1 %; p=1.000) compared to beneficiaries in the no-ARTs therapy group.
CCI characteristics were not included in the propensity matching process thus, beneficiaries in
the PIs group were significantly different from beneficiaries in the non-PIs group in terms of
CCI characteristics. CCI (3+: 37.1 % vs. 25.8 %; p= 0.003).
Within the Caucasian sub-group, a total of 209 Caucasian beneficiaries per therapy
group were matched. (Table 5.7) Matched groups are similar in terms of their clinical and
demographic characteristics - age group (65+ years: 34.5 % vs. 34.5 %, p=1.000), gender
(female: 13.4 % vs. 13.4 %, p=1.000), census region (Midwest: 19.1 % vs. 19.1 %; p=1.000),
HBV & HCV (positive: 5.7 % vs. 5.7 %; p=1.000) and dual eligibility (yes: 53.1 % vs.
53.1%; p=1.000). Beneficiaries in the PIs therapy group were significantly different from
beneficiaries in the no-ARTs therapy group based on CCI characteristics. CCI (3+: 31.1 % vs.
21.4 %; p= 0.008).

117

Table 5.7 Baseline characteristics of matched sample of race subgroups: PIs versus no-ARTs
African American
PIs
(n=245)
N
%
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Age Group
18 - 44 (Ref.)
60
24.5
45 - 54
53
21.6
55 - 64
77
31.4
65+
55
22.5
Gender
Male
171
69.8
Female
74
30.2
Census Region
38
15.5
Midwest
Northeast
48
19.6
South
142
58.0
West
17
6.9
Hepatitis B & C Virus
Negative
226
92.2
Positive
19
7.8
Charlson Comorbidity Index
86
35.1
≤1 (Ref.)
2
68
27.8
3+
91
37.1
Dual Eligibility Status
No
66
26.9
Yes
179
73.1
PI: Protease Inhibitors, ART: Anti-Retroviral Therapy

Non-PIs
(n=245 )
N
%
60
53
77
55

24.5
21.6
31.4
22.5

171
74

69.8
30.2

38
48
142
17

15.5
19.6
58.0
6.9

226
19

92.2
7.8

100
47
51

50.5
23.7
25.8

66
179

26.9
73.1

P

1.000

1.000

1.000

1.000

0.003
1.000

Caucasians
PIs
(n=209)
N
%

ART Naive
(n=209 )
N
%

19
50
68
72

9.1
23.9
32.5
34.5

19
50
68
72

9.1
23.9
32.5
34.5

181
28

86.6
13.4

181
28

86.6
13.4

40
38
68
63

19.1
18.2
32.5
30.1

40
38
68
63

19.1
18.2
32.5
30.1

197
12

94.3
5.7

197
12

94.3
5.7

77
67
65

36.8
32.1
31.1

132
74
56

50.4
28.2
21.4

98
111

46.9
53.1

98
111

46.9
53.1

P

1.000

1.000

1.000

1.000

0.008
1.000

5.2.2 Unadjusted logistic regression analysis
Table 5.8 shows the results of unadjusted logistic regression of the odds of developing
T2DM between therapy group pairs for African American and Caucasian race subgroups. In
the PIs versus non-PIs therapy groups, results show that the odds of developing T2DM is 2.00
times higher in African American beneficiaries treated with PIs compared to African
Americans treated with non-PIs (OR:2.00; 95% CI:1.14 – 3.52). Caucasians treated with PIs
are 98 % more likely to develop T2DM than Caucasians treated with non-PIs (OR:1.98; 95%
CI:1.07-3.65).
In the PIs versus no-ARTs therapy groups, the odds of developing T2DM is 2.23 times
higher among African Americans treated with PIs compared to African Americans who were
not treated with ART (OR:2.23; 95% CI:1.17 -4.25). The odds of developing T2DM is 2.18
times higher in Caucasian beneficiaries treated with PIs compared to those not treated with
ARTs (OR:2.18; 95% CI: 1.29-3.69).
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Table 5.8 Unadjusted association between PI use and development of T2DM: Race Subgroup
African Americans
OR
Medication Exposure
Non-PI (Ref)
PIs
Medication Exposure
ART Naive (Ref)
PIs

95 % CI

Caucasians

PValue

OR

95 % CI

PValue

2.00

1.14

3.52

0.0158

1.98

1.07

3.65

0.0293

2.23

1.17

4.25

0.0150

2.18

1.29

3.69

0.0037

PI: Protease Inhibitors, OR: Odds ratio, T2DM: Types II diabetes Mellitus, ART: AntiRetroviral Therapy, CI: Confidence Interval
5.2.3 Multivariate sub-group analysis
Tables 5.9 and 5.10 show the multivariate logistic results of race sub-group
analysis of PIs use on the development of T2DM for both therapy groups.
5.2.3.1 PIs versus non-PIs
In the adjusted logistic regression for race/ethnicity sub-group analysis, we controlled
for potential confounding factors at the baseline. (Table 5.9) We found that among African
Americans, the odds of developing T2DM between beneficiaries treated with PIs and those
treated with non-PIs was still significant after adjusting for potential confounders. Compared
to African American beneficiaries treated with non-PIs, those treated with PIs were 86 %
more likely to develop T2DM after adjusting for covariates (OR=1.86; 95% CI: 1.03-3.36).
Among other factors controlled, only CCI of 3+ were statistically significantly associated
with the development of T2DM. Compared to African American beneficiaries with
comorbidity of ≤ 1, those with a comorbidity of 3 or more were 2.67 times more likely to
develop T2DM after adjusting for covariates (OR=2.67; 95% CI: 1.31-5.42). Compared to
African American beneficiaries with without dual eligibility, those with dual eligibility were
2.34 times more likely to develop T2DM after adjusting for covariates (OR=2.34; 95% CI:
1.10-4.95).
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Among Caucasian beneficiaries, the odds of developing T2DM between beneficiaries
treated with PIs and those treated with non-PIs was still significant after adjusting for
potential confounders. Compared to Caucasian beneficiaries treated with non-PIs, those
treated with PIs were 3.38 times more likely to develop T2DM after adjusting for covariates
(OR=1.81; 95% CI: 1.02-3.22). Among other factors controlled, only CCI of 3+ were
statistically significantly associated with the development of T2DM. Compared to African
American beneficiaries with comorbidity of ≤ 1, those with a comorbidity of 3 or more were
3.38 times more likely to develop T2DM after adjusting for covariates (OR=3.38; 95% CI:
1.67-6.84).

121

Table 5.9. Multivariate logistic regression analysis of factors associated with development
of T2DM: Race sub-group comparison of PI versus non-PI therapy group
African Americans
Caucasians
AOR 95 % CI
P
AOR 95 % CI
P
Medication Exposure
Non-PIs (Ref)
1.86 1.03 3.36 0.0390
1.81 1.02 3.22 0.0427
PIs
Age Group
18 - 44 (Ref.)
2.26 0.93 5.48 0.1568
0.55 0.22 1.38 0.4374
45 - 54
1.61
0.69
3.77
0.9577
0.50 0.20 1.23 0.2225
55 - 64
1.76 0.71 4.38 0.6861
0.75 0.31 1.84 0.6330
65+
Gender
Female (Ref)
0.90 0.50 1.63 0.7304
1.05 0.52 2.14 0.8864
Male
Census Region
Midwest (Ref)
0.98 0.30 3.23 0.8995
1.01 0.44 2.30 0.7150
Northeast
0.94
0.29
3.02
0.9740
0.76 0.33 1.75 0.5291
South
0.87 0.30 2.49 0.6961
0.89 0.43 1.83 0.9289
West
Hepatitis C Virus
Negative (Ref)
2.16 0.91 5.17 0.0827
1.07 0.38 3.04 0.8963
Positive
Charleson Comorbidity Index
≤1 (Ref.)
2.29 1.08 4.83 0.2734
1.40 0.67 2.93 0.3970
2
2.67
1.31
5.42
0.0489
3.38 1.67 6.84 0.0006
3+
Dual Eligibility Status
No (Ref)
2.34 1.10 4.95 0.0266
1.44 0.77 2.71 0.2586
Yes
PI: Protease Inhibitors, AOR: adjusted odds ratio, T2DM: Types II diabetes Mellitus, CI:
Confidence Interval
5.2.3.2 PIs versus no-ARTs
We controlled for potential confounding factors at the baseline in the adjusted logistic
regression for the race/ethnicity sub-group analysis. (Table 5.10). Results show that among
African Americans, the odds of developing T2DM between beneficiaries treated with PI and
those not treated with ART was still significant after adjusting for potential confounders.
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Compared to African American beneficiaries not treated with ART, those treated with
PIs were 2.05 times more likely to develop T2DM after adjusting for covariates (OR=2.05;
95% CI: 1.03-4.09). Among other factors controlled, only CCI of 3+ was statistically
significantly associated with the development of T2DM. African American beneficiaries with
a comorbidity of ≤ 1 were 4.66 times more likely to develop T2DM than those with a
comorbidity of 3 or more after adjusting for covariates.
Among Caucasian beneficiaries, the odds of developing T2DM between beneficiaries
treated with PI and those not treated with ART was still significant after adjusting for
potential confounders. Compared to Caucasian beneficiaries not treated with ART, those
treated with PIs were 1.96 times more likely to develop T2DM after adjusting for covariates
(OR=1.96; 95% CI: 1.14-3.39). Among factors that were controlled in the logistic regression,
only CCI of 3+ were statistically significantly associated with the development of T2DM.
Caucasian beneficiaries with a comorbidity of ≤ 1 were 2.83 times more likely to develop
T2DM than those with a comorbidity of 3 or more after adjusting for covariates (OR=2.38;
95% CI: 1.52-5.27).
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Table 5.10 Multivariate logistic regression analysis of factors associated with
development of T2DM: Race sub-group comparison of PI versus no-ARTs
African Americans
Caucasians
AOR
95 % CI
P
AOR 95 % CI
P
Medication
Exposure
No-ART (Ref)
PIs
2.05 1.03 4.09 0.0414
1.96 1.14 3.39 0.0158
Age Group
18 - 44 (Ref.)
45 - 54
0.46 0.17 1.25 0.9103
1.50 0.64 3.50 0.5205
55 - 64
0.32 0.12 0.90 0.1671
1.23 0.52 2.93 0.8325
65+
0.33 0.11 1.02 0.2765
1.52 0.63 3.69 0.4930
Gender
Female (Ref)
Male
0.93 0.41 2.11 0.8656
0.95 0.54 1.66 0.8449
Census Region
Midwest (Ref)
Northeast
1.81 0.69 4.76 0.2796
0.85 0.24 2.94 0.4600
South
1.31 0.46 3.71 0.9883
1.27 0.40 3.99 0.5817
West
1.27 0.53 3.03 0.8795
1.29 0.45 3.64 0.4310
Hepatitis B & C
Virus
Negative (Ref)
Positive
0.85 0.29 2.49 0.7693
0.86 0.34 2.18 0.7476
Charleson
Comorbidity Index
≤1 (Ref.)
2
1.71 0.72 4.07 0.5303
1.42 0.69 2.91 0.5896
3+
4.66 2.06 10.54 0.0002
2.83 1.52 5.27 0.0015
Dual Eligibility
Status
No (Ref)
Yes
1.17 0.56 2.47 0.6792
1.61 0.87 2.98 0.1288
PI: Protease Inhibitors, OR: Odds ratio, T2DM: Types II diabetes Mellitus, ART: AntiRetroviral Therapy, CI: Confidence Interval
5. 3 Economic Burden of Comorbid T2DM
Section 5.3 describes the sample selection flow chart for study aim 3, baseline
demographic and clinical characteristics of selected beneficiaries and the multivariate
results of the impact of T2DM on different costs. The costs considered were total inpatient
cost, total outpatient cost, total prescription cost, total OOP cost, total Medicare cost and
total medical cost.
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5.3.1 Flow chat for sample selection
Using 2013 to 2017 Medicare data with 1 million Medicare beneficiaries, we
generated the study aim 3 sample in three steps. (Figure 5.4). First, we identified 2,627
beneficiaries with diagnosis of HIV/AIDS and 182,007 beneficiaries with diagnosis of
T2DM. Second, we excluded a total of 181,488 beneficiaries, who have no record of
HIV/AIDS diagnosis. Thus, leaving behind a total of 2,627 HIV/AIDS beneficiaries with
or without T2DM diagnosis. Third, a total of 118 beneficiaries were exclude (1), if they
either were enrolled in HMO plan or (2) if they were not continuously enrolled in Part A
and B plan. A total of 2,509 HIV/AIDS positive beneficiaries were selected in the final
sample or (3), if beneficiary have ESRD. The final sample consists of 498 HIV/AIDS
positive beneficiaries with a diagnosis of T2DM (Case) and 2,011 HIV/AIDS positive
beneficiaries without a diagnosis of T2DM.
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Inpatient and Outpatient
Medicare Files

Diagnosis of HIV/AIDS
N=2,627

No record of
HIV/AIDS
diagnosis
-181,488

HIV/AIDS beneficiaries
with or without T2DM
N=2,627
126

-118

Exclude if:

Exclude if:

Final Sample
N=2,509

T2DM
N=498

No T2DM
N=2,011

Figure 5.4 Sample selection flow chart for study aims 3

•
•
•

Diagnosis of T2DM
N=182,007
Enrolled in HMO insurance plan
Not continuously enrolled in Part A and B
Presence of ESRD

5.3.2 Descriptive analysis
Table 5.11 summarizes baseline characteristics of beneficiaries with HIV/AIDS,
distinguishing between those with comorbid T2DM and those without comorbid T2DM.
Except for hepatitis B and C variables, low income subsidy and dual eligibility variables,
all other baseline characteristics were statistically significantly different between
beneficiaries with a history of T2DM and those without. Beneficiaries in the T2DM
history group and those in the non-T2DM history group are statistically significantly
different in terms of age-group (P= 0.036), gender; p=0.015, race category; p=0.000,
region; p= 0.008 and CCI scores, (P= <.0001). Beneficiaries with a history of T2DM and
individuals without a history of T2DM are similar in terms of treatment with antiretroviral drugs, hepatitis B/C virus, (p=0.770), and Medicare and Medicaid dual
eligibility status (p=0.312).
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Table 5.11. Baseline characteristics of HIV/AIDS positive beneficiaries with
T2DM versus those without T2DM (N = 2,509)
T2DM Status
T2DM
Non-T2DM
(n=498)
(n=2011)
N
%
N
%
P-Value
Treatment with ART
694
69.1
402
69.2
0.9549
Non-PIs
179
30.8
PIs
311
30.95
Age Group
18
3.6
97
4.8
18 - 44 (Ref.)
43
8.6
205
10.2
0.0360
45 - 54
116
23.3
556
27.7
55 - 64
321
64.5
65+
1153
57.3
Gender
340
68.3
1482
73.7
0.0150
Male
158
31.7
Female
529
26.3
Race
188
37.8
970
48.2
Caucasian
265
53.2
874
167.0
0.0000
African America
45
9.0
Other Race
43.46
8.3
Census Region
77
15.5
341
17.0
Midwest
0.0080
117
23.5
Northeast
447
22.3
248
49.9
881
44.0
South
55
11.1
333
16.6
West
Hepatitis B & C Virus
438
88.0
1759
87.5
0.7700
Negative
60
12.1
Positive
252
12.5
Charleson Comorbidity Index
88
17.7
387
19.2
0
235
47.2
1184
58.9
1
112
22.5
299
14.9
<.0001
2
3+
63
12.7
141
7.0
Low Income Subsidy
131
28.9
581
28.9
0.2520
No
367
73.7
1430
71.1
Yes
Dual Eligibility Status
133
0.3120
No
26.7
583
29.0
365
Yes
73.3
1428
71.0

5.3.4 Average healthcare costs between beneficiaries with comorbid T2DM and those
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without
Table 5.12 presents the unadjusted averages costs for different healthcare costs
between HIV/AIDS positive beneficiaries with comorbid T2DM and those without. On
average, the cost of hospitalization for individuals with comorbid T2DM was statistically
significantly higher than the cost of hospitalization for individuals without comorbid
T2DM: (mean diff.: 32, 622; 95 % CI: 26,329-38,915; p= <.0001). The outpatient cost for
individuals with a T2DM history was statistically significantly higher than in individuals
without comorbid T2DM (mean diff.: 14, 894; 95 % CI: 11,402-18,385; p= <.0001).
Compared to individuals with comorbid T2DM, those without comorbid T2DM had
statistically significantly higher Medicare costs. (mean diff.: 56,459; 95 % CI: 45,26167,658; p-value= <.0001). Beneficiaries with comorbid T2DM incur statistically
significantly higher OOP costs than those without comorbid T2DM (mean diff.: 5,109; 95
% CI: 4,237-5,981; p-value= <.0001). Prescription costs were statistically significantly
higher for individuals with comorbid T2DM than those without (mean diff.: 17,974; 95 %
CI: 9,301-26,648; p= <.0001]. Individuals with comorbid T2DM incurred higher overall
total medical costs than individuals without comorbid T2DM (mean diff.: 65491; 95 %
CI: 52,984-77,988); p= <.0001).
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Table 5.12. Average healthcare costs of HIV/AIDS positive beneficiaries with T2DM versus those without T2DM
T2DM (n=496)

No T2DM (n=2011)

Mean ± Std

Mean ± Std

Mean Cost
Difference

57,628 ± 101,295

25,006 ± 53,882

32,622

26,329

38,915

<.0001

26,600 ± 46,885

11,706 ± 36,436

14,894

11,402

18,385

<.0001

105,315 ± 114,061

87,341 ± 91,886

17,974

9,301

26,648

<.0001

159,901 ± 158,736

103,442 ± 111,759

56,459

45,261

67,658

<.0001

9,976 ±13,514

4,868 ±789

5,109

4,237

5,981

<.0001

65,491

5,2,984 77,988

95 % CI

P- Value

Total hospitalization cost
Total outpatient cost
Total prescription drug
cost
Total Medicare cost
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Total OOP cost
Total medical cost
189,543 ± 176,920 124,052 ± 125,048
T2DM: Types II diabetes Mellitus, CI: Confidence Interval

<.0001

5.3.5 Unadjusted GLM analysis of the impact of comorbid T2DM on healthcare costs
Table 5.13 shows the results of unadjusted GLM analysis with log link and gamma
distribution, comparing different healthcare costs between individuals with comorbid T2DM
and those without. We found that comorbid T2DM in HIV/AIDS is statistically significantly
associated with a 73.19% [(e0.54921-1) *100] increase in hospitalization costs (p=<.0001)
compared to individuals without T2DM on average. Compared to HIV/AIDS positive
beneficiaries without T2DM, those with T2DM had 102.3 % [(e0.7946-1) *100]
higher total outpatient costs on average. (P=<.0001) Compared to HIV/AIDS positive
beneficiaries without T2DM, those with T2DM had 16.57 % [(e0.1533-1) *100] higher
prescription drug costs on average. (p=0.0023). We also found that compared to HIV/AIDS
positive beneficiaries without T2DM, those with T2DM had 103.24% [(e0.7092-1) *100] higher
total OOP costs on average. Considering total Medicare and total medical costs, compared to
HIV/AIDS positive beneficiaries without T2DM, those with T2DM had 54.22% [(e0.4332-1)
*100] higher total Medicare costs and 52.53 % [(e0.4222-1) *100] higher total medical costs on
average.
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Table 5.13 Unadjusted GLM analysis of the effect of comorbid T2DM on total
healthcare costs
Estimates
95 % CI
P-Value
Total Hospitalization Costs
T2DM
Negative (Ref)
Positive
0.5492
0.4355 0.6630
<.0001
Total Outpatient Cost
T2DM
Negative (Ref)
Positive
0.7946
0.6797 0.9094
<.0001
Total Prescription Drug Cost
T2DM
Negative (Ref)
Positive
0.1533
0.0547 0.2519
0.0023
Total OOP Cost
T2DM
Negative (Ref)
Positive
0.7092
0.6049 0.8135
<.0001
Total Medicare Cost
T2DM
Negative (Ref)
Positive
0.4332
0.3405 0.5259
<.0001
Total Medical Cost
T2DM
Negative (Ref)
Positive
0.4222
0.3330 0.5113
<.0001
GLM: Generalized Linear Model, T2DM: Types II diabetes Mellitus, CI: Confidence
Interval
5.3.6 Adjusted GLM analysis of effect of comorbid T2DM on different costs
Table 5.14 to tables 5:18 summarizes the multivariate GLM analysis of the impact of
T2DM on different costs. GLM analysis controls for the baseline characteristics of the
beneficiary such as: age-group, gender, region of the US, race category, CCI, Hepatitis B/C
virus, low income subsidy and Medicare/Medicaid dual eligibility.
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5.3.5.1 Total hospitalization costs
After controlling for potential confounders at the baseline in the GLM analysis (Table
5.14) the impact of T2DM on hospitalization was still statistically significantly higher in
beneficiaries with T2DM compared to those without T2DM. We found that on average,
HIV/AIDS positive beneficiaries with comorbid T2DM had a 63.34 % [(e0.4907-1) *100]
increase in total hospitalization cost (p=<.0001) compared to HIV/AIDS beneficiaries without
comorbid T2DM.
Other covariates that are statistically significantly associated with changes in total
hospitalization costs include race category, southern region, hepatitis B/C Virus, and CCI-1
categories. Compared to Caucasian beneficiaries with HIV/AIDS, African American
HIV/AIDS positive beneficiaries had 39.98 % higher total hospitalization costs on average
(p=<.0001) while HIV/AIDS beneficiaries of ‘other race’ groups had 48.38 % higher total
hospitalization costs on average (p=0.0023). Compared to HIV/AIDS positive beneficiaries
living in the Midwest region, those living in the Southern region had 16.48 % lower total
hospitalization costs on average (p=0.0501). Compared to HIV/AIDS beneficiaries without
hepatitis B/C virus comorbidity, those with hepatitis B/C virus comorbidity had 40.78 %
higher total hospitalization costs on average (p=<.0001). Compared to HIV/AIDS
beneficiaries without any comorbidity (CCI=0), those with a comorbidity of 1 (CCI=1) had
52.14 % lower total hospitalization costs on average (p=0.0054).
Antiretroviral treatment with PIs did not significantly impact hospitalization cost
compare to treatment with non-PIs. Compared to HIV/AIDS positive beneficiaries treated
with non-PIs, those treated with PI had a 9.01 % lower total hospitalization cost on average,
however, incremental cost was not statistically significant (p=0.2007).
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There was no statistically significant differences found in total hospitalization costs
between: male and female beneficiaries (p=0.5792), those living in the Midwest and those
living in the Northeast region ((p=0.8754), and those living in Midwest and those living in the
Western region (p=0.1852), between beneficiaries with CCI=0 and those with CCI=2
(p=0.0857), between beneficiaries with CCI=0 and those with CCI=3 (p=0.9529), and
beneficiaries with dual eligibility and those without dual eligibility (p=0.2007).
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Table 5.14 Adjusted GLM analysis of the effect of comorbid T2DM on total
hospitalization costs
Estimates
95 % CI
P-Value
Intercept
10.8392 10.2662 11.4121 <.0001
T2DM
Negative (Ref)
Positive
0.4907
0.3558 0.6256
<.0001
Treatment with ART
Non-PIs (Ref)
PIs
-0.0863
-0.2186 0.0459
0.2007
Age Group
18 - 44 (Ref.)
45 - 54
0.0473
-0.1651 0.2596
0.6626
55 - 64
0.0413
-0.1661 0.2486
0.6963
65+
0.1011
-0.1109 0.3132
0.3499
Gender
Female (Ref)
Male
-0.0408
-0.1851 0.1035
0.5792
Race
Caucasian (Ref)
African America
0.3363
0.1970 0.4756
<.0001
Other Race
0.3946
0.1409 0.6483
0.0023
Census Region
Midwest (Ref)
Northeast
-0.0162
-0.2187 0.1863
0.8754
South
-0.1801
-0.3603 0.0001
0.0501
West
0.1549
-0.0743 0.3842
0.1852
Hepatitis C Virus
Negative (Ref)
Positive
0.3420
0.1953 0.4888
<.0001
Charleson Comorbidity Index
0 (Ref)
1
-0.7368
-1.2556 -0.2180
0.0054
2
-0.4515
-0.9665 0.0634
0.0857
3+
0.0154
-0.4959 0.5267
0.9529
Dual Eligibility Status
No
Yes
0.0474
-0.1001 0.1948
0.5290
GLM: Generalized Linear Model, T2DM: Types II diabetes Mellitus, CI:
Confidence Interval, PI: Protease Inhibitor, ART: Antiretroviral Therapy
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5.3.5.2 Total outpatient costs
After controlling for potential confounders at the baseline in the GLM analysis (Table
5.15) the impact of T2DM on total outpatient cost was still statistically significantly higher
among beneficiaries with comorbid T2DM than to those without comorbid T2DM. Results
further show that, on average, HIV/AIDS positive beneficiaries with comorbid T2DM had a
50.26% [(e0.4072-1) *100] increase in total outpatient cost (p=<.0001) compared to HIV/AIDS
beneficiaries without comorbid T2DM .
Other covariates that are statistically significantly associated with changes in total
outpatient cost include age group (45-54), race, region and CCI. Compared to HIV/AIDS
positive beneficiaries living in the Midwestern region, those living in the Northeast region had
a 27.10 % lower total outpatient cost on average (p=0.0195). The Southern region had 25.01
% lower total outpatient costs on average (p=0.0187), and the Western region had 26.35 %
lower total outpatient costs on average (p=0.0359). Compared to HIV/AIDS beneficiaries
without any comorbidity (CCI=0), those with a comorbidity of: CCI=1 had 59.94 % higher
total outpatient costs on average (p=0.0045), CCI=2 had 243.36 % higher total outpatient
costs on average (p=<.0001), and CCI=3+ had 577.34 % higher total outpatient cost on
average (p=<.0001).
Antiretroviral treatment with PIs did not significantly impact outpatient cost compare
to treatment with non-PIs. Compared to HIV/AIDS positive beneficiaries treated with nonPIs, those treated with PI had a 4.24 % higher total outpatient cost on average, however,
incremental cost was not statistically significant (p=0.5265). There was no statistically
significant difference in changes in total outpatient cost between: age groups, male and female
beneficiaries (p=0.0662), and beneficiaries with dual eligibility and those without dual
eligibility (p=0.3379).

136

Table 5.15 Adjusted GLM analysis of the effect of comorbid T2DM on total
outpatient costs
Estimates
95 % CI
P-Value
Intercept
T2DM
Negative (Ref)
Positive
Treatment with ART
Non-PIs (Ref)
PIs
Age Group
18 - 44 (Ref.)
45 - 54
55 - 64
65+
Gender
Female (Ref)
Male
Race
Caucasian (Ref)
African America
Other Race
Census Region
Midwest (Ref)
Northeast
South
West
Hepatitis C Virus
Negative (Ref)
Positive
Charleson Comorbidity Index
0 (Ref)
1
2
3+
Dual Eligibility Status
No
Yes

8.3138

7.9020 8.7256

<.0001

0.4072

0.2677 0.5467

<.0001

0.0415

-0.0869 0.1698

0.5265

0.2322
0.1896
0.1380

0.0242 0.4403
-0.0084 0.3877
-0.0690 0.3450

0.0287
0.0605
0.1913

-0.0810

-0.2228 0.0607

0.2625

0.1074
-0.1883

-0.0352 0.2499
-0.4228 0.0462

0.1399
0.1155

-0.2398
-0.2232
-0.2339

-0.4411 -0.0385
-0.4092 -0.0372
-0.4524 -0.0154

0.0195
0.0187
0.0359

0.0708

-0.0821 0.2237

0.3641

0.4696
1.2336
1.9130

0.1453 0.7939
0.9051 1.5621
1.5811 2.2450

0.0045
<.0001
<.0001

-0.0704

-0.2144 0.0736

0.3379

GLM: Generalized Linear Model, T2DM: Types II diabetes Mellitus, CI: Confidence
Interval, PI: Protease Inhibitor, ART: Antiretroviral Therapy
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5.3.5.3 Total OOP
After controlling for potential confounders at the baseline in the GLM analysis (Table
5.16) the impact of T2DM on total OOP cost was still statistically significantly higher among
beneficiaries with comorbid T2DM compared to those without comorbid T2DM. Results
show that on average, HIV/AIDS positive beneficiaries with comorbid T2DM had a 59.15%
[(e0.4647-1) *100] increase in total OOP cost (p=<.0001) compared to HIV/AIDS beneficiaries
without comorbid T2DM.
Other covariates statistically significantly associated with changes in total OOP cost
include race, hepatitis B/C Virus and CCI characteristics. Compared to Caucasian
beneficiaries with HIV/AIDS, beneficiaries of ‘other race’ group had 44.40 % lower total
OOP costs on average (p=0.0009). Compared to HIV/AIDS beneficiaries without hepatitis
B/C virus comorbidity, those with hepatitis B/C virus comorbidity had 32.14 % higher total
OOP costs on average (p=<0.0001). Compared to HIV/AIDS beneficiaries without any
comorbidity (CCI=0), those with a comorbidity of: CCI=1 had 36.15 % higher total OOP
costs on average (p=0.0466), CCI=2 had 119.88 % higher outpatient costs on average
(p=<.0001), and CCI=3+ had 274.75 % higher OOP costs on average (p=<.0001).
Antiretroviral treatment with PIs did not significantly impact OOP cost compare to
treatment with non-PIs. Compared to HIV/AIDS positive beneficiaries treated with non-PIs,
those treated with PI had a 6.97 % higher total OOP cost on average, however, incremental
cost was not statistically significant (p=0.2590). We also found that there was no statistically
significant difference in changes to total OOP costs between: age groups, region, male and
female beneficiaries (p=0.0843), and those without dual eligibility (p=0.8332).
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Table 5.16 Adjusted GLM analysis of the effect of comorbid T2DM on total OOP
costs
Estimates
95 % CI
P-Value
7.9091
7.5290
8.2892
<.0001
Intercept
T2DM
Negative (Ref)
0.4647
0.3366 0.5929
<.0001
Positive
Treatment with ART
Non-PIs (Ref)
0.0674
-0.0496 0.1844
0.2590
PIs
Age Group
18 - 44 (Ref.)
0.1357
-0.3261 0.2548
0.1628
45 - 54
0.1479
-0.3318 0.3359
0.1147
55 - 64
0.1788
-0.2713 0.3734
0.4221
65+
Gender
Female (Ref)
-0.0113
-0.1403 0.1177
0.8635
Male
Race
Caucasian (Ref)
-0.0182
-0.1444 0.1080
0.7774
African America
-0.3674
-0.5836 -0.1512
0.0009
Other Race
Census Region
Midwest (Ref)
-0.1409
-0.3230 0.0411
0.1292
Northeast
-0.0921
-0.2554 0.0712
0.2691
South
-0.1182
-0.3187 0.0823
0.2478
West
Hepatitis C Virus
Negative (Ref)
0.2787
0.1387 0.4186
<.0001
Positive
Charleson Comorbidity Index
0 (Ref)
0.3086
0.0046 0.6125
0.0466
1
0.7879
0.4810
1.0949
<.0001
2
1.3211
1.0121 1.6301
<.0001
3+
Dual Eligibility Status
No
-0.0578
-0.1909 0.0753
0.3945
Yes
GLM: Generalized Linear Model, T2DM: Types II diabetes Mellitus, CI: Confidence
Interval, PI: Protease Inhibitor, ART: Antiretroviral Therapy, OOP: out of Pocket Cost
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5.3.5.4 Total prescription cost
After controlling for potential confounders at the baseline in the GLM analysis (Table
5.17) the difference in total prescription costs between individuals with comorbid T2DM and
those without comorbid T2DM was no longer statistically significant. We found that
compared to HIV/AIDS beneficiaries without comorbid T2DM, those with T2DM had 6.97 %
[(e0.0674-1) *100] higher total prescription costs on average, however, the incremental cost was
not statistically significant. (p=0.3113).
Other covariates statistically significantly associated with changes in total prescription
drug cost include hepatitis B/C and CCI. Compared to HIV/AIDS positive beneficiaries
without hepatitis B/C, those diagnosed with hepatitis B/C had 21.12 % higher total
prescription costs on average (p=0.0076). Compared to HIV/AIDS beneficiaries without any
comorbidity (CCI=0), those with a comorbidity of: CCI=1 had 140.37 % higher total
prescription costs on average (p=<.0001), CCI=2 had 223.88 % higher total prescription costs
on average (p=<.0001), CCI=3+ had 255.41 % higher total prescription costs on average
(p=<.0001).
Antiretroviral treatment with PIs did not significantly impact prescription drug cost
compare to treatment with non-PIs. Compared to HIV/AIDS positive beneficiaries treated
with non-PIs, those treated with PI had a 4.29 % higher total prescription drug cost on
average, however, incremental cost was not statistically significant (p=0.4728). We also
found that there was no statistically significant difference in changes to total prescription costs
between: race, census region, hepatitis B/C (p=0.1251) or beneficiaries with dual eligibility
versus those without dual eligibility (p=0.9318).
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Table 5.17 Adjusted GLM analysis of impact of T2DM on total prescription drug
costs
Estimates
95 % CI
P-Value
10.2656
9.8838
10.6474
<.0001
Intercept
T2DM
Negative (Ref)
0.0674
-0.0631 0.1978
0.3113
Positive
Treatment with ART
Non-PIs (Ref)
0.0420
-0.0727 0.1567
0.4728
PIs
Age Group
18 - 44 (Ref.)
0.0340
-0.1480 0.2161
0.7141
45 - 54
0.0950
-0.0827 0.2727
0.2947
55 - 64
0.1517
-0.2364 0.3330
0.5834
65+
Gender
Female (Ref)
0.1075
-0.0206 0.2355
0.1000
Male
Race
Caucasian (Ref)
-0.0650
-0.1873 0.0572
0.2972
African America
-0.0759
-0.2876 0.1358
0.4823
Other Race
Census Region
Midwest (Ref)
0.0703
-0.1051 0.2458
0.4321
Northeast
-0.0398
-0.1960 0.1165
0.6178
South
0.1241
-0.0736 0.3219
0.2186
West
Hepatitis C Virus
Negative (Ref)
0.1916
0.0510 0.3323
0.0076
Positive
Charleson Comorbidity Index
0 (Ref)
0.8770
0.5654 1.1886
<.0001
1
1.1752
0.8610 1.4895
<.0001
2
1.2681
0.9512
1.5851
<.0001
3+
Dual Eligibility Status
No
0.0274
-0.0994 0.1541
0.6723
Yes
GLM: Generalized Linear Model, T2DM: Types II diabetes Mellitus, CI: Confidence
Interval, PI: Protease Inhibitor, ART: Antiretroviral Therapy
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5.3.5.5 Total Medicare cost
After controlling for potential confounders at the baseline in the GLM analysis
(Table 5.18) the impact of T2DM on total Medicare cost was still statistically significantly
higher among beneficiaries with comorbid T2DM compared to those without comorbid
T2DM. Result show that compared to HIV/AIDS beneficiaries without comorbid T2DM,
those with comorbid T2DM had 27.95 % [(e0.2465-1) *100] higher total Medicare costs on
average (p=<.0001).
Other covariates statistically significantly associated with changes in total Medicare
cost include hepatitis B/C Virus and CCI characteristics. Compared to HIV/AIDS
beneficiaries without hepatitis B/C virus comorbidity, those with hepatitis B/C virus
comorbidity had 29.15 % higher total Medicare costs on average (p=<.0001). Compared to
HIV/AIDS beneficiaries without any comorbidity (CCI=0), those with comorbidity of: CCI=1
had 93.00 % higher total Medicare costs on average (p=<.0001), CCI=2 had 189.33 % higher
total Medicare cost on average (p=<.0001), CCI=3+ had 309.68 % higher total Medicare cost
on average (p=<.0001).
Antiretroviral treatment with PIs did not significantly impact Medicare cost compare
to treatment with non-PIs. Compared to HIV/AIDS positive beneficiaries treated with nonPIs, those treated with PI had a 2.80 % higher total Medicare cost on average, however,
incremental cost was not statistically significant (p=0.6036). Also, there was no statistically
significant difference in changes to total Medicare cost between: age, race, region, male and
female beneficiaries (p=0.5089) or beneficiaries with dual eligibility and those without dual
eligibility (p=0.9611).
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Table 5.18 Adjusted GLM analysis of impact of T2DM on total Medicare
costs
Estimates
10.4320

95 % CI
10.0895 10.7744

P-Value
<.0001

Intercept
T2DM
Negative (Ref)
0.2465
0.1294 0.3636
<.0001
Positive
Treatment with ART
Non-PIs (Ref)
0.0276
-0.0765 0.1316
0.6036
PIs
Age Group
18 - 44 (Ref.)
0.0341
-0.1336 0.2018
0.6900
45 - 54
0.0786
-0.0848 0.2420
0.3456
55 - 64
0.0962
-0.0762 0.1638
0.9430
65+
Gender
Female (Ref)
0.0393
-0.0772 0.1558
0.5089
Male
Race
Caucasian (Ref)
0.0524
-0.0588 0.1636
0.3559
African America
0.0129
-0.1802 0.2060
0.8956
Other Race
Census Region
Midwest (Ref)
-0.0019
-0.1625 0.1587
0.9815
Northeast
-0.0809
-0.2243 0.0625
0.2691
South
0.1022
-0.0769 0.2813
0.2633
West
Hepatitis C Virus
Negative (Ref)
0.2558
0.1290 0.3826
<.0001
Positive
Charleson Comorbidity Index
0 (Ref)
0.6575
0.3831 0.9318
<.0001
1
1.0624
0.7859 1.3388
<.0001
2
1.4102
1.1332 1.6872
<.0001
3+
Dual Eligibility Status
No
-0.0029
-0.1199 0.1141
0.9611
Yes
GLM: Generalized Linear Model, T2DM: Types II diabetes Mellitus, CI: Confidence
Interval, PI: Protease Inhibitor, ART: Antiretroviral Therapy
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5.3.5.6 Total medical cost
After controlling for potential confounders at the baseline in the GLM analysis
(Table 5.19) the impact of comorbid T2DM on total medical costs was still statistically
significantly higher among beneficiaries with comorbid T2DM compared to those without
comorbid T2DM. Results show that compared to HIV/AIDS beneficiaries without comorbid
of T2DM, those with comorbid T2DM had 27..82 % [(e0.2455-1) *100] higher total medical
costs on average (p=<.0001).
Other covariates statistically significantly associated with changes in total medical
costs include hepatitis B/C Virus and CCI characteristics. Compared to HIV/AIDS
beneficiaries without hepatitis B/C virus comorbidity, those with hepatitis B/C virus
comorbidity had 27.21 % higher total medical costs on average (p=0.0001). Compared to
HIV/AIDS beneficiaries without any comorbidity (CCI=0), those with a comorbidity of:
CCI=1 had 92.97 % higher total medical costs on average (p=<.0001), CCI=2 had 185.68 %
higher total medical costs on average (p=<.0001), CCI=3+ had 289.00 % higher total medical
costs on average (p=<.0001).
Antiretroviral treatment with PIs did not significantly impact total medical cost
compare to treatment with non-PIs. Compared to HIV/AIDS positive beneficiaries treated
with non-PIs, those treated with PI had a 2.93 % higher total medical cost on average,
however, incremental cost was not statistically significant (p=0.5706). No statistically
significant difference was found in the changes to total medical cost between male and female
beneficiaries (p=0.3729), age category, race category, gender, region, and dual eligibility
versus those without dual eligibility (p=0.8912).
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Table 5.19 Adjusted GLM analysis of impact of T2DM on total medical costs
Estimates
95 % CI
P-Value
Intercept
10.6445
10.3171 10.9718
<.0001
T2DM
Negative (Ref)
Positive
0.2455
0.1334 0.3577
<.0001
Treatment with ART
Non-PIs (Ref)
PIs
0.0289
-0.0710 0.1289
0.5706
Age Group
18 - 44 (Ref.)
45 - 54
0.0078
-0.1532 0.1687
0.9246
55 - 64
0.0522
-0.1047 0.2090
0.5146
65+
0.0758
-0.1691 0.2575
0.9444
Gender
Female (Ref)
Male
0.0526
-0.0589 0.1642
0.3552
Race
Caucasian (Ref)
African America
0.0661
-0.0406 0.1727
0.2248
Other Race
-0.0014
-0.1862 0.1833
0.9877
Census Region
Midwest (Ref)
Northeast
-0.0175
-0.1721 0.1371
0.8244
South
-0.1029
-0.2409 0.0351
0.1440
West
0.0727
-0.0995 0.2450
0.4077
Hepatitis C Virus
Negative (Ref)
Positive
0.2407
0.1189 0.3625
0.0001
Charleson Comorbidity Index
0 (Ref)
1
0.6574
0.3957 0.9191
<.0001
2
1.0497
0.7858 1.3137
<.0001
3+
1.3584
1.0937 1.6230
<.0001
Dual Eligibility Status
No
Yes
0.0078
-0.1041 0.1198
0.8912
GLM: Generalized Linear Model, T2DM: Types II diabetes Mellitus, CI: Confidence
Interval, PI: Protease Inhibitor, ART: Antiretroviral Therapy
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5. 4

Sensitivity Analysis
The use of the PS matching approach in study aim 1 and 2 included only matched

beneficiaries in the analytical sample and excluded unmatched beneficiaries, which may
substantially impact the main results. To evaluate the sensitivity of these exclusions on the
results, adjusted logistic regressions were re-fitted using the inverse probability-of-treatment
weighting (IPTW) (instead of matching) which is a type of PS analytical method that uses
complete samples in the analysis. This section presents the summary of the results of the
sensitivity analysis of treatment with PI and the odds of developing T2DM, and the race subgroup analysis of these effects. (Table 5.20). The results of sensitivity analysis are consisted
with the main results based on PS matching approach in terms magnitude and direction of
association.
Compared to beneficiaries treated with non-PIs, those treated with PIs were shown to
be 69% more likely to develop T2DM after adjusting for covariates (OR=1.69; 95% CI: 1.422.01). (Table 5.20). Compared to beneficiaries who are not treated with ART, those treated
with PIs were 73% more likely to develop T2DM after adjusting for covariates (OR=1.73;
95% CI: 1.46-2.05).
Considering race sub-group results, among Caucasian beneficiaries, it was found that
compared to Caucasian beneficiaries treated with non-PI, those treated with PIs were 1.70
times more likely to develop T2DM after adjusting for covariates (OR=1.70; 95% CI: 1.302.22). Odds of developing T2DM among Caucasian beneficiaries who were treated with PI
were 2.05 times higher than the odds of developing T2DM in Caucasian beneficiaries who
were not treated with ART, after adjusting for covariates (OR=2.05; 95% CI: 1.52-2.77). We
found that odds of developing T2DM among African American beneficiaries treated with PI
were 2.17 times higher than odds of developing T2DM in African American beneficiaries
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treated with non-PI. (OR=2.17; 95% CI: 1.71 -2.76). Odds of developing T2DM among
African American beneficiaries treated with PI were 2.20 times higher than the odds of
developing T2DM in African American beneficiaries who were not treated with ART.
(OR=2.20; 95% CI: 1.74 -2.79).
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Table 5.20 Sensitivity analysis: Adjusted logistic regression analysis of factors
associated with development of T2DM
AOR
95 % CI
P-Value
Medication Exposure
Non-PIs (Ref)
1.69
1.42
2.01
<.0001
PIs
Medication Exposure
No-ART (Ref)
1.73
1.46
2.05
<.0001
PIs
Caucasians Sub-groups
Medication Exposure
Non-PIs (Ref)
1.70
1.30
2.22
0.0001
PIs
Medication Exposure
No-ART (Ref)
2.05
1.52
2.77
<.0001
PIs
African Americans Sub-groups
Medication Exposure
Non-PIs (Ref)
2.17
1.71
2.76
<.0001
PIs
Medication Exposure
No-ART (Ref)
2.20
1.74
2.79
<.0001
PIs
PI: Protease Inhibitors, AOR: Adjusted Odds ratio, T2DM: Types II diabetes
Mellitus, ART: Anti-Retroviral Therapy, CI: Confidence Interval
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CHAPTER 6
DISCUSSION
This chapter presents the discussion of all results in the context of existing
evidence and presents the significance, innovation, strengths and limitations of this
dissertation.
6.1 Treatment with PI and Development of T2DM
One of the objectives of this dissertation is to assess the association between PIs
use and incidences of T2DM comparing beneficiaries in both therapy group pairs- PIs
versus non-PIs and PIs verse no-ART therapy groups. We compared PIs versus non-PIs
therapy groups and found that among Medicare beneficiaries diagnosed with HIV/AIDS,
beneficiaries treated with PIs had higher adjusted odds of developing T2DM compared to
beneficiaries treated with non-PIs. Although this study reports evidence among the
population of Medicare recipients, our results are similar to the findings in some previous
studies which examined subjects sampled from other populations. Studies conducted by
Capeau et al., in France analyzed medical records of a cohort of 1,046 patients followed
over a 10-year period. Conclusions showed that short term exposure to indinavir was
associated with increased incidences of T2DM 74, which is similar to the increased odds
of developing T2DM found in this study. Similarly, Ledergerber et al followed 6,513
HIV patients over a six year analytical period and found that the use of PIs based RTIs
were associated with an increased risk of T2DM. 100 Studies conducted by both Tsiodras
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et al. and Hughes et al. demonstrated that use of PI was independently associated with
elevated hyperglycemia and an increase in development of T2DM, respectively.102,103 A
2-fold increase (two-fold (AOR: 1.52) in the odds of developing T2DM in Hughes et
al.103 is similar to the two-fold (AOR: 1.74) increase found in this study.
This study incorporated non-PIs groups as a control group (mainly the NNRTIs
and NRTIs) when assessing association between T2DM and PIs use, which is similar to
the control group used in Justman et al.104 Justman and his colleagues analyzed the risk of
diabetes in a cohort of 1,785 non-pregnant HIV positive women treated with PIs versus
those treated with RTIs.104 After a four-year follow-up, they found that patients treated
with PIs had an increase in incidences of diabetes compare to RTI users, which is similar
to the findings of this study.104 Our result is similar to findings from a previous study
which incorporated a PI naïve group as a control group. Carr et al. compared PIs with PIs
naïve HIV patients after 2-years of follow-up and found that hyperlipidemia and impaired
glucose were significantly common among PI users compared to PI-naïve HIV
patients.105 Given that subjects in the PI-naïve control group in Carr et al were exposed to
other ARTs just as the non-PI control group in this study, our findings corroborates the
findings of Carr et al.
Although this study demonstrates an association of treatment with PIs and
increased odds of developing T2DM within the Medicare population, our result is similar
to Tripathi et al. which analyzed South Carolina Medicaid HIV/AIDS population. They
found that cumulative exposure to protease inhibitors are significantly associated with a
higher risk of diabetes among the South Carolina Medicaid population.108 Evidence from
Tripathi et al. can only be generalized to South Carolina Medicaid recipients and cannot
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be extended to the national level. However, since similar evidence exists in the Medicare
population as we found in this study, it could be hypothesized that the treatment with PI
may be associated with an increased risk of developing diabetes within the national
Medicaid HIV/AIDS population as well, just as the national Medicare population in this
study. Future studies should focus on analyzing national Medicaid beneficiaries with
HIV/AIDS in other to provide evidence on both national Medicare and Medicaid
populations. This will help the CMS in developing a risk management approach for
clinical management of HIV in both Medicaid and Medicare beneficiaries when using
PIs.
This study incorporated no-ARTs as a control group and directly compared PIs
versus no-ART therapy groups. Results based on this therapy group pair shows the extent
to which the odds of developing T2DM could vary between individuals treated with PIs
versus those who were not treated with any ART, which, at best, provides a clear-cut
estimate of association of PIs and T2DM. None of the published studies that reported
association between PIs and increased incidences of T2DM incorporated or directly
compared a no-ART group as a control group with a PIs group when estimating the risk
of T2DM. In this study, we found that among Medicare beneficiaries diagnosed with
HIV/AIDS, those treated with PIs had higher adjusted odds of developing T2DM
compared to beneficiaries not treated with ARTs. In Justman et al, RTIs were
incorporated as a control group for comparison pairs – RTI versus PI and RTI versus noART comparison pairs.104 In RTIs versus no-ART, they found an increasing risk of
T2DM among the RTI groups compared to no-ART, although the result was not
statistically significant.104 In RTI versus PI comparison pair, they found increasing risk in
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PI compared to RTI groups. While RTI versus no-ART comparison is not similar to the
PI versus no-ART used in this study, it could be carefully deduced from Justman et al
that a PIs versus no-ART comparison may show in increasing risk of developing T2DM
if it was compared in their study.
This study analyzed the odds of developing T2DM between a PIs versus non-PIs
group and PIs versus no-ARTs group and found increased odds of developing T2DM in
PIs versus non-PIs (AOR: 1.74) and PI versus no-ART groups (AOR: 1.83), respectively.
As expected, the odds of developing T2DM is higher in the no-ARTs comparison group
than in the non-PIs comparison group. Given that previous studies had shown that the use
of RTIs are association with an increased risk of developing T2DM 121-123,174, thus
individuals in the PIs versus non-PIs comparison groups have T2DM risks higher than
the baseline risk. Hence, comparing PIs versus non-PIs would results to a smaller odds
ratio than in PI versus no-ART (the probability of T2DM in PI group/ divided by the
probability of T2DM in non-PIs group). On the other hand, the T2DM risk in the no-ART
arm are generally the baseline T2DM risk and much smaller than the risk of T2DM in the
PIs arm, thus comparison of PIs versus no-ARTs will result to a larger odds ratio
(probability of T2DM in PI group divided by the probability of T2DM in non-PIs group)
than in PIs versus no-ARTs comparison.
6.2

Race Sub-group Analysis of PI Use and Development of T2DM
This study is the first to report racial disparities in odds of developing T2DM

among patients treated with PIs. We examined racial disparities in odds of developing
T2DM comparing beneficiaries treated with PIs versus those treated with non-PIs, and
comparing beneficiaries treated with PIs versus those not treated with ARTs.
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In the PIs versus non-PIs comparison groups, we found that African American
beneficiaries treated with PI had higher odds of developing T2DM compared to African
American beneficiaries treated with non-PIs. We also found that Caucasian beneficiaries
treated with PIs had higher odds of developing T2DM compared to Caucasian
beneficiaries treated with non-PI. The odds of developing T2DM was higher in African
American race-subgroup (OR=2.09) compare to the odds among Caucasian racesubgroup (OR=1.90). This finding agrees with our hypothesis which states that in
comparing PIs and non-PIs therapy group, the odds of developing T2DM after PIs use is
higher among African American race compared to the odds of developing T2DM after
PIs use among the Caucasian beneficiaries.
In the PI versus no-ART comparison groups, we found that African American
beneficiaries treated with PI had higher odds of developing T2DM compared to African
American beneficiaries who were not treated with ARTs. We also found that Caucasian
beneficiaries treated with PIs had higher odds of developing T2DM compared to
Caucasian beneficiaries not treated with ART. Again, we found that the odds of
developing T2DM was higher in African American race-subgroup (OR=2.39) compared
to the odds among Caucasian race-subgroup (OR=1.86). These findings agree with our
hypothesis which states that in comparing PIs and no-ARTs therapy group, the odds of
developing T2DM after PIs use are higher among African American race compared to the
odds of developing T2DM after PIs use among the Caucasian beneficiaries.
In the analysis of each therapy group pairs, our study demonstrates that use of PIs
is associated with higher odds of developing T2DM in both race subgroups. Specifically,
treatment with PIs was associated with development of T2DM in both African American
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and Caucasian Medicare beneficiaries with HIV/AIDS infection. However, we found that
the impact was higher in one race sub-group than the other. This study reports that the
odds of developing T2DM was higher in African Americans treated with PIs compared to
Caucasians treated with PIs.
Previous racial disparities studies had reported that African Americans have
higher prevalence of T2DM compare to Caucasians. According to the CDC, African
American and other racial and ethnic minority populations remain at higher risk for
incident T2DM and its complications.175 However, recent studies by Bancks et al
suggested that African Americans and Caucasians actually have the same biological risk
of developing T2DM.176 They concluded that the there is no racial disparities in risk of
developing T2DM after accounting for various modifiable risk factors such as family
history of diabetes, racial segregation, tract-level poverty, depressive symptoms, family
education, current employment, alcohol consumption, and smoking rather than genetic
factors.176 The difference in odds of developing T2DM between African Americans and
Caucasians in our study could result from some of the underlying factors which were not
controlled for in this study. Factors such as family history of diabetes, depressive
symptoms, education, employment and behavioral factors such as alcohol consumption
and smoking.
6.3

Economic Burden of Comorbid T2DM
This study is the first to evaluate the national economic burden of comorbid

T2DM in HIV/AIDS. We found that compared to HIV/AIDS positive beneficiaries
without comorbid T2DM, those with comorbid T2DM had higher total hospitalization
cost, higher total outpatient cost, higher total OOP costs, higher total Medicare cost and
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higher total medical cost on average. Conversely, this study did not detect a significant
difference in total cost of prescription drugs between beneficiaries with history of T2DM
and those without. Except for total cost of prescription drugs, the findings of this study
are similar to our hypothesis for all other health costs.
This finding is in tandem with the study conducted by Zingmond et al which
described the comorbidities in people living with HIV/AIDS in relation to hospitalization,
inpatient and prescription drug costs.7 They reported that among California Medicare
beneficiaries with HIV/AIDS, comorbidity is associated with increase in median inpatient
costs and outpatient costs paid by the Medicare and patients.7 Given the clinical
breakthrough in HIV/AIDS management since advent of ARTs which includes
decreasing hospitalization rates and ambulatory care for HIV/AIDS patients,
hospitalization is now largely due to non-HIV/AIDS comorbidities, infections and
complications.177 Approximately 71 % of deaths among hospitalized HIV/AIDS patients
is attributed to non-HIV related conditions such as other infections and various chronic
diseases.177 In other words, comorbidities itself has a significant impact on mortality rate
among hospitalized patients with HIV/AIDS as well as total hospitalization cost paid by
patients and their insurance providers. Thus, the total hospitalization costs, outpatient
costs, OOP costs, total Medicare costs and total medical costs is expected to be sensitive
to comorbid T2DM as found in this study.
In contrast to the sensitivity of these costs to comorbid T2DM, we found that
prescription drug cost is insensitive to comorbid T2DM. Prescription drug cost is not
sensitive to comorbid T2DM because the high cost of ARTs outweighs the cost of antidiabetes drugs, and so the total cost of anti-diabetes drugs would not make a significant
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difference in terms of total prescription drug costs for HIV/AIDS patients. This finding is
in tandem with the study conducted by Zingmond et al which found that ARTs constitute
the largest share of cost of care for HIV patients and suggested that because ARTs are
more expensive than medication for other comorbidities, comorbidities would have no
significant impact on cost of prescription for patients with HIV/AIDS which outweighs
medication costs for other conditions. 7
6.4

Sensitivity Analysis
We performed a sensitivity analysis using IPTW approach to evaluate the

sensitivity of excluding unmatched beneficiaries on the results of study aim 1 and 2 using
adjusted logistic regressions. We found that the sensitivity analysis results were similar to
the main result in aim 1 and 2 in terms of between group associations and direction of
associations. Analysis of the PS matched sample in this study is not sensitive to the
exclusion of unmatched samples.
6.5

Innovation
This study is innovative in the following three important areas. To begin with, it is

the first study of its kind to examine the odds of developing T2DM following PIs use
among Medicare beneficiaries diagnosed with HIV/AIDS. Second, the most recent
Medicare data (2012-2017) was used for this study enabling the evaluation of the odds of
T2DM using current and recent FDA approved ARTs and generate the most current
evidence. No previous studies in the current literature have examined this topic. Third,
this study is the first to determine racial disparity in the odds of developing T2DM
following PI use among Medicare beneficiaries with HIV/AIDS. No previous studies
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have examined the race/ethnicity disparity in the odds of developing T2DM among
Medicare beneficiaries with HIV in current literature. Fourth, this study is the first of its
kind to explore the economic burden of comorbid T2DM among the HIV/AIDS positive
Medicare population. The evidence generated by this study is the first and the most
current national economic burden with estimates that are adjusted to the 2017 dollar. No
previous studies have examined the national economic burden of comorbid T2DM.
6.6

Limitations
Several data and study design related limitations may exist in this study. This

study is a non-randomized observational study. Although we used PS matching approach
to account for potential selection bias due to non-randomization into therapy groups.
However, only the beneficiary characteristics available in the Medicare data were used
for the PS matching. Also, as a limitation of the PS matching approach, it is unable to
account for unmeasured confounders that could have impacted the results of this study.
The study aim 3 used cross-sectional study design to analyze economic burden of T2DM
on health care costs however, this study design could not establish causality of
association. Thus, the change in healthcare cost between beneficiaries with T2DM and
those without cannot be causally attributed to T2DM in this study.
Some data related limitations have been noted. Several potential confounders
were not observed in this study and thus were not controlled for. Medicare data has
limited information on risk factors of diabetes including physical activities of the
beneficiaries, a family history of diabetes, diets and other lifestyle behaviors. The
Medicare database does not have vital HIV related clinical information such as CD4
count and viral load information of the beneficiaries, which is a very important
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determinant of the type ART prescribed. As a secondary data which is originally
collected for administrative and billing purposes rather than for this study, and of which
data collection were not under the control of the investigators of this study, we suspect a
potential information bias consequently.
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CHAPTER 7
CONCLUSION
This study found that use of PIs in HIV/AIDS positive Medicare beneficiaries
may be associated with higher odds of developing T2DM than those who were managed
with non-PIs and higher than those who were not treated with ARTs. These findings are
consistent within both African American and Caucasian race sub-groups. However,
African American race-subgroup had higher odds of developing T2DM in both PI versus
no-ART and PI-versus non-PI comparison pairs than the odds among the Caucasian racesubgroup. Furthermore, this study found that HIV/AIDS Medicare beneficiaries with a
history of T2DM have higher total hospitalization costs, total outpatient costs, total OOP
costs, total Medicare costs and total medical costs than HIV/AIDS positive beneficiaries
without a history of T2DM
This study presents three policy impacting significances. First, in the light of the
controversies regarding safety and tolerability of PIs, a clinical risk management
approach is a necessity when treating the elderly and the Medicare beneficiaries who
have HIV/AIDS. This becomes important because treatment of HIV infection and
consequently creating or exacerbating the onset of another condition, such as T2DM, is a
huge concern to clinicians, the Medicare system, and patients. As a preventable adverse
event, the findings of this study will guide clinicians and infectious disease experts in
preventing this adverse effect by making evidence-based risk management decisions in
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the clinical use of PIs among the Medicare population with HIV/AIDS. Evidence-based
risk management approach will help avoid HIV treatment related T2DM in this
population, who are already enormously predisposed.
Second, racial/ethnic variations in HIV/AIDS epidemiology and treatment has
been established. As a vulnerable population with less HIV-care and attention, evidence
of racial/ethnic disparity in the odds of developing T2DM following PIs use is key in
ensuring proper risk management across race sub-groups. The findings of our study
suggest that while the odds of developing T2DM is consistent in both African American
and Caucasian race sub-groups, the odds were higher in African Americans than in
Caucasians. Our study suggests that personalized medicine should be considered when
planning clinical risk management approach for use of PIs with a consideration for the
race-subgroup in whom risks of T2DM are higher.
The increasing population of Medicare beneficiaries with HIV, who are at higher
risk for T2DM, suggests an increasing population of HIV positive beneficiaries with
comorbid T2DM. This may pose a significant economic burden on the Medicare system,
which is already the largest source of Federal spending for HIV care. As the population
ages and life expectancies increase, Medicare plans to continue to play an increasingly
significant role in HIV care, which is why it is important to understand the economic
burden of comorbid T2DM. Given the growing aging population and increasing per
capita costs for HIV positive beneficiaries, evidence of the national economic burden of
comorbid T2DM among Medicare beneficiaries with HIV/AIDS would be important to
Medicare policy makers as they consider options and ways to address concerns about
Medicare’s future financial solvency. Also, findings of this study include current
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evidence on specific cost domains which are specific for evaluating and generating
policies that target a specific aspect of health care use and cost domains. For instance,
evidence of total OOP costs and total prescription drug costs would benefit Medicare
policy makers as they draft proposals to reduce drug costs, which could be beneficial to
HIV positive beneficiaries facing high OOP expenses.
In summary, the significance of this study cannot be over emphasized. It
addresses issues that impact both the Medicare system and the patients and their racial
identification. The odds of developing T2DM after PIs use and the economic burden of
comorbid T2DM provides critical empirical evidence for policy considerations that
affects patients and the Medicare.
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